AU2022258968A1 - Mek inhibitors and uses thereof - Google Patents
Mek inhibitors and uses thereof Download PDFInfo
- Publication number
- AU2022258968A1 AU2022258968A1 AU2022258968A AU2022258968A AU2022258968A1 AU 2022258968 A1 AU2022258968 A1 AU 2022258968A1 AU 2022258968 A AU2022258968 A AU 2022258968A AU 2022258968 A AU2022258968 A AU 2022258968A AU 2022258968 A1 AU2022258968 A1 AU 2022258968A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- ring
- cancer
- optionally substituted
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims description 311
- 206010028980 Neoplasm Diseases 0.000 claims description 160
- 201000011510 cancer Diseases 0.000 claims description 101
- 125000001931 aliphatic group Chemical group 0.000 claims description 81
- 125000005842 heteroatom Chemical group 0.000 claims description 78
- 229910052760 oxygen Inorganic materials 0.000 claims description 76
- 230000000694 effects Effects 0.000 claims description 71
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 64
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 56
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 230000002401 inhibitory effect Effects 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000002619 bicyclic group Chemical group 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 12
- 239000003981 vehicle Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 7
- 125000001627 3 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 93
- 239000003814 drug Substances 0.000 description 105
- 239000003112 inhibitor Substances 0.000 description 99
- -1 monocyclic hydrocarbon Chemical class 0.000 description 93
- 229940045207 immuno-oncology agent Drugs 0.000 description 50
- 239000002584 immunological anticancer agent Substances 0.000 description 50
- 229940124597 therapeutic agent Drugs 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 34
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- 230000008685 targeting Effects 0.000 description 29
- 239000000556 agonist Substances 0.000 description 28
- 229940124647 MEK inhibitor Drugs 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 27
- 208000035475 disorder Diseases 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 201000010099 disease Diseases 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 25
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 25
- 230000001270 agonistic effect Effects 0.000 description 25
- 239000005557 antagonist Substances 0.000 description 25
- 229910001868 water Inorganic materials 0.000 description 25
- 101710113436 GTPase KRas Proteins 0.000 description 23
- 230000003247 decreasing effect Effects 0.000 description 22
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 19
- 150000002430 hydrocarbons Chemical group 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 201000001441 melanoma Diseases 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 206010009944 Colon cancer Diseases 0.000 description 16
- 101001137640 Homo sapiens Kinase suppressor of Ras 2 Proteins 0.000 description 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 229960003301 nivolumab Drugs 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- 239000011593 sulfur Substances 0.000 description 16
- 229940045513 CTLA4 antagonist Drugs 0.000 description 15
- 102100021000 Kinase suppressor of Ras 2 Human genes 0.000 description 15
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 14
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 14
- 101001137642 Homo sapiens Kinase suppressor of Ras 1 Proteins 0.000 description 14
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 14
- 102100021001 Kinase suppressor of Ras 1 Human genes 0.000 description 14
- 206010025323 Lymphomas Diseases 0.000 description 14
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 14
- 206010033128 Ovarian cancer Diseases 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 229960002621 pembrolizumab Drugs 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 150000003384 small molecules Chemical class 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 11
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 11
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 208000005017 glioblastoma Diseases 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 201000002528 pancreatic cancer Diseases 0.000 description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 230000003042 antagnostic effect Effects 0.000 description 10
- 208000014829 head and neck neoplasm Diseases 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
- 206010003571 Astrocytoma Diseases 0.000 description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 8
- 101150015280 Cel gene Proteins 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 101000749825 Homo sapiens Connector enhancer of kinase suppressor of ras 1 Proteins 0.000 description 8
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 8
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 8
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 description 8
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 8
- 239000012190 activator Substances 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229950009791 durvalumab Drugs 0.000 description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 8
- 230000003308 immunostimulating effect Effects 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 102000016914 ras Proteins Human genes 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 102100038078 CD276 antigen Human genes 0.000 description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 7
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 description 7
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 230000000981 bystander Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229960005386 ipilimumab Drugs 0.000 description 7
- 229940043355 kinase inhibitor Drugs 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 208000029974 neurofibrosarcoma Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 101710185679 CD276 antigen Proteins 0.000 description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 6
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 6
- 108090000172 Interleukin-15 Proteins 0.000 description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 6
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 6
- 208000000172 Medulloblastoma Diseases 0.000 description 6
- 206010027406 Mesothelioma Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010038389 Renal cancer Diseases 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 201000010982 kidney cancer Diseases 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 6
- 229950010895 midostaurin Drugs 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108010014186 ras Proteins Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229960000237 vorinostat Drugs 0.000 description 6
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 5
- 239000012664 BCL-2-inhibitor Substances 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 102100024263 CD160 antigen Human genes 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
- 102100031351 Galectin-9 Human genes 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 5
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 101000749824 Homo sapiens Connector enhancer of kinase suppressor of ras 2 Proteins 0.000 description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 5
- 102000003812 Interleukin-15 Human genes 0.000 description 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 108091008606 PDGF receptors Proteins 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 5
- 229940079156 Proteasome inhibitor Drugs 0.000 description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 5
- 108010016672 Syk Kinase Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 5
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 208000037844 advanced solid tumor Diseases 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000003886 aromatase inhibitor Substances 0.000 description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 201000010536 head and neck cancer Diseases 0.000 description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 5
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 5
- 229960002411 imatinib Drugs 0.000 description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 5
- 108091008042 inhibitory receptors Proteins 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 229950010773 pidilizumab Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003207 proteasome inhibitor Substances 0.000 description 5
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229950007217 tremelimumab Drugs 0.000 description 5
- 229950005972 urelumab Drugs 0.000 description 5
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 4
- YJZSUCFGHXQWDM-UHFFFAOYSA-N 1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate Chemical compound OC1=CC=C(O)C(CNC=2C=CC(=CC=2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1 YJZSUCFGHXQWDM-UHFFFAOYSA-N 0.000 description 4
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 208000009798 Craniopharyngioma Diseases 0.000 description 4
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 4
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 4
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010014967 Ependymoma Diseases 0.000 description 4
- 201000001342 Fallopian tube cancer Diseases 0.000 description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 4
- 101710113864 Heat shock protein 90 Proteins 0.000 description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 4
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 4
- 102100034980 ICOS ligand Human genes 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000004473 OX40 Ligand Human genes 0.000 description 4
- 108010042215 OX40 Ligand Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229940124060 PD-1 antagonist Drugs 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- RCCOZJPSLZNDFV-UHFFFAOYSA-N [3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxopyrido[2,3-d]pyrimidin-5-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=C(C)C(=O)N(C)C2=C1C(=O)N(C1CC1)C(=O)N2C1=CC=C(I)C=C1F RCCOZJPSLZNDFV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229950010482 alpelisib Drugs 0.000 description 4
- 229950002916 avelumab Drugs 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229940126587 biotherapeutics Drugs 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical group C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000005865 ionizing radiation Effects 0.000 description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 229940124302 mTOR inhibitor Drugs 0.000 description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 229960003347 obinutuzumab Drugs 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229960003278 osimertinib Drugs 0.000 description 4
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 4
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 4
- 108010091666 romidepsin Proteins 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 4
- 229960001183 venetoclax Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 4
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 101150051188 Adora2a gene Proteins 0.000 description 3
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 3
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 229940125565 BMS-986016 Drugs 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 206010006143 Brain stem glioma Diseases 0.000 description 3
- ZOXSLGZKVFCZEA-UHFFFAOYSA-N CC(C(N)=CC=C1)=C1NC(C(C(N1C2CC2)=O)=C(N2C)N(C(C=CC(I)=C3)=C3F)C1=O)=C(C)C2=O Chemical compound CC(C(N)=CC=C1)=C1NC(C(C(N1C2CC2)=O)=C(N2C)N(C(C=CC(I)=C3)=C3F)C1=O)=C(C)C2=O ZOXSLGZKVFCZEA-UHFFFAOYSA-N 0.000 description 3
- YAXLAHGGOUUACE-UHFFFAOYSA-N CC(C(NS(NC)(=O)=O)=CC=C1)=C1N(C(C(C(N1C2CC2)=O)=C(NC(C=CC(I)=C2)=C2F)N2C)=C(C)C2=O)C1=O Chemical compound CC(C(NS(NC)(=O)=O)=CC=C1)=C1N(C(C(C(N1C2CC2)=O)=C(NC(C=CC(I)=C2)=C2F)N2C)=C(C)C2=O)C1=O YAXLAHGGOUUACE-UHFFFAOYSA-N 0.000 description 3
- IZSDNTSWNWXBIM-UHFFFAOYSA-N CC(C(NS(NC)(=O)=O)=CC=C1)=C1NC(C(C(N1C2CC2)=O)=C(N2C)N(C(C=CC(I)=C3)=C3F)C1=O)=C(C)C2=O Chemical compound CC(C(NS(NC)(=O)=O)=CC=C1)=C1NC(C(C(N1C2CC2)=O)=C(N2C)N(C(C=CC(I)=C3)=C3F)C1=O)=C(C)C2=O IZSDNTSWNWXBIM-UHFFFAOYSA-N 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 102100025221 CD70 antigen Human genes 0.000 description 3
- 101150050673 CHK1 gene Proteins 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
- 108010065556 Drug Receptors Proteins 0.000 description 3
- 102000013138 Drug Receptors Human genes 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010069236 Goserelin Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 3
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 3
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000042838 JAK family Human genes 0.000 description 3
- 108091082332 JAK family Proteins 0.000 description 3
- 108010003046 KSR-1 protein kinase Proteins 0.000 description 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 229940122255 Microtubule inhibitor Drugs 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910017906 NH3H2O Inorganic materials 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
- 229940123751 PD-L1 antagonist Drugs 0.000 description 3
- 239000012828 PI3K inhibitor Substances 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000007641 Pinealoma Diseases 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 208000004064 acoustic neuroma Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 230000002927 anti-mitotic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 229960001467 bortezomib Drugs 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 3
- 229950009221 chidamide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 229940056913 eftilagimod alfa Drugs 0.000 description 3
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 229960000255 exemestane Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229960000908 idarubicin Drugs 0.000 description 3
- 229960003445 idelalisib Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003121 in-cell western assay Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 3
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- 229950011263 lirilumab Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 208000026037 malignant tumor of neck Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 231100000782 microtubule inhibitor Toxicity 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 108700043045 nanoluc Proteins 0.000 description 3
- 229950004847 navitoclax Drugs 0.000 description 3
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 3
- 208000007538 neurilemmoma Diseases 0.000 description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 3
- 230000036963 noncompetitive effect Effects 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 229960002450 ofatumumab Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 3
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 3
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 229960002087 pertuzumab Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 208000024724 pineal body neoplasm Diseases 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229950004043 radotinib Drugs 0.000 description 3
- DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 229960003452 romidepsin Drugs 0.000 description 3
- 102200006539 rs121913529 Human genes 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 206010039667 schwannoma Diseases 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 206010042863 synovial sarcoma Diseases 0.000 description 3
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 229950001067 varlilumab Drugs 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 3
- 229940055760 yervoy Drugs 0.000 description 3
- 229960004276 zoledronic acid Drugs 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical group NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 2
- FDSDDLLOMXWXRY-JAQKLANPSA-N (3s)-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid;acetate Chemical compound CC([O-])=O.C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O)CCOCC1 FDSDDLLOMXWXRY-JAQKLANPSA-N 0.000 description 2
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- UMGQVUWXNOJOSJ-KMHUVPDISA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-[(1r)-1-phenylethyl]prop-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 UMGQVUWXNOJOSJ-KMHUVPDISA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- RLYCRLGLCUXUPO-UHFFFAOYSA-N 2,6-diaminotoluene Chemical compound CC1=C(N)C=CC=C1N RLYCRLGLCUXUPO-UHFFFAOYSA-N 0.000 description 2
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 2
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 2
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 2
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 2
- 102000002627 4-1BB Ligand Human genes 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 description 2
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- BLGGKKSPLASNBA-UHFFFAOYSA-N CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC=CC(OS(NC)(=O)=O)=C1)C2=O Chemical compound CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC=CC(OS(NC)(=O)=O)=C1)C2=O BLGGKKSPLASNBA-UHFFFAOYSA-N 0.000 description 2
- 229940121697 CD27 agonist Drugs 0.000 description 2
- 229940123189 CD40 agonist Drugs 0.000 description 2
- 229940122551 CD40 antagonist Drugs 0.000 description 2
- 229940127272 CD73 inhibitor Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 2
- 102100037354 Ectodysplasin-A Human genes 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 102100038595 Estrogen receptor Human genes 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 229940126656 GS-4224 Drugs 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 244000060234 Gmelina philippensis Species 0.000 description 2
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 101150112082 Gpnmb gene Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 2
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 2
- 101000716693 Homo sapiens Sodium/iodide cotransporter Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 description 2
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 101710093458 ICOS ligand Proteins 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 2
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- MVBPAIHFZZKRGD-UHFFFAOYSA-N MTIC Chemical compound CNN=NC=1NC=NC=1C(N)=O MVBPAIHFZZKRGD-UHFFFAOYSA-N 0.000 description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 2
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 2
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010073338 Optic glioma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 2
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 2
- HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 102000042888 RAF family Human genes 0.000 description 2
- 108091082327 RAF family Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 229940125566 REGN3767 Drugs 0.000 description 2
- 239000005464 Radotinib Substances 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 108010040181 SF 1126 Proteins 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 102000013380 Smoothened Receptor Human genes 0.000 description 2
- 108010090739 Smoothened Receptor Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 description 2
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 150000005215 alkyl ethers Chemical group 0.000 description 2
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- ZAXCMPAWRCMABN-UHFFFAOYSA-N azane;2-hydroxyacetic acid;platinum Chemical compound N.N.[Pt].OCC(O)=O ZAXCMPAWRCMABN-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960003008 blinatumomab Drugs 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 229950004272 brigatinib Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 229960001573 cabazitaxel Drugs 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229950006295 cerdulatinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 2
- 230000002508 compound effect Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229950006370 epacadostat Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- QAMYWGZHLCQOOJ-WRNBYXCMSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-WRNBYXCMSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 208000002409 gliosarcoma Diseases 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960001442 gonadorelin Drugs 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 208000006359 hepatoblastoma Diseases 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 229940040731 human interleukin-12 Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960005236 ibandronic acid Drugs 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229950009034 indoximod Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 2
- 229960003648 ixazomib Drugs 0.000 description 2
- 229940025735 jevtana Drugs 0.000 description 2
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950001907 monalizumab Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- UJJUEJRWNWVHCM-UHFFFAOYSA-N n-methylsulfamoyl chloride Chemical compound CNS(Cl)(=O)=O UJJUEJRWNWVHCM-UHFFFAOYSA-N 0.000 description 2
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229960000513 necitumumab Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 2
- 229950008835 neratinib Drugs 0.000 description 2
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 2
- 229950011068 niraparib Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 229960000435 oblimersen Drugs 0.000 description 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 2
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 2
- 229950008516 olaratumab Drugs 0.000 description 2
- JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 2
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 208000008511 optic nerve glioma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 229960003978 pamidronic acid Drugs 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229960005547 pelareorep Drugs 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 201000004123 pineal gland cancer Diseases 0.000 description 2
- 229960004403 pixantrone Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 239000012562 protein A resin Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 239000002718 pyrimidine nucleoside Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
- 229960002119 raloxifene hydrochloride Drugs 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 229940099538 rapamune Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229950003687 ribociclib Drugs 0.000 description 2
- 229960000759 risedronic acid Drugs 0.000 description 2
- 102200006531 rs121913529 Human genes 0.000 description 2
- 102200006538 rs121913530 Human genes 0.000 description 2
- 102200006540 rs121913530 Human genes 0.000 description 2
- 102200006541 rs121913530 Human genes 0.000 description 2
- 229950004707 rucaparib Drugs 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 229960005569 saridegib Drugs 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 229960005325 sonidegib Drugs 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VDLGAZDAHPLOIR-VAZUXJHFSA-N sulanemadlin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@]2(C)CCCCCC\C=C\CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC5=CC=C(O)C=C5)NC(=O)[C@H](CCC(O)=O)NC2=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(N)=O VDLGAZDAHPLOIR-VAZUXJHFSA-N 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229950001269 taselisib Drugs 0.000 description 2
- 239000003277 telomerase inhibitor Substances 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 229960005324 tiludronic acid Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical group C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229950011257 veliparib Drugs 0.000 description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
- 229960004982 vinblastine sulfate Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 229960004449 vismodegib Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
- RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- SRSHBZRURUNOSM-DEOSSOPVSA-N (4-chlorophenyl) (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1[C@H]1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 SRSHBZRURUNOSM-DEOSSOPVSA-N 0.000 description 1
- DCGDPJCUIKLTDU-SUNYJGFJSA-N (4r)-4-[(1s)-1-fluoroethyl]-3-[2-[[(1s)-1-[4-methyl-5-[2-(trifluoromethyl)pyridin-4-yl]pyridin-2-yl]ethyl]amino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C[C@H](F)[C@H]1COC(=O)N1C1=CC=NC(N[C@@H](C)C=2N=CC(=C(C)C=2)C=2C=C(N=CC=2)C(F)(F)F)=N1 DCGDPJCUIKLTDU-SUNYJGFJSA-N 0.000 description 1
- ONKCBKDTKZIWHZ-MRWFHJSOSA-N (4r)-4-[[(2r)-6-amino-2-[[(2r)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2r)-1-amino-6-[bis[2-[[4-[2-(1h-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxope Chemical compound C([C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(N)=O)NC(=O)C=1C=CC(NC(=S)NN)=CC=1)C1=CC=C(O)C=C1 ONKCBKDTKZIWHZ-MRWFHJSOSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- GSQOBTOAOGXIFL-LFIBNONCSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-(3-phenylpropyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCC1=CC=CC=C1 GSQOBTOAOGXIFL-LFIBNONCSA-N 0.000 description 1
- GWCNJMUSWLTSCW-SFQUDFHCSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-(4-phenylbutyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCCC1=CC=CC=C1 GWCNJMUSWLTSCW-SFQUDFHCSA-N 0.000 description 1
- HKHOVJYOELRGMV-XYOKQWHBSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-phenylprop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NC1=CC=CC=C1 HKHOVJYOELRGMV-XYOKQWHBSA-N 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SOJJMSYMCLIQCZ-CYBMUJFWSA-N 1-[(2r)-4-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)purin-8-yl]-2-methylpiperazin-1-yl]ethanone Chemical compound C1CN(C(C)=O)[C@H](C)CN1C1=NC2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N1CC(F)(F)F SOJJMSYMCLIQCZ-CYBMUJFWSA-N 0.000 description 1
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- KUFRQPKVAWMTJO-QSTRRNJOSA-N 17-dmag Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-QSTRRNJOSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical group C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TXGKRVFSSHPBAJ-JKSUJKDBSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 TXGKRVFSSHPBAJ-JKSUJKDBSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 1
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical class C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- 125000004011 3 membered carbocyclic group Chemical group 0.000 description 1
- HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- RNMAUIMMNAHKQR-QFBILLFUSA-N 3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid Chemical compound FC(OC1=CC=C(C=C1)NC1=NC2=C(N1[C@H]1CC(C[C@H](C1)C)(C)C)C=CC(=C2)CCC(=O)O)(F)F RNMAUIMMNAHKQR-QFBILLFUSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- PBJKWGWHZVXBGU-UHFFFAOYSA-N 3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol Chemical compound CC(C)C1=C(O)C(O)=CC2=C(O)C(C=3C(O)=C4C=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 PBJKWGWHZVXBGU-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- 125000001845 4 membered carbocyclic group Chemical group 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- FPHVRPCVNPHPBH-UHFFFAOYSA-N 4-benzylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CC1=CC=CC=C1 FPHVRPCVNPHPBH-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- SVAGFBGXEWPNJC-SPIKMXEPSA-N 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN SVAGFBGXEWPNJC-SPIKMXEPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
- 229940126253 ADU-S100 Drugs 0.000 description 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229940080328 Arginase inhibitor Drugs 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
- 229940125557 BMS-986207 Drugs 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- FRLROGKKYSJZEF-UHFFFAOYSA-N CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC(NS(NCCN(C)C)(=O)=O)=CC=C1)C2=O Chemical compound CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC(NS(NCCN(C)C)(=O)=O)=CC=C1)C2=O FRLROGKKYSJZEF-UHFFFAOYSA-N 0.000 description 1
- FHSZAHUZITWHIM-UHFFFAOYSA-N CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC(O)=CC=C1)C2=O Chemical compound CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC(O)=CC=C1)C2=O FHSZAHUZITWHIM-UHFFFAOYSA-N 0.000 description 1
- HVAZPTCGRKSFOJ-UHFFFAOYSA-N CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC=CC(NC(NS(NC)(=O)=O)=O)=C1)C2=O Chemical compound CC(C(N(C)C(NC(C=CC(I)=C1)=C1F)=C1C(N2C3CC3)=O)=O)=C1N(C1=CC=CC(NC(NS(NC)(=O)=O)=O)=C1)C2=O HVAZPTCGRKSFOJ-UHFFFAOYSA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 102000004498 CCR4 Receptors Human genes 0.000 description 1
- 108010017317 CCR4 Receptors Proteins 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- CUDVHEFYRIWYQD-UHFFFAOYSA-N E-3810 free base Chemical compound C=1C=C2C(C(=O)NC)=CC=CC2=CC=1OC(C1=CC=2OC)=CC=NC1=CC=2OCC1(N)CC1 CUDVHEFYRIWYQD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940122558 EGFR antagonist Drugs 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 102000044591 ErbB-4 Receptor Human genes 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 108091006010 FLAG-tagged proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 108010082772 GFB 111 Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- 229940121727 Glutaminase inhibitor Drugs 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 229940122588 Heparanase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 230000004655 Hippo pathway Effects 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001115402 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 1
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 1
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010051676 Metastases to peritoneum Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100035487 Nectin-3 Human genes 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 108010064641 ONX 0912 Proteins 0.000 description 1
- 229910004749 OS(O)2 Inorganic materials 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000012896 Peritoneal disease Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000018795 RELT Human genes 0.000 description 1
- 108010052562 RELT Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102400000046 Soluble interleukin-15 receptor subunit alpha Human genes 0.000 description 1
- 101800000582 Soluble interleukin-15 receptor subunit alpha Proteins 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000001662 Subependymal Glioma Diseases 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 108091021474 TMEM173 Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 229940126302 TTI-621 Drugs 0.000 description 1
- 102000016946 TWEAK Receptor Human genes 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- JXAGDPXECXQWBC-LJQANCHMSA-N Tanomastat Chemical compound C([C@H](C(=O)O)CC(=O)C=1C=CC(=CC=1)C=1C=CC(Cl)=CC=1)SC1=CC=CC=C1 JXAGDPXECXQWBC-LJQANCHMSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123582 Telomerase inhibitor Drugs 0.000 description 1
- 108091033399 Telomestatin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229940122020 Thymidine phosphorylase inhibitor Drugs 0.000 description 1
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000245032 Trillium Species 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 1
- 101800003344 Vaccinia growth factor Proteins 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- MQTBAGAVFDZXKF-UHFFFAOYSA-N [2-fluoro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1F MQTBAGAVFDZXKF-UHFFFAOYSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- YJVBLROMQZEFPA-UHFFFAOYSA-L acid red 26 Chemical compound [Na+].[Na+].CC1=CC(C)=CC=C1N=NC1=C(O)C(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=CC=C12 YJVBLROMQZEFPA-UHFFFAOYSA-L 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 229950006061 anatumomab mafenatox Drugs 0.000 description 1
- 229950004189 andecaliximab Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 150000003974 aralkylamines Chemical group 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229940014583 arranon Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940102797 asparaginase erwinia chrysanthemi Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940077840 beleodaq Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229930195545 bengamide Natural products 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 229940101815 blincyto Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940083476 bosulif Drugs 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229940056434 caprelsa Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000006243 carbonyl protecting group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- NNXDIGHYPZHXTR-ONEGZZNKSA-N chembl2035185 Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(O3)=CC=C3COC\C=C\COCC=2C=1OCCN1CCCC1 NNXDIGHYPZHXTR-ONEGZZNKSA-N 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- ZGHQGWOETPXKLY-XVNBXDOJSA-N chembl77030 Chemical compound NC(=S)C(\C#N)=C\C1=CC=C(O)C(O)=C1 ZGHQGWOETPXKLY-XVNBXDOJSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- GULSIMHVQYBADX-FQEVSTJZSA-N cintirorgon Chemical group CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O GULSIMHVQYBADX-FQEVSTJZSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229940103380 clolar Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940034568 cometriq Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940034075 cytarabine injection Drugs 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229940094732 darzalex Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- GJJVAFUKOBZPCB-HQLRYZJNSA-N desmethyl tocotrienol Chemical compound OC1=CC=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-HQLRYZJNSA-N 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229940065910 docefrez Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 229950002830 enadenotucirev Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229960000439 eribulin mesylate Drugs 0.000 description 1
- 229940014684 erivedge Drugs 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229940051398 erwinaze Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229940002006 firmagon Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 229940087158 gilotrif Drugs 0.000 description 1
- 229950009073 gimatecan Drugs 0.000 description 1
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229950000918 glembatumumab Drugs 0.000 description 1
- 229940110231 gleostine Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 229940118951 halaven Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000050152 human BRAF Human genes 0.000 description 1
- 102000044459 human CD47 Human genes 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 102000047208 human KSR2 Human genes 0.000 description 1
- 102000050154 human MAP2K2 Human genes 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940061301 ibrance Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229940091204 imlygic Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960002993 ingenol mebutate Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 229940111707 ixempra Drugs 0.000 description 1
- 229940045773 jakafi Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940000764 kyprolis Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- 229940064847 lenvima Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002216 linifanib Drugs 0.000 description 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950004231 lucitanib Drugs 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000026807 lung carcinoid tumor Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940100352 lynparza Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 229940034322 marqibo Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229940083118 mekinist Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 229950007627 motolimod Drugs 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229940030115 ninlaro Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229940024847 odomzo Drugs 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940048191 onivyde Drugs 0.000 description 1
- 229950005750 oprozomib Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 108700017947 pasireotide Proteins 0.000 description 1
- 229960005415 pasireotide Drugs 0.000 description 1
- NEEFMPSSNFRRNC-HQUONIRXSA-N pasireotide aspartate Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 NEEFMPSSNFRRNC-HQUONIRXSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000010918 peritoneal neoplasm Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229950011309 pexastimogene devacirepvec Drugs 0.000 description 1
- 229950001457 pexidartinib Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 229940107670 picato Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229950005566 picoplatin Drugs 0.000 description 1
- 229950004941 pictilisib Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 229940008606 pomalyst Drugs 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 229950003608 prinomastat Drugs 0.000 description 1
- YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229950001626 quizartinib Drugs 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 description 1
- JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical compound OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- 229950000106 samalizumab Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- SARBMGXGWXCXFW-GJHVZSAVSA-M sodium;2-[[(2s)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl [(2r)-2,3-di(hexadecanoyloxy)propyl] phosphate;hydrate Chemical compound O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O SARBMGXGWXCXFW-GJHVZSAVSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 229940090374 stivarga Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000030819 subependymoma Diseases 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940022873 synribo Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940081616 tafinlar Drugs 0.000 description 1
- 229950004550 talazoparib Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940069905 tasigna Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- PRAAPINBUWJLGA-UHFFFAOYSA-N telaglenastat Chemical compound FC(F)(F)OC1=CC=CC(CC(=O)NC=2N=NC(CCCCC=3SC(NC(=O)CC=4N=CC=CC=4)=NN=3)=CC=2)=C1 PRAAPINBUWJLGA-UHFFFAOYSA-N 0.000 description 1
- YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N tetraethylthiuram disulfide Natural products CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 description 1
- 229960002952 tipiracil Drugs 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000940 tivozanib Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940100411 torisel Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 1
- 229940125117 ulevostinag Drugs 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940022919 unituxin Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229940050482 valchlor Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229940028393 vincasar Drugs 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000012498 virus associated tumor Diseases 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940049068 xalkori Drugs 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229940085728 xtandi Drugs 0.000 description 1
- 229940004212 yondelis Drugs 0.000 description 1
- 229940036061 zaltrap Drugs 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960002760 ziv-aflibercept Drugs 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- 229940095188 zydelig Drugs 0.000 description 1
- 229940052129 zykadia Drugs 0.000 description 1
- 229940051084 zytiga Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention provides MEK inhibitors of formula (I'), compositions thereof, and methods of using the same.
Description
MEK INHIBITORS AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the priority of US provisional application number 63/175,837 filed April 16, 2021 and US provisional application number 63/262,093 filed October 5, 2021, each of which is hereby incorporated by reference in its entirety.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to compounds and methods useful for inhibiting mitogen- activated protein kinase/extracellular signal-regulated kinase kinase (MEK). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of proliferative disorders, such as cancers.
BACKGROUND
[0003] Activation of the p42/44 MAPK signaling pathway comprising mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK has been implicated in the pathogenesis and progression of various cancers. The MEK-ERK pathway is often activated by mutation of upstream factors, BRAF or Ras, or by the signals of constitutively activated cell-surface receptors. Inhibition of MEK can be a promising strategy for controlling the growth of tumors, for example, the tumors associated with MEK pathway signaling.
SUMMARY OF THE INVENTION
[0004] It has now been found that compounds of the present invention, and pharmaceutically acceptable compositions thereof, are effective as MEK inhibitors.
[0005] In one aspect, the instant invention provides a compound of formula (G):
or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0006] In one aspect, the instant invention provides a compound of formula (I):
(I). or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.
[0007] Another aspect of the invention provides a method of treating a disorder mediated by
MEK in a subject. The method comprises administering a therapeutically effective amount of a compound described herein to a subject in need thereof to treat the disorder mediated by MEK, as further described in the detailed description.
[0008] Another aspect of the invention provides a method of inhibiting MEK activity. The method comprises contacting MEK or a KSR-MEK complex or a RAF-MEK complex with an
effective amount of a compound described herein, as further described in the detailed description. In some embodiments, a method provided herein comprises contacting a MEK- KSR-RAF complex with an effective amount of a compound described herein, as further described in the detailed description.
[0009] In some aspects, compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating proliferative disorders, such as the cancers as described herein.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
1. General Description of Certain Embodiments of the Invention:
[0010] Compounds of the present invention, and pharmaceutical compositions thereof, are useful as MEK inhibitors. Without wishing to be bound by any particular theory, it is believed that the compounds of the present invention may directly engage members of the RAF family of proteins at the MEK interface, and that RAF family members, specifically BRAF or CRAF, may remodel the prototypical allosteric pocket of the MEK inhibitor in the RAF-MEK complex. Without wishing to be bound by any particular theory, it is believed that the compounds of the present invention may bind the RAF-MEK complex and may disrupt the related RAF-MEK complex.
[0011] In one aspect, the present invention provides a compound of Formula (I’):
( ) or a pharmaceutically acceptable salt thereof, wherein:
Ring A is selected from: R3 R3 N
each R1 is independently H, halogen, -CN, or optionally substituted C1-6 aliphatic; X is C, CH, or N; Y is CR6, C(O), or N; L’ is a covalent bond, -O-, -C(R9)2-, or -NR8-; each of R2, R5, and R8 is independently H or optionally substituted C1-6 aliphatic; each of R3, R4, R6, and R9 is independently H, halogen, or optionally substituted C1-6 aliphatic; Ring B is an optionally substituted ring selected from a 3-8 membered monocyclic carbocyclic ring, a 3-8 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a 5-11 membered bicyclic carbocyclic ring, a 5-11 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S, a phenyl ring, a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-11 membered bicyclic aromatic ring, and a 8-11 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S; L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, - N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, - S(O)2-N(R)-, -P(O)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S;
R7 is R, -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)- N(R)2, -C(O)-R, -S(O)-R, -N(R)2, -OR, -SR, o each R is independently H, -CN, or optionally subs and
n is 0, 1, 2, 3, 4, or 5. [0012] In one aspect, the present invention provides a compound of Formula (I’): or a pharmaceutically acceptabl Ring A is selected from:
R3 R3
each R1 is independently H, halogen, -CN, or optionally substituted C1-6 aliphatic; X is C, CH, or N; Y is CR6, C(O), or N; L’ is a covalent bond, -O-, -C(R9)2-, or -NR8-; each of R2, R3, R4, R5, R6, R8, and R9 is independently H or optionally substituted C1-6 aliphatic;
Ring B is an optionally substituted ring selected from a 3-8 membered monocyclic carbocyclic ring, a 3-8 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a 5-11 membered bicyclic carbocyclic ring, a 5-11 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S, a phenyl ring, a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-11 membered bicyclic aromatic ring, and a 8-11 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S; L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, - N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, - S(O)2-N(R)-, -P(O)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S; R7 is R, -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)- N(R)2, -C(O)-R, -S(O)-R, -N(R)2, -OR, -SR, o each R is independently H, -CN, or optionally subs c; and
n is 0, 1, 2, 3, 4, or 5. [0013] In one aspect, the present invention provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from:
each == independently represents a single bond or a double bond; each R1 is independently H, halogen, -CN, or optionally substituted Ci-6 aliphatic;
X is C or N;
Y is CR6, C(O), orN; each of R2, R3, R4, R5, and R6 is independently H or optionally substituted Ci-6 aliphatic;
Ring B is an optionally substituted ring selected from a phenyl ring, a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-10 membered bicyclic aromatic ring, and a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S;
L is a covalent bond or a Ci-io bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -0-, -S-, -
N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, -CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(0)2-, -P(0)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently
selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S; R7 is -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)-N(R)2, -C(O)-R, -N(R)2, -OR, -SR, each R is independently H, -CN,
ed C1-6 aliphatic; and n is 0, 1, 2, 3, 4, or 5. 2. Compounds and Definitions: [0014] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference. [0015] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle," “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6
hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0016] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as ortho- fused or spirocyclic. As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e ., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:
Exemplary bridged bicyclics include:
NH H
[0017] The term “lower alkyl” refers to a C1-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl. [0018] The term “lower haloalkyl” refers to a C1-4 straight or branched alkyl group that is substituted with one or more halogen atoms. [0019] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl)). [0020] The term “unsaturated”, as used herein, means that a moiety has one or more units of unsaturation. [0021] As used herein, the term “bivalent C1-8 (or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
[0022] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0023] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
[0024] As used herein, the term “cyclopropylenyl” refers to a bivalent cyclopropyl group of the following structure:
[0025] The term “halogen” means F, Cl, Br, or I.
[0026] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or
“aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
[0027] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g. , “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 p electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and
pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, AH quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
[0028] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro- 2H pyrrolyl), NH (as in pyrrolidinyl), or +NR (as in N substituted pyrrolidinyl).
[0029] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group
may be mono– or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. [0030] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined. [0031] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein. [0032] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from halogen; –(CH2)0–4R ^; –(CH2)0–4OR ^; -O(CH2)0-4Ro, –O–(CH2)0– 4C(O)OR°; –(CH2)0–4CH(OR ^)2; –(CH2)0–4SR ^; –(CH2)0–4Ph, which may be substituted with R°; –(CH2)0–4O(CH2)0–1Ph which may be substituted with R°; –CH=CHPh, which may be substituted with R°; –(CH2)0–4O(CH2)0–1-pyridyl which may be substituted with R°; –NO2; –CN; – N3; -(CH2)0–4N(R ^)2; –(CH2)0–4N(R ^)C(O)R ^; –N(R ^)C(S)R ^; –(CH2)0– 4N(R ^)C(O)NR ^2; -N(R ^)C(S)NR ^2; –(CH2)0–4N(R ^)C(O)OR ^; – N(R ^)N(R ^)C(O)R ^; -N(R ^)N(R ^)C(O)NR ^2; -N(R ^)N(R ^)C(O)OR ^; –(CH2)0–4C(O)R ^; – C(S)R ^; –(CH2)0–4C(O)OR ^; –(CH2)0–4C(O)SR ^; -(CH2)0–4C(O)OSiR ^3; –(CH2)0–4OC(O)R ^; – OC(O)(CH2)0–4SR–, SC(S)SR°; –(CH2)0–4SC(O)R ^; –(CH2)0–4C(O)NR ^2; –C(S)NR ^2; –C(S)SR°; –SC(S)SR°, -(CH2)0–4OC(O)NR ^2; -C(O)N(OR ^)R ^; –C(O)C(O)R ^; –C(O)CH2C(O)R ^; –
C(NOR ^)R ^; -(CH2)0–4SSR ^; –(CH2)0–4S(O)2R ^; –(CH2)0–4S(O)2OR ^; –(CH2)0–4OS(O)2R ^; – S(O)2NR ^2; –S(O)(NR°)R°; –S(O)2N=C(NR°2)2; -(CH2)0–4S(O)R ^; -N(R ^)S(O)2NR ^2; – N(R ^)S(O)2R ^; –N(OR ^)R ^; –C(NH)NR ^2; –P(O)2R ^; -P(O)R ^2; -OP(O)R ^2; –OP(O)(OR ^)2; SiR ^3; –(C1–4 straight or branched alkylene)O–N(R ^)2; or –(C1–4 straight or branched alkylene)C(O)O–N(R ^)2. [0033] Each R ^ is independently hydrogen, C1–6 aliphatic, –CH2Ph, –O(CH2)0–1Ph, -CH2-(5-6 membered heteroaryl ring), or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ^, taken together with their intervening atom(s), form a 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0– 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted by a divalent substituent on a saturated carbon atom of R ^ selected from =O and =S; or each R ^ is optionally substituted with a monovalent substituent independently selected from halogen, – (CH2)0–2R ^, –(haloR ^), –(CH2)0–2OH, –(CH2)0–2OR ^, –(CH2)0–2CH(OR ^)2; -O(haloR ^), –CN, –N3, –(CH2)0–2C(O)R ^, –(CH2)0–2C(O)OH, –(CH2)0–2C(O)OR ^, –(CH2)0–2SR ^, –(CH2)0–2SH, –(CH2)0– 2NH2, –(CH2)0–2NHR ^, –(CH2)0–2NR ^2, –NO2, –SiR ^3, –OSiR ^3, -C(O)SR ^, –(C1–4 straight or branched alkylene)C(O)OR ^, or –SSR ^. [0034] Each R ^ is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5– 6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ^ is unsubstituted or where preceded by halo is substituted only with one or more halogens; or wherein an optional substituent on a saturated carbon is a divalent substituent independently selected from =O, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*, =NOR*, –O(C(R* 2))2–3O–, or – S(C(R*2))2–3S–, or a divalent substituent bound to vicinal substitutable carbons of an “optionally substituted” group is –O(CR*2)2–3O–, wherein each independent occurrence of R* is selected from hydrogen, C1–6 aliphatic or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0035] When R* is C1–6 aliphatic, R* is optionally substituted with halogen, – R ^, -(haloR ^), -OH, –OR ^, –O(haloR ^), –CN, –C(O)OH, –C(O)OR ^, –NH2, –NHR ^, –NR ^2, or –
NO2, wherein each R ^ is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ^ is unsubstituted or where preceded by halo is substituted only with one or more halogens. [0036] An optional substituent on a substitutable nitrogen is independently –R†, –NR†2, – C(O)R†, –C(O)OR†, –C(O)C(O)R†, –C(O)CH2C(O)R†, -S(O)2R†, -S(O)2NR†2, –C(S)NR†2, – C(NH)NR† 2, or –N(R†)S(O)2R†; wherein each R† is independently hydrogen, C1–6 aliphatic, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when R† is C1–6 aliphatic, R† is optionally substituted with halogen, –R ^, -(haloR ^), -OH, –OR ^, –O(haloR ^), – CN, –C(O)OH, –C(O)OR ^, –NH2, –NHR ^, –NR ^ 2, or –NO2, wherein each R ^ is independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ^ is unsubstituted or where preceded by halo is substituted only with one or more halogens. [0037] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other
pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
[0038] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci^alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[0039] Unless otherwise stated, structures depicted herein are also meant to include all isomeric ( e.g ., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
[0040] As used herein, the term “provided compound” refers to any MEK inhibitor genus, subgenus, and/or species set forth herein.
[0041] As used herein, the terms “inhibitor” or “MEK inhibitor” or “MEK antagonist” are defined as a compound that binds to and/or inhibits MEK with measurable affinity. In some embodiments, inhibition in the presence of a MEK inhibitor or a MEK antagonist is observed in a dose-dependent manner. In some embodiments, the measured signal ( e.g ., signaling activity or biological activity) is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% lower than the signal measured with a negative control under comparable conditions. The potency of an inhibitor is usually defined by its IC50 value (half maximal inhibitory concentration or concentration required to inhibit 50% of the agonist response). The lower the IC50 value the greater the potency of the antagonist and the lower the concentration that is required to inhibit the maximum biological response. In certain embodiments, an inhibitor has an IC50 and/or binding constant of less than about 100 mM, less than about 50 mM, less than about 1 mM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
[0042] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change or inhibition in MEK activity between a sample comprising a compound of the present invention, or composition thereof, and MEK, and an equivalent sample comprising MEK, in the absence of said compound, or composition thereof.
[0043] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.
[0044] As used herein, the term “treating” includes any effect, e.g, lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. In some embodiments, treatment can be administered after one or more symptoms have developed. In other embodiments, treatment can be administered in the absence of symptoms. For example,
treatment can be administered to a susceptible individual prior to the onset of symptoms ( e.g ., in light of a history of symptoms and/or in light of genetic or other susceptibility factors).
Treatment can also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.
[0045] The phrases “disorder mediated by MEK” or “disease mediated by MEK” or “MEK- associated disease or disorder,” as used herein, refer to diseases or disorders associated with, or mediated by, MEK or MEK activity. A non-limiting example of a MEK-associated disease or disorder is a MEK-associated cancer.
[0046] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
[0047] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g, Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975],
[0048] As used herein, a “non- ATP competitive” or “ATP non-competitive” MEK inhibitor refers to an inhibitor of MEK that does not bind in the ATP pocket of MEK, or does not displace ATP from the MEK active site, and can form direct contacts when co-bound to the MEK-ATP complex. Non- ATP competitive inhibition by a compound of the invention can be confirmed by art-recognized methods such as enzymology studies, competition assays, biophysical methods, including X-ray co-crystallography. An exemplary non-ATP competitive inhibitor of the invention inhibits recombinant MEK1 or MEK2 with an IC50 of from about 1 nM to about 50 mM. In some embodiments, an exemplary non-ATP competitive inhibitor of the invention inhibits recombinant MEK1 or MEK2 with an IC50 of about 1 nM to about 1000 nM, about 1 mM to about 50 mM, about 1 mM to about 25 mM, about 1 mM to about 10 mM, about 500 nM to about 5 mM, or about 10 nM to about 500 nM,
[0049] An “inhibitor pocket”, as used herein, refers to a structure formed at the interface of the interaction between MEK and KSR or BRAF or CRAF with which an inhibitor of the invention is engaged.
[0050] As used herein, a compound of the invention “allosterically binds an inhibitor pocket” when a compound binds outside the active site, including, for example, outside or adjacent to the ATP-binding site of a kinase.
[0051] As used herein, an “inhibitor-inhibitor pocket complex” describes a species in which an inhibitor of the invention allosterically binds an inhibitor pocket formed at an interaction interface between human MEK (MEKl or MEK2) and human Kinase Suppressor of Ras (KSR1, KSR2, or the KSR homolog BRAF or CRAF) adjacent to ATP in a physiological complex between MEK and KSR.
[0052] As used herein, when a moiety on an inhibitor “engages” an amino acid residue of MEK and/or KSR and/or BRAF or CRAF in an inhibitor pocket, this interaction is detectable by X-ray crystallography, or similar structural methods, such as cryo-electron microscopy, NMR, or in silico docking, including fragment binding and computational simulations, which demonstrates that the interaction defining the engagement is a separation between the inhibitor moiety and the amino acid residue of not more than about 8 A, including, for example, from about 2 A to about 5 A, or from about 5 A to about 8 A. The distances provided herein allow for the implicit inclusion of hydrogen atoms, however, hydrogen atoms were not included in the present crystallographic models, which is appropriate unless crystals diffract to very high resolutions (i.e., better than 1.5 Angstroms). Literature surveys of drug-receptor atom pairs across all structures in the protein data bank have used 4-5 Angstrom distance cutoffs (PMID 29308120, 26517868, 19221587) to evaluate reasonable small molecule hydrophobic bonding interactions and have found that intermolecular carbon-carbon interactions similar to the trametinib-KSR contacts are among the most highly represented drug-receptor atom pairs within the protein data bank. With respect to the interactions between the inhibitors of the invention and the MEK -KSR and/or BRAF or CRAF complex, a 4 Angstrom contact is reasonable based on the nature of the trametinib-KSR interaction and precedence of known drug-receptor complexes. This contact is within the range of known contacts as defined by several independent groups (PMID 29308120, 26517868, 19221587),
3. Description of Exemplary Embodiments:
[0053] In one aspect, the present invention provides a compound of Formula (G):
or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from:
each == independently represents a single bond or a double bond; each R1 is independently H, halogen, -CN, or optionally substituted Ci-6 aliphatic;
X is C, CH, orN;
Y is CR6, C(O), orN;
L’ is a covalent bond, -0-, -C(R9)2-, or -NR8-; each of R2, R5, and R8 is independently H or optionally substituted Ci-6 aliphatic; each of R3, R4, R6, and R9 is independently H, halogen, or optionally substituted Ci-6 aliphatic; Ring B is an optionally substituted ring selected from a 3-8 membered monocyclic carbocyclic ring, a 3-8 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a 5-11 membered bicyclic carbocyclic ring, a 5-11 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S, a
phenyl ring, a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-11 membered bicyclic aromatic ring, and a 8-11 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S; L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, - N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, - S(O)2-N(R)-, -P(O)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S; R7 is R, -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)- N(R)2, -C(O)-R, -S(O)-R, -N(R)2, -OR, -SR, o ; each R is independently H, -CN, or optionally subs phatic; and
n is 0, 1, 2, 3, 4, or 5. [0054] In one aspect, the present invention provides a compound of Formula (I’):
or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from: R3 R3 ;
each R1 is independently H, halogen, -CN, or optionally substituted C1-6 aliphatic; X is C, CH, or N; Y is CR6, C(O), or N; each of R2, R3, R4, R5, R6, and R8 is independently H or optionally substituted C1-6 aliphatic; Ring B is an optionally substituted ring selected from a 3-8 membered monocyclic carbocyclic ring, a 3-8 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a 5-11 membered bicyclic carbocyclic ring, a 5-11 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S, a phenyl ring, a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-11 membered bicyclic aromatic ring, and a 8-11 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S; L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, - N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, - S(O)2-N(R)-, -P(O)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S;
R7 is R, -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)- N(R)2, -C(O)-R, -S(O)-R, -N(R)2, -OR, -SR , or a fluorescent probe; each R is independently H, -CN, or optionally su aliphatic; and
n is 0, 1, 2, 3, 4, or 5. [0055] In one aspect, the present invention provides a compound of Formula (I): or a pharmaceutically acceptabl
Ring A is selected from: R3 R3 a double bond;
each R1 is independently H, halogen, -CN, or optionally substituted C1-6 aliphatic; X is C or N; Y is CR6, C(O), or N; each of R2, R3, R4, R5, and R6 is independently H or optionally substituted C1-6 aliphatic; Ring B is an optionally substituted ring selected from a phenyl ring, a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-10
membered bicyclic aromatic ring, and a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S; L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, - N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -P(O)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S; R7 is -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)-N(R)2, -C(O)-R, -N(R)2, -OR, -SR, o each R is independently H, -CN, o ted C1-6 aliphatic; and
n is 0, 1, 2, 3, 4, or 5. [0056] As defined generally above, Ring A is an optionally substituted 6-membered ring R3 R3 selected f , wherein each of R3 and R4 is independe
[0057] In some embodiments, Ring A is an optionally substituted 6-membered ring selected R3 R3 N from , wherein each of R3 and R4 is inde
[0058] In some embodiments, Ring A is an optionally substituted 6-membered ring selected R3 R3 N from , wherein each of R
R3 N [0059] In some embodiments, Ring A i , wherein each of R3 and R4 is independently as defined and described in emb n. In some embodiments, Ring A is
.
R3 [0060] In some embodiments, Ring A i , wherein each of R3 and R4 is independently as defined and described in emb in. In some embodiments, Ring A is
[0061] In some embodiments, Ring A , wherein R3 is as defined and described
in embodiments herein. In some embodiments, Ring A
[0062] In some embodiments, Rin .
[0063] In some embodiments, Rin , wherein each of R3 and R4 is as defined
and described in embodiments herein. In some embodiments, Rin . [0064] In some embodiments, Ring A is selected from those d
, below. [0065] As defined generally above, each independently represents a single bond or a double bond. [0066] In some embodiments, represents a single bond. In some embodiments, represents a double bond. [0067] In some embodiments, is selected from those depicted in Table 1, below. [0068] As defined generally above, R1 is H, halogen, -CN, or optionally substituted C1-6 aliphatic. [0069] In some embodiments, R1 is H. [0070] In some embodiments, R1 is halogen. In some embodiments, R1 is F. In some embodiments, R1 is Cl. In some embodiments, R1 is Br. In some embodiments, R1 is I. [0071] In some embodiments, R1 is -CN. [0072] In some embodiments, R1 is optionally substituted C1-6 aliphatic. In some embodiments, R1 is optionally substituted C1-6 alkyl. In some embodiments, R1 is C1-6 aliphatic substituted 1-6 times by halogen. In some embodiments, R1 is C1-6 alkyl substituted 1-6 times by halogen. In some embodiments, R1 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R1 is cyclopropyl. In some embodiments, R1 is -CH=CH. In some embodiments, R1 is . In some embodiments, R1 is . In some embodiments, R1 is -CH2F, -CHF2, or -CF3. [0073] In some embodiments, R1 is selected from those depicted in Table 1, below. [0074] As defined generally above, X is C or N.
[0075] In some embodiments, X is C. In some embodiments, X is CH. In some embodiments, X is N. [0076] In some embodiments, X is selected from those depicted in Table 1, below. [0077] As defined generally above, Y is CR6, C(O), or N. [0078] In some embodiments, Y is CR6, wherein R6 is as defined and described in embodiments herein. In some embodiments, Y is C(O). In some embodiments, Y is N. [0079] In some embodiments, Y is selected from those depicted in Table 1, below. [0080] As defined generally above, L’ is a covalent bond, -O-, -C(R9)2-, or -NR8-, wherein in R8 is as defined and described in embodiments herein. [0081] In some embodiments, L’ is a covalent bond. In some embodiments, L’ is -O-. In some embodiments, L’ is -C(R9)2-. In some embodiments, L’ is -CH2-. In some embodiments, L’ is -NR8-. In some embodiments, L’ is -NH-. [0082] In some embodiments, L’ is selected from those depicted in Table 1, below. [0083] As defined generally above, each of R2, R3, R4, R5, and R6 is independently H or optionally substituted C1-6 aliphatic. [0084] In some embodiments, R2 is H or optionally substituted C1-6 aliphatic. In some embodiments, R2 is H. In some embodiments, R2 is optionally substituted C1-6 aliphatic. In some embodiments, R2 is optionally substituted C1-6 alkyl. In some embodiments, R2 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R2 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R2 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R2 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R2 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R2 is cyclopropyl. In some embodiments, R2 is -CH=CH2. In some embodiments, R2 is . In some embodiments, R2 is . In some embodiments, R2 is -CH2F, -CHF2, or -CF3. [0085] In some embodiments, R3 is H, halogen, or optionally substituted C1-6 aliphatic. In some embodiments, R3 is H or optionally substituted C1-6 aliphatic. In some embodiments, R3 is H. In some embodiments, R3 is halogen. In some embodiments, R3 is -F. In some embodiments, R3 is -Cl. In some embodiments, R3 is -I. In some embodiments, R3 is optionally substituted C1-6 aliphatic. In some embodiments, R3 is optionally substituted C1-6 alkyl. In some embodiments, R3 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R3 is C1-6
alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R3 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R3 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R3 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R3 is cyclopropyl. In some embodiments, R3 is -CH=CH2. In some embodiments, R3 is . In some embodiments, R3 is . In some embodiments, R3 is -CH2F, -CHF2, or -CF3. [0086] In some embodiments, R4 is H, halogen, or optionally substituted C1-6 aliphatic. In some embodiments, R4 is H or optionally substituted C1-6 aliphatic. In some embodiments, R4 is H. In some embodiments, R4 is halogen. In some embodiments, R4 is -F. In some embodiments, R4 is -Cl. In some embodiments, R4 is -I. In some embodiments, R4 is optionally substituted C1-6 aliphatic. In some embodiments, R4 is optionally substituted C1-6 alkyl. In some embodiments, R4 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R4 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R4 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R4 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R4 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R4 is cyclopropyl. In some embodiments, R4 is -CH=CH2. In some embodiments, R4 is . In some embodiments, R4 is . In some embodiments, R4 is -CH2F, -CHF2, or -CF3. [0087] In some embodiments, R5 is H or optionally substituted C1-6 aliphatic. In some embodiments, R5 is H. In some embodiments, R5 is optionally substituted C1-6 aliphatic. In some embodiments, R5 is optionally substituted 3, 4, 5, or 6 membered saturated or unsaturated carbocyclyl. In some embodiments, R5 is optionally substituted C1-6 alkyl. In some embodiments, R5 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R5 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R5 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R5 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R5 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R5 is cyclopropyl. In some embodiments, R5 is -CH=CH2. In some embodiments, R5 is . In some embodiments, R5 is . In some
embodiments, R5 is -CH2F, -CHF2, or -CF3. In some embodiments, R5 i . In some
embodiments, R5 i , or .
some embodiments, R6 is H, halogen, or optionally substituted C1-6 aliphatic. In some embodiments, R6 is H or optionally substituted C1-6 aliphatic. In some embodiments, R6 is H. In some embodiments, R6 is halogen. In some embodiments, R6 is -F. In some embodiments, R6 is -Cl. In some embodiments, R6 is -I. In some embodiments, R6 is optionally substituted C1-6 aliphatic. In some embodiments, R6 is optionally substituted C1-6 alkyl. In some embodiments, R6 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R6 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R6 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R6 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R6 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R6 is cyclopropyl. In some embodiments, R6 is -CH=CH2. In some embodiments, R6 is . In some embodiments, R6 is . In some embodiments, R6 is -CH2F, -CHF2, or -CF3. [0089] In some embodiments, R8 is H or optionally substituted C1-6 aliphatic. In some embodiments, R8 is H. In some embodiments, R8 is optionally substituted C1-6 aliphatic. In some embodiments, R8 is optionally substituted C1-6 alkyl. In some embodiments, R8 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R8 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R8 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R8 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R8 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R8 is cyclopropyl. In some embodiments, R8 is -CH=CH2. In some embodiments, R8 is . In some embodiments, R8 is . In some embodiments, R8 is -CH2F, -CHF2, or -CF3. In some embodiments, R8 is selected from those depicted in Table 1, below. [0090] In some embodiments, R9 is H, halogen, or optionally substituted C1-6 aliphatic. In some embodiments, R9 is H or optionally substituted C1-6 aliphatic. In some embodiments, R9 is H. In some embodiments, R9 is halogen. In some embodiments, R9 is -F. In some embodiments, R9 is -Cl. In some embodiments, R9 is -I. In some embodiments, R9 is optionally substituted C1-6
aliphatic. In some embodiments, R9 is optionally substituted C1-6 alkyl. In some embodiments, R9 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R9 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R9 is C1-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R9 is C1-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R9 is methyl, ethyl, propyl, or isopropyl. In some embodiments, R9 is cyclopropyl. In some embodiments, R9 is -CH=CH2. In some embodiments, R9 is . In some embodiments, R9 is . In some embodiments, R9 is -CH2F, -CHF2, or -CF3. In some embodiments, R9 is selected from those depicted in Table 1, below. [0091] In some embodiments, each of R2, R3, R4, R5, and R6 is independently selected from those depicted in Table 1, below. [0092] As defined generally above, Ring B is an optionally substituted ring selected from a phenyl ring, a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-10 membered bicyclic aromatic ring, and a 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S. [0093] In some embodiments, Ring B is an optionally substituted ring selected from a 3-8 membered monocyclic carbocyclic ring, a 3-8 membered monocyclic heterocyclic ring having 1- 3 heteroatoms independently selected from N, O, or S, a 5-11 membered bicyclic carbocyclic ring, a 5-11 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S, a phenyl ring, a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-11 membered bicyclic aromatic ring, and a 8-11 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S. [0094] In some embodiments, Ring B is an optionally substituted phenyl ring. [0095] In some embodiments, Ring B is an optionally substituted 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an optionally substituted 5 membered heteroaromatic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an optionally substituted 5 membered heteroaromatic ring selected from ,
and H
which is substituted by a methyl group. In some embodiments, Ring B is an optionally substituted 5 membered heteroaromatic ring selected from
. In some embodiments, Ring B is an optionally substituted 6 membered heteroaromatic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an
[0096] In some embodiments, Ring B is an optionally substituted 8, 9, or 10 membered bicyclic aromatic ring. In some embodiments, Ring B is an optionally substituted 11 membered bicyclic aromatic ring.
[0097] In some embodiments, Ring B is an optionally substituted 8, 9, or 10 membered bicyclic heteroaromatic ring having 1, 2, 3, 4, or 5 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an optionally substituted 11 membered bicyclic heteroaromatic ring having 1, 2, 3, 4, or 5 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an optionally substituted 9 membered bicyclic heteroaromatic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an optionally substituted 11 membered bicyclic heteroaromatic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is an optionally substituted 9 membered bicyclic heteroaromatic ring selected from
In some
ng , ents,
.
nally substituted 3, 4, 5, 6, 7, or 8 membered monocyclic carbocyclic ring. In some embodiments, Ring B is . [0099] In some embodiments, Ring B is an optionally
ted 3, 4, 5, 6, 7, or 8 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B is . [00100] In some embodiments, Ring B is an optionally substituted 5, 6, 7, 8, 9, 10, or 11 membered bicyclic carbocyclic ring. In some embodiments, Ring B is . [00101] In some embodiments, Ring B is an optionally substituted
7, 8, 9, 10, or 11 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S. In some embodiments, Ring B i .
[00102] In some embodiments, Ring B is substituted 1-2 times by halogen. In some embodiments, Ring B is substituted 1-2 times by R, wherein each R is independently as defined and described in embodiments herein. In some embodiments, R is optionally substituted C1-6 alkyl. In some embodiments, R is C1-6 aliphatic substituted 1-6 times by halogen. In some embodiments, R is C1-6 alkyl substituted 1-6 times by halogen. In some embodiments, R is methyl, ethyl, propyl, or isopropyl. In some embodiments, R is cyclopropyl. In some embodiments, R is -CH=CH2. In some embodiments, R is . In some embodiments, R is . In some embodiments, R is -CH2F, -CHF2, or -CF3. [00103] In some embodiments, Ring B is selected from those depicted in Table 1, below. [00104] As defined generally above, L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, -N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(O)2-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. [00105] In some embodiments, L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, -N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, -S(O)2-N(R)-, -P(O)(OR)-, or -Cy-. [00106] In some embodiments, L is a covalent bond. [00107] In some embodiments, L is a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - O-, -S-, -N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)- , -C(O)-, -S(O)2-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. In some embodiments, L is a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -N(R)-, -CH(R)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(O)2-, - P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. In some embodiments, R is hydrogen. In some embodiments, R is methyl. In some embodiments, R is -CN. In some embodiments, L is a C1-10 bivalent straight or branched
hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, -N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, -S(O)2-N(R)-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. In some embodiments, L is a C1- 10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -N(R)-, -CH(R)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, -S(O)2- N(R)-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. The moiety -(CH2-CH2-O)1-10- can be -CH2-CH2-O-, -(CH2- CH2-O)2-, -(CH2-CH2-O)3-, -(CH2-CH2-O)4-, -(CH2-CH2-O)5-, -(CH2-CH2-O)6-, -(CH2-CH2-O)7- , -(CH2-CH2-O)8-, -(CH2-CH2-O)9-, or -(CH2-CH2-O)10-. [00108] In some embodiments, L is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with - O-, -S-, -N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)- , -C(O)-, -S(O)2-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. In some embodiments, L is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -N(R)-, -CH(R)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(O)2-, - P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. In some embodiments, R is hydrogen. In some embodiments, R is methyl. In some embodiments, R is -CN. In some embodiments, L is a C1-6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, -N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, – CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, -S(O)2-N(R)-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. In some embodiments, L is a C1- 6 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -N(R)-, -CH(R)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-,-(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, -S(O)2-
N(R)-, -P(O)(OR)-, or -Cy-, wherein each of R and -Cy- is independently as defined and described in embodiments herein. [00109] In some embodiments, L is selected from -CH2-, -NH-, -S(O)2-, -NH-S(O)2-, -CH2- S(O)2-, -CH2-P(O)(OH)-, -CH(CF3)-, -CH(CF3)-S(O)2-, -NH-C(O)-NH-, -NH-C(O)-, -O-, -O- d
,
[00111] As defined generally above, each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S. [00112] In some embodiments, -Cy- is an optionally substituted 3, 4, 5, 6, or 7 membered carbocyclic ring. [00113] In some embodiments, -Cy- is an optionally substituted 3, 4, 5, 6, or 7 membered heterocyclic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S. In some
embodiments, ,
. In some embodiments, .
ents, -Cy- is an optionally
[00115] In some embodiments, -Cy- is an optionally substituted 5 or 6 membered heteroaromatic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S. In some embodiment . [00116] In som
y- is selected from those depicted in Table 1, below. [00117] As defined generally above, R7 is -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)- ,
[00118] In some embodiments, R7 is R, -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, - .
. In some embodiments, R7 is -CN. In some embodiments, R7 is -S(O)2-N(R)2. In some embodiments, R7 is -S(O)2-NHR. In some embodiments, R7 is -NR-S(O)2-R. In some embodiments, R7 is -NH-S(O)2-R. In some embodiments, R7 is -P(O)(OR)-N(R)2. In some embodiments, R7 is -P(O)(OH)-N(R)2. In some embodiments, R7 is -P(O)(OR)-NHR. In some embodiments, R7 is -P(O)(OH)-NHR. In some embodiments, R7 is -C(=N-R)-N(R)2. In some embodiments, R7 is -C(=N-R)-NHR. In some embodiments, R7 is -C(=N-H)-N(R)2. In some embodiments, R7 is -C(=N-CN)-N(R)2. In some embodiments, R7 is -C(=N-H)-NHR. In some embodiments, R7 is -C(=N-CN)-NHR. In some embodiments, R7 is -C(=N-OR)-N(R)2. In some
embodiments, R7 is -C(=N-OR)-NHR. In some embodiments, R7 is -C(=N-OH)-NHR. In some embodiments, R7 is -C(O)-R. In some embodiments, R7 is -S(O)-R. In some embodiments, R7 is -N(R)2. In some embodiments, R7 is -NHR. In some embodiments, R7 is -OR. In some embodiments, R7 is -SR. In some embodiments, R7 is . In some embodiments, R7 is
. In some embodiments, R is hydrogen. In some embodiments, R is methyl. In some embodiments, R is -CN. ,
or ents, R7 is
H O N S In some
[00121] In some embodiments, R7 is selected from those depicted in Table 1, below.
[00122] As defined generally above, each R is independently H, -CN, or optionally substituted Ci-6 aliphatic.
[00123] In some embodiments, R is H. In some embodiments, R is -CN.
[00124] In some embodiments, R is optionally substituted Ci-6 aliphatic. In some embodiments, R is optionally substituted Ci-6 alkyl. In some embodiments, R is Ci-6 aliphatic substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R is Ci-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by halogen. In some embodiments, R is Ci-6 aliphatic substituted 1, 2, 3,
4, 5, or 6 times by -OH. In some embodiments, R is Ci-6 alkyl substituted 1, 2, 3, 4, 5, or 6 times by -OH. In some embodiments, R is methyl, ethyl, propyl, or isopropyl. In some embodiments, R is cyclopropyl. In some embodiments, R is -CH=CH2. In some embodiments, R is C=CH jn some embodiments, R is C=C-CH3 jn some embodiments, R is -CH2F, -CHF2, or -CF3. [00125] In some embodiments, R is selected from those depicted in Table 1, below.
[00126] As defined generally above, n is 0, 1, 2, 3, 4, or 5.
[00127] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. [00128] In some embodiments, R is selected from those depicted in Table 1, below.
[00129] In some embodiments, the present invention provides a compound of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described in embodiments herein, both singly and in combination.
[00130] In some embodiments, the present invention provides a compound selected from Formulae (Il-a) to (II-o):
or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described in embodiments herein, both singly and in combination.
[00131] In some embodiments, the present invention provides a compound of Formula (III):
or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described in embodiments herein, both singly and in combination.
[00132] In some embodiments, the present invention provides a compound selected from Formulae (Ill-a) to (Ill-e):
or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described in embodiments herein, both singly and in combination.
[00133] In some embodiments, the present invention provides a compound of Formula (IV):
or a pharmaceutically acceptable sa
h variable is as defined above and described in embodiments herein, both singly and in combination. [00134] In some embodiments, the present invention provides a compound selected from Formulae (IV-a) to (IV-e):
or a pharmaceutically acceptable salt thereof, wherein each variable is as defined above and described in embodiments herein, both singly and in combination. Table 1: Exemplary Compounds.
[00135] In some embodiments, the present invention provides a compound set forth in Table 1 above, or a pharmaceutically acceptable salt thereof.
[00136] In some embodiments, the present invention provides a compound selected from the starting materials, intermediates, and products as described in the Examples herein, or a salt thereof.
4. General Methods of Providing the Present Compounds:
[00137] The compounds of this invention may be prepared or isolated in general by synthetic and/or semi-synthetic methods known to those skilled in the art for analogous compounds and by methods described in detail in the Examples, herein.
[00138] In the Schemes below, where a particular protecting group (“PG”), leaving group (“LG”), or transformation condition is depicted, one of ordinary skill in the art will appreciate that other protecting groups, leaving groups, and transformation conditions are also suitable and are contemplated. Such groups and transformations are described in detail in March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 5th Edition, John Wiley & Sons, 2001, Comprehensive Organic Transformations, R. C. Larock, 2nd Edition, John Wiley & Sons, 1999, and Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of each of which is hereby incorporated herein by reference.
[00139] As used herein, the phrase “leaving group” (LG) includes, but is not limited to, halogens ( e.g. , fluoride, chloride, bromide, iodide), sulfonates (e.g, mesylate, tosylate, benzenesulfonate, brosylate, nosylate, triflate), diazonium, and the like.
[00140] As used herein, the phrase “oxygen protecting group” includes, for example, carbonyl protecting groups, hydroxyl protecting groups, etc. Hydroxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, and Philip Kocienski, in “Protecting Groups”, Georg Thieme Verlag Stuttgart, New York, 1994, the entireties of which is incorporated herein by reference. Examples of suitable hydroxyl protecting groups include, but are not limited to, esters, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates.
Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4- oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy- crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9- fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxy carbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-
(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, and 2- and 4-picolyl.
[00141] Amino protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, and Philip Kocienski, in “Protecting Groups”, Georg Thieme Verlag Stuttgart, New York, 1994, the entireties of which is incorporated herein by reference. Suitable amino protecting groups include, but are not limited to, aralkylamines, carbamates, cyclic imides, allyl amines, amides, and the like. Examples of such groups include t-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyl oxocarbonyl (CBZ), allyl, phthalimide, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), formyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, phenylacetyl, trifluoroacetyl, benzoyl, and the like.
[00142] One of skill in the art will appreciate that various functional groups present in compounds of the invention such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens and nitriles can be interconverted by techniques well known in the art including, but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration, and hydration. See, for example, “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entirety of which is incorporated herein by reference. Such
interconversions may require one or more of the aforementioned techniques, and certain methods for synthesizing compounds of the invention are described below.
[00143] In one aspect, certain compounds of the present invention of Formula I, or salts thereof, are generally prepared according to Scheme 1 set forth below:
Scheme 1.
[00144] In Scheme 1 above, LG is a leaving group, and each of the variables, for example, R1, R2, R3, R4, R5, R7, L, n, and Ring B, is as defined above and described in embodiments herein, both singly and in combination.
[00145] As shown generally in Scheme 1, the starting material compound A is converted to compound B, for example by reacting with triphosgene and R5-NH2. Compound B is then
0 0 converted to compound C, for example by a condensation with
and acetic anhydride to form a ring. Compound C is reduced to Compound D, for example by reacting with POCb and
R3NH2. Compound D can be converted to Compound E, for example, by a reaction with O O
, followed by activating the resulting alcohol to form a leaving group, for example by reacting the resulting alcohol with TsCl and a base. Compound E is then converted to
(D- NH2
Compound F, for example, by a coupling reaction with . Compound F can undergo a rearrangement to provide compound G, for example, in a basic condition. Compound G is then converted to Compound H, for example, by reacting with L-R7.
[00146] In some embodiment, the present invention provides a synthesis method as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing compound B from Compound A, as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing compound C from Compound B, as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing compound D from Compound C, as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing Compound E from Compound D, as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing compound F from Compound E, as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing compound G from Compound F, as depicted in Scheme 1, above. In some embodiment, the present invention provides a method of preparing compound H from Compound G, as depicted in Scheme 1, above.
[00147] In some embodiment, the present invention provides a compound selected from Compound A, Compound B, Compound C, Compound D, Compound E, Compound F, Compound G, and Compound H, wherein each variable is as defined above and described in embodiments herein, both singly and in combination.
5. Uses, Formulation and Administration:
Pharmaceutically acceptable compositions
[00148] According to another embodiment, the invention provides a pharmaceutical composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound
in compositions of this invention is such that is effective to measurably inhibit MEK, or a variant or mutant thereof, in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this invention is such that is effective to measurably inhibit MEK, or a variant or mutant thereof, in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.
[00149] As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals ( e.g ., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, humans.
[00150] The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[00151] A “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an active metabolite or residue thereof.
[00152] As used herein, the term "active metabolite or residue thereof' means that a metabolite or residue thereof also inhibits MEK, or a variant or mutant thereof.
[00153] Compositions of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The
term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrastemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
[00154] For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[00155] Pharmaceutically acceptable compositions of this invention can be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and com starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents can also be added.
[00156] Alternatively, pharmaceutically acceptable compositions of this invention can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
[00157] Pharmaceutically acceptable compositions of this invention can also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[00158] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches can also be used.
[00159] For topical applications, provided pharmaceutically acceptable compositions can be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[00160] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions can be formulated in an ointment such as petrolatum.
[00161] Pharmaceutically acceptable compositions of this invention can also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline,
employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[00162] Most preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
[00163] The amount of compounds of the present invention that can be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
[00164] It should also be understood that a specific dosage and treatment regimen for any particular patient depends upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition also depends upon the particular compound in the composition.
Uses of Compounds and Pharmaceutically Acceptable Compositions [00165] In some embodiments, the present invention provides a method of using a compound as described herein for treating a disease or disorder associated with MEK. In some embodiments, a disease or disorder associated with MEK is a proliferative disorder. In some embodiments, a disease or disorder associated with MEK is a cancer. In some embodiments, a disease or disorder associated with MEK is a cancer as described herein.
[00166] In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, of a disease or disorder characterized by or associated with increased MEK expression and/or increased MEK activity, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present
invention, or pharmaceutically acceptable composition thereof. In some aspects and embodiments, provided herein are methods of treating, reducing the severity of, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof of a disease or disorder in which inhibition or antagonizing of MEK activity is beneficial, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable composition thereof.
[00167] In some embodiments, a compound as described herein is an “ATP non-competitive MEK inhibitor” that stabilizes or “glues” the complex formed between MEK and KSR, and/or BRAF/CRAF. In some embodiments, a compound as described herein allosterically binds an “inhibitor pocket” formed at an interaction interface between human MEK (MEK1 or MEK2) and human Kinase Suppressor of Ras (KSR1 or KSR2 or the KSR homolog BRAF or CRAF) adjacent to ATP in a physiological complex between MEK and KSR (or BRAF or CRAF), forming an inhibitor-inhibitor pocket complex. In some embodiments, a compound as described herein is an ATP non-competitive kinase inhibitor. In some embodiments, a compound as described herein has a structure such that when bound to the inhibitor-inhibitor pocket complex, the complex comprises the structural elements: (a) at least one moiety of the inhibitor engaging A825 of hKSRl, or P878 of hKSR2, or R662 of BRAF, or R554 of CRAF (b) at least one moiety engaging R234 of hMEKl or R238 of hMEK2, wherein R234 is within about 5 A to about 8 A from any atoms of hKSRl or hKSR2 or BRAF or CRAF. The structures of complexes described herein, including for example, the MEK and KSR (or BRAF or CRAF) complex, and the inhibitor-inhibitor pocket complex, can be found in WO 2021142345, the content of which is incorporated herein by reference in its entirety. Reference Uniprot sequences for human MEKl, human MEK2, human KSR1, human KSR2, human BRAF, and human CRAF are Uniprot ID Q02750, Uniprot ID P36507, Uniprot ID Q8IVT5, Uniprot ID Q6VAB6, Uniprot ID P15056, and Uniprot ID P04049, respectively.
[00168] In some embodiments, a compound as described herein does not engage one or more of 1216 in hMEKl or 1220 of hMEK2 and A825 in KSR1 or P878 in KSR2. In some embodiments, a compound as described herein comprises a structural element according to (a) as described in the above paragraph, which is an H-bond acceptor, inter alia , an oxygen or nitrogen atom, or a fluorine atom attached to an aromatic ring, or an H bond donor. In some
embodiments, a compound as described herein comprises a structural element according to (a) as described in the above paragraph, which is a moiety of a linker engaging the backbone of A825 of hKSRl, or P878 of hKSR2, or R662 of hBRAF, or R554 of CRAF, directly or through a water-mediated contact.
[00169] In some embodiments, a compound as described herein comprising one or more of the following:
(c) at least one moiety engaging M230 of hMEKl or M234 of hMEK2, wherein M230 or M234 are within about 5 A to about 8 A from terminal atom (CB) of A825 of KSR1 or (CG) of P878 of hKSR2 or (CG) N661 of hBRAF or N553 of CRAF;
(d) at least one moiety is a H-bond acceptor or donor engaging the backbone carbonyl of N823 of hKSRl, or T876 of hKSR2 through a water-mediated contact or backbone amino group of R662 of hBRAF or R554 of hCRAF directly;
(e) at least one moiety engaging Q824 of hKSRl or Q877 of hKSR2 or Q664 of hBRAF or Q556 of hCRAF;
(f) at least one moiety engaging a side chain atom of A826 of hKSRl or A879 of hKSR2 or R662 of BRAF or R554 of CRAF;
(g) at least one moiety is a heteroaryl group engaging Ml 43 of hMEKl or Ml 47 of hMEK2;
(h) at least one moiety is a heteroaryl group engaging F209 of hMEKl or F213 of hMEK2;
(i) at least one moiety {inter alia , a H-bond acceptor) is engaging the backbone amino group of S212 of hMEKl or S216 of hMEK2;
(j) at least one moiety engaging L215 of of hMEKl or L219 of hMEK2;
(k) at least one moiety engaging 1216 of hMEKl or 1220 of hMEK2; and
(l) at least one moiety engaging M219 of hMEKl or M223 of hMEK2 where hMEKl residues 215-219 adopt a helical conformation.
[00170] In some embodiments, a moiety corresponding to (c) as described above is selected from substituted or unsubstituted alkyl or cycloalkyl.
[00171] In some embodiments, a backbone CO residue of a compound as described herein engages with T876 of hKSR2 or N823 of hKSRl.
[00172] In some embodiments, a compound as described herein engages with a binding pocket, which is lined by the hMEKl residues R234 and M230, or hMEK2 residues R238 and M234, and P877 ofKSR2 or A825 ofKSRl orR662 ofBRAF orR554 of CRAF.
[00173] In some embodiments, a compound as described herein engages a binding pocket via multiple hydrogen bond contacts, including through a water mediated H-bond to Argl89 and Arg234 in hMEKl or ARG193 and A238 of hMEK2, as well as a direct H-bond to the backbone of the pre-helix aG loop -NH- of Arg662 ofBRAF or ARG 554 of CRAF.
[00174] In some embodiments, a compound as described herein engage A825 of hKSRl or P878 of hKSR2 or R662 ofBRAF or R554 of CRAF. In some embodiments, a compound as described herein has a distance of less than or equal to about 5 A to about 8 A from at least one moiety selected from A825 of hKSRl, P878 of hKSR2, and R662 ofBRAF and R554 of CRAF. [00175] Accordingly, in some aspects and embodiments, the present invention provides a method for treating one or more disorders, diseases, and/or conditions wherein the disorder, disease, or condition includes, but is not limited to, a cellular proliferative disorder, comprising administering to a patient in need thereof, a MEK inhibitor compound as described herein, or a pharmaceutical salt or composition thereof. In some embodiments, the cellular proliferative disorder is cancer. In some embodiments, the cancer is characterized by increased MEK expression and/or increased MEK activity, i.e., “increased activated MEK.”
[00176] As used herein, the terms "increased," "elevated," or "enhanced," are used interchangeably and encompass any measurable increase in a biological function and/or biological activity and/or a concentration. For example, an increase can be by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3- fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10- fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to a control or baseline amount of a function, or activity, or concentration.
[00177] As used herein, the terms "increased expression" and/or "increased activity" of a substance, such as MEK, in a sample or cancer or patient, refers to an increase in the amount of the substance, such as MEK, of about 5%, about 10%, about 15%, about 20%, about 25%, about
30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6- fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 20-fold, about 25-fold, about 50-fold, about 100-fold, or higher, relative to the amount of the substance, such as MEK, in a control sample or control samples, such as an individual or group of individuals who are not suffering from the disease or disorder ( e.g ., cancer) or an internal control, as determined by techniques known in the art. A subject can also be determined to have an "increased expression" or "increased activity" of MEK if the expression and/or activity of MEK is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations, five standard deviations, or more, relative to the mean (average) or median amount of MEK in a control group of samples or a baseline group of samples or a retrospective analysis of patient samples. As practiced in the art, such control or baseline expression levels can be previously determined, or measured prior to the measurement in the sample or cancer or subject, or can be obtained from a database of such control samples.
Cancer
[00178] In some embodiments, the present invention provides a method for treating or preventing or reducing the risk of a cancer in patient comprising administering to the patient a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[00179] A "cancer," as used herein, refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth divide and grow results in the formation of malignant tumors that invade neighboring tissues and can also metastasize to distant parts of the body through the lymphatic system or bloodstream.
[00180] The cancer or proliferative disorder or tumor to be treated using the compounds and methods and uses described herein include, but are not limited to, a hematological cancer, a lymphoma, a myeloma, a leukemia, a neurological cancer, skin cancer, breast cancer, a prostate cancer, a colorectal cancer, a lung cancer, a head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a bone cancer, renal cancer, and
a vascular cancer. In some embodiments, the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor.
[00181] In some embodiments, the cancer is a K-Ras mutant cancer. In some embodiments, the K-Ras mutant cancer is a K-Ras G12 mutant cancer. In some embodiments, the K-Ras mutant G12 cancer is a K-Ras G12D mutant cancer, K-Ras G12V mutant cancer, K-Ras G12C mutant cancer, K-Ras G12R mutant cancer, or K-Ras G12S mutant cancer. In some embodiments, the K- Ras mutant cancer is a K-Ras G12D mutant cancer. In some embodiments, the K-Ras mutant cancer is a K-Ras G12V mutant cancer. In some embodiments, the K-Ras mutant cancer is a K- Ras G12C mutant cancer. In some embodiments, the cancer is a mutant B-Raf cancer, such as a B-Raf V600E mutant cancer. In some embodiments, the K-Ras mutant cancer is a K-Ras G13 mutant cancer. In some embodiments, the K-Ras mutant cancer is a K-Ras G13D mutant cancer. In some embodiments, the K-Ras mutant cancer is a K-Ras G12R mutant cancer. In some embodiments, the K-Ras mutant cancer is a K-Ras G12S mutant cancer.
[00182] In some embodiments of the methods and uses described herein, the cancer is lung cancer, thyroid cancer, ovarian cancer, colorectal cancer, prostate cancer, cancer of the pancreas, cancer of the esophagus, liver cancer, breast cancer, skin cancer, or mesothelioma. In some embodiments, the cancer is mesothelioma, such as malignant mesothelioma. In some embodiments, a cancer includes, without limitation, leukemias ( e.g ., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin’s disease or non-Hodgkin’s disease), Waldenstrom's macroglobulinemia, multiple myeloma, heavy chain disease, and solid tumors such as sarcomas and carcinomas (e.g, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).
[00183] In some embodiments, a cancer is glioma, astrocytoma, glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, neurofibrosarcoma, meningioma, melanoma, neuroblastoma, or retinoblastoma.
[00184] In some embodiments, a cancer is acoustic neuroma, astrocytoma (e.g. Grade I - Pilocytic Astrocytoma, Grade II - Low-grade Astrocytoma, Grade III - Anaplastic Astrocytoma, or Grade IV - Glioblastoma (GBM)), chordoma, CNS lymphoma, craniopharyngioma, brain stem glioma, ependymoma, mixed glioma, optic nerve glioma, subependymoma, medulloblastoma, meningioma, metastatic brain tumor, oligodendroglioma, pituitary tumors, primitive neuroectodermal (PNET) tumor, or schwannoma. In some embodiments, the cancer is a type found more commonly in children than adults, such as brain stem glioma, craniopharyngioma, ependymoma, juvenile pilocytic astrocytoma (JPA), medulloblastoma, optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor. In some embodiments, the patient is an adult human. In some embodiments, the patient is a child or pediatric patient. [00185] Cancer includes, in another embodiment, without limitation, mesothelioma, hepatobilliary (hepatic and billiary duct), bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, testicular cancer, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney
or ureter, renal cell carcinoma, carcinoma of the renal pelvis, non-Hodgkins’ s lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, multiple myeloma, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma, or a combination of one or more of the foregoing cancers.
[00186] In some embodiments, a cancer is a solid tumor, such as a sarcoma, carcinoma, or lymphoma. Solid tumors generally comprise an abnormal mass of tissue that typically does not include cysts or liquid areas. In some embodiments, the cancer is selected from renal cell carcinoma, or kidney cancer; hepatocellular carcinoma (HCC) or hepatoblastoma, or liver cancer; melanoma; breast cancer; colorectal carcinoma, or colorectal cancer; colon cancer; rectal cancer; anal cancer; lung cancer, such as non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); ovarian cancer, ovarian epithelial cancer, ovarian carcinoma, or fallopian tube cancer; papillary serous cystadenocarcinoma or uterine papillary serous carcinoma (UPSC); prostate cancer; testicular cancer; gallbladder cancer; hepatocholangiocarcinoma; soft tissue and bone synovial sarcoma; rhabdomyosarcoma; osteosarcoma; chondrosarcoma; Ewing sarcoma; anaplastic thyroid cancer; adrenocortical carcinoma; pancreatic cancer; pancreatic ductal carcinoma or pancreatic adenocarcinoma; gastrointestinal/stomach (GIST) cancer; lymphoma; squamous cell carcinoma of the head and neck (SCCHN); salivary gland cancer; glioma, or brain cancer; neurofibromatosis- 1 associated malignant peripheral nerve sheath tumors (MPNST); Waldenstrom’s macroglobulinemia; or medulloblastoma.
[00187] In some embodiments, a cancer is hepatocellular carcinoma (HCC). In some embodiments, the cancer is hepatoblastoma. In some embodiments, the cancer is colon cancer. In some embodiments, the cancer is rectal cancer. In some embodiments, the cancer is ovarian cancer, or ovarian carcinoma. In some embodiments, the cancer is ovarian epithelial cancer. In some embodiments, the cancer is fallopian tube cancer. In some embodiments, the cancer is papillary serous cystadenocarcinoma. In some embodiments, the cancer is uterine papillary serous carcinoma (UPSC). In some embodiments, the cancer is hepatocholangiocarcinoma. In some embodiments, the cancer is soft tissue and bone synovial sarcoma. In some embodiments, the cancer is rhabdomyosarcoma. In some embodiments, the cancer is osteosarcoma. In some embodiments, the cancer is anaplastic thyroid cancer. In some embodiments, the cancer is adrenocortical carcinoma. In some embodiments, the cancer is pancreatic cancer, or pancreatic
ductal carcinoma. In some embodiments, the cancer is pancreatic adenocarcinoma. In some embodiments, the cancer is glioma. In some embodiments, the cancer is malignant peripheral nerve sheath tumors (MPNST). In some embodiments, the cancer is neurofibromatosis- 1 associated MPNST. In some embodiments, the cancer is Waldenstrom’s macroglobulinemia. In some embodiments, the cancer is medulloblastoma.
[00188] In some embodiments, a cancer is a viral-associated cancer, including human immunodeficiency virus (HIV) associated solid tumors, human papillomavirus (HPV)-16 positive incurable solid tumors, and adult T-cell leukemia, which is caused by human T-cell leukemia virus type I (HTLV-I) and is a highly aggressive form of CD4+ T-cell leukemia characterized by clonal integration of HTLV-I in leukemic cells (See https://clinicaltrials.gov/ct2/show/study/ NCT02631746); as well as virus-associated tumors in gastric cancer, nasopharyngeal carcinoma, cervical cancer, vaginal cancer, vulvar cancer, squamous cell carcinoma of the head and neck, and Merkel cell carcinoma. (See https://clinicaltrials.gov/ct2/show/study/NCT02488759; see also https://clinicaltrials.gov/ct2/show/study/NCT0240886; https://clinicaltrials.gov/ct2/show/
NCT02426892)
[00189] In some embodiments, the methods or uses described herein inhibit or reduce or arrest or ameliorate the growth or spread of a cancer or tumor. In some embodiments, the tumor is treated by arresting, reducing, or inhibiting further growth of the cancer or tumor. In some embodiments, the methods or uses described herein increase or potentiate or activate one or more immune responses to inhibit or reduce or arrest or ameliorate the growth or spread of a cancer or tumor. In some embodiments, the cancer or tumor is treated by reducing the size ( e.g ., volume or mass) of the cancer or tumor by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% relative to the size of the cancer or tumor prior to treatment. In some embodiments, cancers or tumors are treated by reducing the quantity of the cancers or tumors in the patient by at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% relative to the quantity of cancers or tumors prior to treatment.
[00190] In some embodiments, a patient treated using the methods or uses described herein exhibits progression-free survival of at least about one month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least
about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about one year, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after the treatment is initiated. In some embodiments, a patient treated using the methods or uses described herein exhibits an overall survival of at least about one month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about one year, at least about 14 months, at least about 16 months, at least about 18 months, at least about 20 months, at least about 22 months, at least about two years, at least about three years, at least about four years, or at least about five years after the treatment is initiated.
[00191] In some embodiments, a patient treated using the methods or uses described herein exhibits an objective response rate (ORR) of at least about 15%, at least about 20%, at least about 25%, at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%. [00192] The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for inhibiting MEK and treating or lessening the severity of a disease, for example, as those described herein. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease or condition, the particular agent, its mode of administration, and the like. Compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the
treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.
[00193] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the disease or disorder being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00194] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[00195] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[00196] Injectable formulations can be sterilized, for example, by filtration through a bacterial- retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. [00197] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide- polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[00198] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00199] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and
glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00200] Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
[00201] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g ., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00202] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable
carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
Co-Administration with One or More Other Therapeutic Agent(s)
[00203] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents that are normally administered to treat that condition, can also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated."
[00204] In some embodiments, the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In some embodiments, the method includes co-administering one additional therapeutic agent. In some embodiments, the method includes co-administering two additional therapeutic agents. In some embodiments, the combination of the disclosed compound and the additional therapeutic agent or agents acts synergistically.
[00205] A compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds.
[00206] One or more other therapeutic agent(s) can be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agent(s) may be part of a single dosage form, mixed together with a
compound of this invention in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent(s) and a compound or composition of the invention can be administered simultaneously, sequentially or within a period of time from one another, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours from one another. In some embodiments, one or more other therapeutic agent(s) and a compound or composition of the invention are administered as a multiple dosage regimen within greater than 24 hours apart.
[00207] As used herein, the term "combination," "combined," and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention can be administered with one or more other therapeutic agent(s) simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, one or more other therapeutic agent(s), and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[00208] The amount of a compound of the invention and one or more other therapeutic agent(s) (in those compositions which comprise an additional therapeutic agent as described above) that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Preferably, a composition of the invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of a compound of the invention can be administered.
[00209] In those compositions which comprise one or more other therapeutic agent(s), the one or more other therapeutic agent(s) and a compound of the invention can act synergistically. Therefore, the amount of the one or more other therapeutic agent(s) in such compositions may be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 g/kg body weight/day of the one or more other therapeutic agent(s) can be administered.
[00210] The amount of one or more other therapeutic agent(s) present in the compositions of this invention may be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of one or more other therapeutic agent(s) in the presently disclosed compositions ranges from about
50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent. In some embodiments, one or more other therapeutic agent(s) is administered at a dosage of about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% of the amount normally administered for that agent. As used herein, the phrase "normally administered" means the amount an FDA approved therapeutic agent is approved for dosing per the FDA label insert.
[00211] The compounds of this invention, or pharmaceutical compositions thereof, can also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with a compound of this invention are another embodiment of the present invention.
Exemplary Other Therapeutic Agents
[00212] In some embodiments, the one or more other therapeutic agent is a TEAD inhibitor.
In certain embodiments, the TEAD inhibitor is selected from those described in WO 2020/243415, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the TEAD inhibitor is selected from those described in WO 2020/243423, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the TEAD inhibitor is selected from those described in US Patent No. 11,247,082, the contents of which are herein incorporated by reference in their entirety.
[00213] TEAD inhibitors can be produced by organic synthesis methods known to one of ordinary skill in the art. Additionally, certain TEAD inhibitors can be prepared as described in Pobbati et al ., "Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy," Structure 2015, 23, 2076-2086; Gibault et al., "Targeting Transcriptional Enhanced Associate Domains (TEADs)," J. Med. Chem. 2018, 61, 5057-5072; Bum-Erdene et al., "Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEADoYap Protein-Protein Interaction," Cell Chemical Biology 2019, 26, 1-12; Holden et al., "Small Molecule Dysregulation of TEAD Lipidation Induces a
Dominant-Negative Inhibition of HippoPathway Signaling," Cell Reports 2020, 31, 107809; WO 2017/053706, WO 2017/111076, WO 2018/204532, WO 2018/235926, US 20190010136, WO 2019/040380, WO 2019/113236, WO 2019/222431, WO 2019/232216, WO 2020/051099, WO 2020/081572, WO 2020/097389, WO 2020/190774, WO 2020/214734, PCT/US2020/35098, and PCT/US2020/35111, the contents of each of which are herein incorporated by reference in its entirety.
[00214] In some embodiments, the one or more other therapeutic agent is an ERK5 inhibitor. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022/051567, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022/051565, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022/051569, the contents of which are herein incorporated by reference in their entirety. In certain embodiments, the ERK5 inhibitor is selected from those described in WO 2022/051568, the contents of which are herein incorporated by reference in their entirety.
[00215] In some embodiments, one or more other therapeutic agent is a Poly ADP ribose polymerase (PARP) inhibitor. In some embodiments, a PARP inhibitor is selected from olaparib (LYNPARZA®, AstraZeneca); rucaparib (RUBRACA®, Clovis Oncology); niraparib (ZEJULA®, Tesaro); talazoparib (MDV3800/BMN 673/LT00673, Medivation/Pfizer/Biomarin); veliparib (ABT-888, Abb Vie); and BGB-290 (BeiGene, Inc.).
[00216] In some embodiments, one or more other therapeutic agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, an HDAC inhibitor is selected from vorinostat (ZOLINZA®, Merck); romidepsin (ISTODAX®, Celgene); panobinostat (FARYDAK®, Novartis); belinostat (BELEODAQ®, Spectrum Pharmaceuticals); entinostat (SNDX-275, Syndax Pharmaceuticals) (NCT00866333); and chidamide (EPIDAZA®, HBI-8000, Chipscreen Biosciences, China).
[00217] In some embodiments, one or more other therapeutic agent is a CDK inhibitor, such as a CDK4/CDK6 inhibitor. In some embodiments, a CDK 4/6 inhibitor is selected from palbociclib (IBRANCE®, Pfizer); ribociclib (KISQALI®, Novartis); abemaciclib (Ly2835219, Eli Lilly); and trilaciclib (G1T28, G1 Therapeutics).
[00218] In some embodiments, one or more other therapeutic agent is a phosphatidylinositol 3 kinase (PI3K) inhibitor. In some embodiments, a PI3K inhibitor is selected from idelalisib (ZYDELIG®, Gilead), alpelisib (BYL719, Novartis), taselisib (GDC-0032, Genentech/Roche); pictilisib (GDC-0941, Genentech/Roche); copanlisib (BAY806946, Bayer); duvelisib (formerly IPI-145, Infinity Pharmaceuticals); PQR309 (Piqur Therapeutics, Switzerland); and TGR1202 (formerly RP5230, TG Therapeutics).
[00219] In some embodiments, one or more other therapeutic agent is a platinum-based therapeutic, also referred to as platins. Platins cause cross-linking of DNA, such that they inhibit DNA repair and/or DNA synthesis, mostly in rapidly reproducing cells, such as cancer cells. [00220] In some embodiments, a platinum-based therapeutic is selected from cisplatin (PLATINOL®, Bristol-Myers Squibb); carboplatin (PARAPLATIN®, Bristol-Myers Squibb; also, Teva; Pfizer); oxaliplatin (ELOXITIN® Sanofi-Aventis); nedaplatin (AQUPLA®, Shionogi), picoplatin (Poniard Pharmaceuticals); and satraplatin (JM-216, Agennix).
[00221] In some embodiments, one or more other therapeutic agent is a taxane compound, which causes disruption of microtubules, which are essential for cell division. In some embodiments, a taxane compound is selected from paclitaxel (TAXOL®, Bristol-Myers Squibb), docetaxel (TAXOTERE®, Sanofi-Aventis; DOCEFREZ®, Sun Pharmaceutical), albumin-bound paclitaxel (ABRAXANE®; Abraxis/Celgene), cabazitaxel (JEVTANA®, Sanofi-Aventis), and SID530 (SK Chemicals, Co.) (NCT00931008).
[00222] In some embodiments, one or more other therapeutic agent is a nucleoside inhibitor, or a therapeutic agent that interferes with normal DNA synthesis, protein synthesis, cell replication, or will otherwise inhibit rapidly proliferating cells.
[00223] In some embodiments, a nucleoside inhibitor is selected from trabectedin (guanidine alkylating agent, YONDELIS®, Janssen Oncology), mechlorethamine (alkylating agent, VALCHLOR®, Aktelion Pharmaceuticals); vincristine (ONCOVIN®, Eli Lilly; VINCASAR®, Teva Pharmaceuticals; MARQIBO®, Talon Therapeutics); temozolomide (prodrug to alkylating agent 5-(3-methyltriazen-l-yl)-imidazole-4-carboxamide (MTIC) TEMODAR®, Merck); cytarabine injection (ara-C, antimetabolic cytidine analog, Pfizer); lomustine (alkylating agent, CEENU®, Bristol-Myers Squibb; GLEOSTINE®, NextSource Biotechnology); azacitidine (pyrimidine nucleoside analog of cytidine, VIDAZA®, Celgene); omacetaxine mepesuccinate
(cephalotaxine ester) (protein synthesis inhibitor, SYNRIBO®; Teva Pharmaceuticals); asparaginase Erwinia chrysanthemi (enzyme for depletion of asparagine, ELSPAR®, Lundbeck; ERWINAZE®, EUSA Pharma); eribulin mesylate (microtubule inhibitor, tubulin-based antimitotic, HALAVEN®, Eisai); cabazitaxel (microtubule inhibitor, tubulin-based antimitotic, JEVTANA®, Sanofi-Aventis); capacetrine (thymidylate synthase inhibitor, XELODA®, Genentech); bendamustine (bifunctional mechlorethamine derivative, believed to form interstrand DNA cross-links, TREANDA®, Cephalon/Teva); ixabepilone (semi-synthetic analog of epothilone B, microtubule inhibitor, tubulin-based antimitotic, IXEMPRA®, Bristol-Myers Squibb); nelarabine (prodrug of deoxyguanosine analog, nucleoside metabolic inhibitor, ARRANON®, Novartis); clorafabine (prodrug of ribonucleotide reductase inhibitor, competitive inhibitor of deoxycytidine, CLOLAR®, Sanofi-Aventis); and trifluridine and tipiracil (thymidine- based nucleoside analog and thymidine phosphorylase inhibitor, LONSEIRF®, Taiho Oncology). [00224] In some embodiments, one or more other therapeutic agent is a kinase inhibitor or VEGF-R antagonist. Approved VEGF inhibitors and kinase inhibitors useful in the present invention include: bevacizumab (AVASTIN®, Genentech/Roche) an anti-VEGF monoclonal antibody; ramucirumab (CYRAMZA®, Eli Lilly), an anti-VEGFR-2 antibody and ziv-aflibercept, also known as VEGF Trap (ZALTRAP®; Regeneron/Sanofi). VEGFR inhibitors, such as regorafenib (STIVARGA®, Bayer); vandetanib (CAPRELSA®, AstraZeneca); axitinib (INLYTA®, Pfizer); and lenvatinib (LENVIMA®, Eisai); Raf inhibitors, such as sorafenib (NEXAVAR®, Bayer AG and Onyx); dabrafenib (TAFINLAR®, Novartis); and vemurafenib (ZELBORAF®, Genentech/Roche); MEK inhibitors, such as cobimetanib (COTELLIC®, Exelexis/Genentech/Roche); trametinib (MEKINIST®, Novartis); Bcr-Abl tyrosine kinase inhibitors, such as imatinib (GLEEVEC®, Novartis); nilotinib (TASIGNA®, Novartis); dasatinib (SPRYCEL®, BristolMyersSquibb); bosutinib (BOSULIF®, Pfizer); and ponatinib (INCLUSIG®, Ariad Pharmaceuticals); Her2 and EGFR inhibitors, such as gefitinib (IRESSA®, AstraZeneca); erlotinib (TARCEEVA®, Genentech/Roche/Astellas); lapatinib (TYKERB®, Novartis); afatinib (GILOTRIF®, Boehringer Ingelheim); osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca); and brigatinib (ALUNBRIG®, Ariad Pharmaceuticals); c-Met and VEGFR2 inhibitors, such as cabozanitib (COMETRIQ®, Exelexis); and multikinase inhibitors, such as sunitinib (SUTENT®, Pfizer); pazopanib (VOTRIENT®, Novartis); ALK inhibitors, such
as crizotinib (XALKORI®, Pfizer); ceritinib (ZYKADIA®, Novartis); and alectinib (ALECENZa®, Genentech/Roche); Bruton’s tyrosine kinase inhibitors, such as ibrutinib (IMBRErVICA®, Pharmacyclics/Janssen); and Flt3 receptor inhibitors, such as midostaurin (RYDAPT®, Novartis).
[00225] Other kinase inhibitors and VEGF-R antagonists that are in development and may be used in the present invention include tivozanib (Aveo Pharmaecuticals); vatalanib (Bayer/Novartis); lucitanib (Clovis Oncology); dovitinib (TKI258, Novartis); Chiauanib (Chipscreen Biosciences); CEP-11981 (Cephalon); linifanib (Abbott Laboratories); neratinib (HKI-272, Puma Biotechnology); radotinib (SUPECT®, IY5511, Il-Yang Pharmaceuticals, S. Korea); ruxolitinib (JAKAFI®, Incyte Corporation); PTC299 (PTC Therapeutics); CP-547,632 (Pfizer); foretinib (Exelexis, GlaxoSmithKline); quizartinib (Daiichi Sankyo) and motesanib ( Amgen/T akeda) .
[00226] In some embodiments, one or more other therapeutic agent is an mTOR inhibitor, which inhibits cell proliferation, angiogenesis and glucose uptake. In some embodiments, an mTOR inhibitor is everolimus (AFINITOR®, Novartis); temsirolimus (TORISEL®, Pfizer); and sirolimus (RAPAMUNE®, Pfizer).
[00227] In some embodiments, one or more other therapeutic agent is a proteasome inhibitor. Approved proteasome inhibitors useful in the present invention include bortezomib (VELCADE®, Takeda); carfilzomib (KYPROLIS®, Amgen); and ixazomib (NINLARO®, Takeda).
[00228] In some embodiments, one or more other therapeutic agent is a growth factor antagonist, such as an antagonist of platelet-derived growth factor (PDGF), or epidermal growth factor (EGF) or its receptor (EGFR). Approved PDGF antagonists which may be used in the present invention include olaratumab (LARTRUVO®; Eli Lilly). Approved EGFR antagonists which may be used in the present invention include cetuximab (ERBITUX®, Eli Lilly); necitumumab (PORTRAZZA®, Eli Lilly), panitumumab (VECTIBIX®, Amgen); and osimertinib (targeting activated EGFR, TAGRISSO®, AstraZeneca).
[00229] In some embodiments, one or more other therapeutic agent is an aromatase inhibitor. In some embodiments, an aromatase inhibitor is selected from exemestane (AROMASIN®, Pfizer); anastazole (ARIMIDEX®, AstraZeneca) and letrozole (FEMARA®, Novartis).
[00230] In some embodiments, one or more other therapeutic agent is an antagonist of the hedgehog pathway. Approved hedgehog pathway inhibitors which may be used in the present invention include sonidegib (ODOMZO®, Sun Pharmaceuticals); and vismodegib (ERIVEDGE®, Genentech), both for treatment of basal cell carcinoma.
[00231] In some embodiments, one or more other therapeutic agent is a folic acid inhibitor. Approved folic acid inhibitors useful in the present invention include pemetrexed (ALIMTA®, Eli Lilly).
[00232] In some embodiments, one or more other therapeutic agent is a CC chemokine receptor 4 (CCR4) inhibitor. CCR4 inhibitors being studied that may be useful in the present invention include mogamulizumab (POTELIGEO®, Kyowa Hakko Kirin, Japan).
[00233] In some embodiments, one or more other therapeutic agent is an isocitrate dehydrogenase (IDH) inhibitor. IDH inhibitors being studied which may be used in the present invention include AG120 (Celgene; NCT02677922); AG221 (Celgene, NCT02677922; NCT02577406); BAY1436032 (Bayer, NCT02746081); IDH305 (Novartis, NCT02987010). [00234] In some embodiments, one or more other therapeutic agent is an arginase inhibitor. Arginase inhibitors being studied which may be used in the present invention include AEB1102 (pegylated recombinant arginase, Aeglea Biotherapeutics), which is being studied in Phase 1 clinical trials for acute myeloid leukemia and myelodysplastic syndrome (NCT02732184) and solid tumors (NCT02561234); and CB-1158 (Calithera Biosciences).
[00235] In some embodiments, one or more other therapeutic agent is a glutaminase inhibitor. Glutaminase inhibitors being studied which may be used in the present invention include CB-839 (Calithera Biosciences).
[00236] In some embodiments, one or more other therapeutic agent is an antibody that binds to tumor antigens, that is, proteins expressed on the cell surface of tumor cells. Approved antibodies that bind to tumor antigens which may be used in the present invention include rituximab (RITUXAN®, Genentech/Biogenldec); ofatumumab (anti-CD20, ARZERRA®, GlaxoSmithKline); obinutuzumab (anti-CD20, GAZYVA®, Genentech), ibritumomab (anti- CD20 and Yttrium-90, ZEVALIN®, Spectrum Pharmaceuticals); daratumumab (anti-CD38, DARZALEX®, Janssen Biotech), dinutuximab (anti-glycolipid GD2, UNITUXIN®, United Therapeutics); trastuzumab (anti-HER2, HERCEPTIN®, Genentech); ado-trastuzumab emtansine
(anti-HER2, fused to emtansine, KADCYLA®, Genentech); and pertuzumab (anti-HER2, PERJETA®, Genentech); and brentuximab vedotin (anti-CD30-drug conjugate, ADCETRIS®, Seattle Genetics).
[00237] In some embodiments, one or more other therapeutic agent is a topoisomerase inhibitor. Approved topoisomerase inhibitors useful in the present invention include irinotecan (ONIVYDE®, Merrimack Pharmaceuticals); topotecan (HYCAMTIN®, GlaxoSmithKline). Topoisomerase inhibitors being studied which may be used in the present invention include pixantrone (PIXUVRI®, CTI Biopharma).
[00238] In some embodiments, one or more other therapeutic agent is an inhibitor of anti- apoptotic proteins, such as BCL-2. Approved anti-apoptotics which may be used in the present invention include venetoclax (VENCLEXTA®, AbbVie/Genentech); and blinatumomab (BLINCYTO®, Amgen). Other therapeutic agents targeting apoptotic proteins which have undergone clinical testing and may be used in the present invention include navitoclax (ABT-263, Abbott), a BCL-2 inhibitor (NCT02079740).
[00239] In some embodiments, one or more other therapeutic agent is an androgen receptor inhibitor. Approved androgen receptor inhibitors useful in the present invention include enzalutamide (XTANDI®, Astellas/Medivation); approved inhibitors of androgen synthesis include abiraterone (ZYTIGA®, Centocor/Ortho); approved antagonist of gonadotropin-releasing hormone (GnRH) receptor (degaralix, FIRMAGON®, Ferring Pharmaceuticals).
[00240] In some embodiments, one or more other therapeutic agent is a selective estrogen receptor modulator (SERM), which interferes with the synthesis or activity of estrogens. Approved SERMs useful in the present invention include raloxifene (EVISTA®, Eli Lilly). [00241] In some embodiments, one or more other therapeutic agent is an inhibitor of bone resorption. An approved therapeutic which inhibits bone resorption is Denosumab (XGEVA®, Amgen), an antibody that binds to RANKL, prevents binding to its receptor RANK, found on the surface of osteoclasts, their precursors, and osteoclast-like giant cells, which mediates bone pathology in solid tumors with osseous metastases. Other approved therapeutics that inhibit bone resorption include bisphosphonates, such as zoledronic acid (ZOMETA®, Novartis).
[00242] In some embodiments, one or more other therapeutic agent is an inhibitor of interaction between the two primary p53 suppressor proteins, MDMX and MDM2. Inhibitors of p53
suppression proteins being studied which may be used in the present invention include ALRN- 6924 (Aileron), a stapled peptide that equipotently binds to and disrupts the interaction of MDMX and MDM2 with p53. ALRN-6924 is currently being evaluated in clinical trials for the treatment of AML, advanced myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL) (NCT02909972; NCT02264613).
[00243] In some embodiments, one or more other therapeutic agent is an inhibitor of transforming growth factor-beta (TGF-beta or TGF-b). Inhibitors of TGF-beta proteins being studied which may be used in the present invention include NIS793 (Novartis), an anti-TGF-beta antibody being tested in the clinic for treatment of various cancers, including breast, lung, hepatocellular, colorectal, pancreatic, prostate and renal cancer (NCT 02947165). In some embodiments, the inhibitor of TGF-beta proteins is fresolimumab (GC1008; Sanofi-Genzyme), which is being studied for melanoma (NCT00923169); renal cell carcinoma (NCT00356460); and non-small cell lung cancer (NCT02581787). Additionally, in some embodiments, the additional therapeutic agent is a TGF-beta trap, such as described in Connolly et al. (2012) IntT J. Biological Sciences 8:964-978. One therapeutic compound currently in clinical trials for treatment of solid tumors is M7824 (Merck KgaA - formerly MSB0011459X), which is a bispecific, anti-PD- Ll/TGF-b trap compound (NCT02699515); and (NCT02517398). M7824 is comprised of a fully human IgGl antibody against PD-L1 fused to the extracellular domain of human TGF-beta receptor II, which functions as a TGF-b “trap.”
[00244] In some embodiments, one or more other therapeutic agent is selected from glembatumumab vedotin-monomethyl auristatin E (MMAE) (Celldex), an anti -gly coprotein NMB (gpNMB) antibody (CR011) linked to the cytotoxic MMAE. gpNMB is a protein overexpressed by multiple tumor types associated with cancer cells’ ability to metastasize.
[00245] In some embodiments, one or more other therapeutic agents is an antiproliferative compound. Such antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or
inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17- DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF 1010, CNF2024, CNFIOIO from Conforma Therapeutics; temozolomide (TEMODAL®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array BioPharma, AZd6244 from AstraZeneca, PD 181461 from Pfizer and leucovorin.
[00246] The term “aromatase inhibitor” as used herein relates to a compound which inhibits estrogen production, for instance, the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name AROMASIN™. Formestane is marketed under the trade name LENTARON™. Fadrozole is marketed under the trade name AFEMA™. Anastrozole is marketed under the trade name ARTMTDEX™ Letrozole is marketed under the trade names FEMARA™ or FEMAr™. Aminoglutethimide is marketed under the trade name ORIMETEN™. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, such as breast tumors.
[00247] The term "antiestrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen is marketed under the trade name NOLVADEX™. Raloxifene hydrochloride is marketed under the trade name EVISTA™. Fulvestrant can be administered under the trade name FASLODEX™Fulvestrant can be administered under the trade name Faslodex™. A combination of the invention comprising a
chemotherapeutic agent which is an anti estrogen is particularly useful for the treatment of estrogen receptor positive tumors, such as breast tumors.
[00248] The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX™). The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin, and goserelin acetate. Goserelin can be administered under the trade name ZOLADEX™
[00249] The term "topoisom erase I inhibitor" as used herein includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be administered, e.g. , in the form as it is marketed, e.g., under the trademark CAMPTOSAR™. Topotecan is marketed under the trade name HYCAMPTIN™.
[00250] The term "topoisom erase II inhibitor" as used herein includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, such as CAELYX™), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name ETOPOPHOS™. Teniposide is marketed under the trade name VM 26-Bristol Doxorubicin is marketed under the trade name ACRIBLASTIN™ or ADRIAMYCIN™. Epirubicin is marketed under the trade name FARMORUBICIN™. Idarubicin is marketed, under the trade name ZAVEDOS™. Mitoxantrone is marketed under the trade name NOVANTRON™. [00251] The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate, and vinorelbine; discodermolides; cochicine and epothilones and derivatives thereof. Paclitaxel is marketed under the trade name TAXOL™. Docetaxel is marketed under the trade name TAXOTERE™. Vinblastine sulfate is marketed under the trade name VINBLASTIN R.P™. Vincristine sulfate is marketed under the trade name FARMISTIN™.
[00252] The term "alkylating agent" as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide
is marketed under the trade name CYCLOSTIN™. Ifosfamide is marketed under the trade name HOLOXAN™
[00253] The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).
[00254] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name XELODA™. Gemcitabine is marketed under the trade name GEMZAR™.
[00255] The term "platin compound" as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g ., in the form as it is marketed, e.g. , under the trademark CARBOPLAT™. Oxaliplatin can be administered, e.g. , in the form as it is marketed, e.g. under the trademark ELOXATIN™.
[00256] The term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti-angiogenic compounds" as used herein includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib, SU101, SU6668 and GFB- 111; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor- receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the kinase activity of IGF-I receptor, or antibodies that target the extracellular domain of IGF-I receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the activity of the
Kit/SCFR receptor tyrosine kinase, such as imatinib; h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases, which are part of the PDGFR family, such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, such as imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products ( e.g ., BCR-Abl kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as an N-phenyl-2-pyrimidine-amine derivative, such as imatinib or nilotinib (AMN107); PD 180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825); j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK/pan-JAK, FAR, PDK1, PKB/Akt, Ras/MAPK, PI3K, SYK, TYK2, BTK and TEC family, and/or members of the cyclin- dependent kinase family (CDK) including staurosporine derivatives, such as midostaurin; examples of further compounds include UCN-01, safmgol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521; LY333531/LY379196; isochinoline compounds; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC™) or tyrphostin such as Tyrphostin A23/RG-50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4- {[(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFRi ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, such as EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, CP 358774, ZD 1839, ZM 105180; trastuzumab (HERCEPTIN™), cetuximab (ERBITUX™), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, El.l, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-
pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF, n) compounds targeting, decreasing or inhibiting the kinase activity of one or more JAK family members (JAK1/JAK2/JAK3/TYK2 and/or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-101348, tofacitinib, and ruxolitinib; o) compounds targeting, decreasing or inhibiting the kinase activity of PI3 kinase (PI3K) including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib; and; and q) compounds targeting, decreasing or inhibiting the signaling effects of hedgehog protein (Hh) or smoothened receptor (SMO) pathways, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib, and IPI-926 (saridegib).
[00257] The term “PI3K inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3 -kinase family, including, but not limited to RI3Ka, RI3Kg, RBKd, RI3Kb, PI3K-C2a, PI3K-C2p, PI3K- C2 g, Vps34, pi 10-a, pi 10-b, pi 10-g, pi 10-d, p85-a, r85-b, r55-g, pl50, plOl, and p87. Examples of PI3K inhibitors useful in this invention include but are not limited to ATU-027, SF-1126, DS- 7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, XL-147, XL-765, and idelalisib.
[00258] The term “Bcl-2 inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including but not limited to ABT-199, ABT-731, ABT-737, apogossypol, Ascenta’s pan-Bcl-2 inhibitors, curcumin (and analogs thereof), dual Bcl-2/Bcl-xL inhibitors (Infinity Pharmaceuticals/Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and analogs thereof; see W02008118802), navitoclax (and analogs thereof, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and analogs thereof, see W02004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ. of Michigan), and venetoclax. In some embodiments the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments the Bcl-2 inhibitor is a peptidomimetic.
[00259] The term “BTK inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against Bruton’s Tyrosine Kinase (BTK), including, but not limited to AVL-292 and ibrutinib.
[00260] The term “SYK inhibitor” as used herein includes, but is not limited to compounds having inhibitory activity against spleen tyrosine kinase (SYK), including but not limited to PRT- 062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.
[00261] Further examples of BTK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02008039218 and WO2011090760, the entirety of which are incorporated herein by reference.
[00262] Further examples of SYK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02003063794, W02005007623, and W02006078846, the entirety of which are incorporated herein by reference. [00263] Further examples of PI3K inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02004019973, W02004089925, W02007016176, US8138347, W02002088112, W02007084786,
W02007129161, W02006122806, W02005113554, and W02007044729 the entirety of which are incorporated herein by reference.
[00264] Further examples of JAK inhibitory compounds, and conditions treatable by such compounds in combination with compounds of this invention can be found in W02009114512, W02008109943, W02007053452, W02000142246, and W02007070514, the entirety of which are incorporated herein by reference.
[00265] Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. , unrelated to protein or lipid kinase inhibition e.g. , thalidomide (THALOMID™) and TNP-470.
[00266] Examples of proteasome inhibitors useful for use in combination with compounds of the invention include, but are not limited to bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.
[00267] Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. , inhibitors of phosphatase 1, phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.
[00268] Compounds which induce cell differentiation processes include, but are not limited to, retinoic acid, a- g- or d- tocopherol or a- g- or d-tocotrienol.
[00269] The term cyclooxygenase inhibitor as used herein includes, but is not limited to, Cox- 2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib ( [00270] CELEBREX™), rofecoxib (VIOXX™), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
[00271] The term "bisphosphonates" as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid. Etridonic acid is marketed under the trade name DIDRONEL™. Clodronic acid is marketed under the trade name BONEFOS™. Tiludronic acid is marketed under the trade name Skelid™. Pamidronic acid is marketed under the trade name AREDIA™. Alendronic acid is marketed under the trade name FOSAMAX™. Ibandronic acid is marketed under the trade name BONDRANAT™. Risedronic acid is marketed under the trade name ACTONEL™. Zoledronic acid is marketed under the trade name ZOMETA™. The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (RAPAMUNE®), everolimus (CERTICAN™), CCI-779 and ABT578.
[00272] The term "heparanase inhibitor" as used herein refers to compounds which target, decrease or inhibit heparin sulfate degradation. The term includes, but is not limited to, PI-88. The term "biological response modifier" as used herein refers to a lymphokine or interferons.
[00273] The term "inhibitor of Ras oncogenic isoforms", such as H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras; for example, a "famesyl transferase inhibitor" such as L-744832, DK8G557 or R115777 (ZARNESTRA ™). The term "telomerase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, such as telomestatin.
[00274] The term "methionine aminopeptidase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which
target, decrease or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or a derivative thereof.
[00275] The term "proteasome inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include, but are not limited to, Bortezomib (VELCADE™) and MLN 341.
[00276] The term "matrix metalloproteinase inhibitor" or ("MMP" inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g ., hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211 , MMI270B or AAJ996.
[00277] The term "compounds used in the treatment of hematologic malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, I-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, which are compounds which target, decrease or inhibit anaplastic lymphoma kinase.
[00278] Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
[00279] The term "HSP90 inhibitors" as used herein includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, such as 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HD AC inhibitors.
[00280] The term "antiproliferative antibodies" as used herein includes, but is not limited to, trastuzumab (HERCEPTIN™), Trastuzumab-DMl, erbitux, bevacizumab (AVASTIN™), rituximab (RTFUXAN®), PR064553 (anti-CD40) and 2C4 Antibody. By antibodies is meant intact
monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity. [00281] For the treatment of acute myeloid leukemia (AML), compounds of the current invention can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of the current invention can be administered in combination with, for example, farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP- 16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
[00282] Other anti-leukemic compounds include, for example, Ara-C, a pyrimidine analog, which is the 2-alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate. Compounds which target, decrease or inhibit activity of histone deacetylase (HD AC) inhibitors such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the activity of the enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065 including, but not limited to, N-hydroxy-3-[4-[[[2-(2-methyl-lH-indol-3-yl)-ethyl]- amino]methyl]phenyl]- 2E-2-propenamide, or a pharmaceutically acceptable salt thereof and N-hydroxy-3-[4-[(2- hydroxyethyl){2-(lH-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt. Somatostatin receptor antagonists as used herein refer to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230. Tumor cell damaging approaches refer to approaches such as ionizing radiation. The term "ionizing radiation" referred to above and hereinafter means ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Heilman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et ah, Eds., 4th Edition, Vol. 1 , pp. 248-275 (1993). [00283] Also included are EDG binders and ribonucleotide reductase inhibitors. The term “EDG binders” as used herein refers to a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720. The term “ribonucleotide reductase inhibitors” refers to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside
(ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2 -hydroxy- lH-isoindole-1 ,3-dione derivatives.
[00284] Also included are in particular those compounds, proteins or monoclonal antibodies of VEGF such as l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, l-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; AN GIO S T ATIN™ ; ENDOSTATIN™; anthranilic acid amides; ZD4190; Zd6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamer such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibody, Angiozyme (RPI 4610) and Bevacizumab (AVASTIN™).
[00285] Photodynamic therapy as used herein refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as VISUDYNE™ and porfimer sodium.
[00286] Angiostatic steroids as used herein refers to compounds which block or inhibit angiogenesis, such as, e.g ., anecortave, triamcinolone, hydrocortisone, 11-a-epihydrocotisol, cortexolone, 17a-hydroxyprogesterone, corticosterone, desoxy corticosterone, testosterone, estrone and dexamethasone.
[00287] Implants containing corticosteroids refers to compounds, such as fluocinolone and dexamethasone.
[00288] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.
[00289] The structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. , Patents International (e.g, IMS World Publications).
Exemplary Immuno-Oncology agents
[00290] In some embodiments, one or more other therapeutic agent is an immuno-oncology agent. As used herein, the term “an immuno-oncology agent” refers to an agent which is effective
to enhance, stimulate, and/or up-regulate immune responses in a subject. In some embodiments, the administration of an immuno-oncology agent with a compound of the invention has a synergic effect in treating a cancer.
[00291] An immuno-oncology agent can be, for example, a small molecule drug, an antibody, or a biologic or small molecule. Examples of biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In some embodiments, an antibody is a monoclonal antibody. In some embodiments, a monoclonal antibody is humanized or human. [00292] In some embodiments, an immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co- inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses. [00293] Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF). One important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to cognate TNF receptor family members, which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/ Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fnl4, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTpR, LIGHT, DcR3, HVEM, VEGETL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2, TNFR1, Lymphotoxin a/TNFp, TNFR2, TNFa, LTpR, Lymphotoxin a1b2, FAS, FASL, RELT, DR6, TROY, NGFR.
[00294] In some embodiments, an immuno-oncology agent is a cytokine that inhibits T cell activation ( e.g ., IL-6, IL-10, TGF-b, VEGF, and other immunosuppressive cytokines) or a cytokine that stimulates T cell activation, for stimulating an immune response.
[00295] In some embodiments, a combination of a compound of the invention and an immuno- oncology agent can stimulate T cell responses. In some embodiments, an immuno-oncology agent is: (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIRl, TIM-1, and TIM-
4; or (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD 137), 4-1BBL, ICOS, ICOS-L, 0X40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.
[00296] In some embodiments, an immuno-oncology agent is an antagonist of inhibitory receptors on NK cells or an agonist of activating receptors on NK cells. In some embodiments, an immuno-oncology agent is an antagonist of KIR, such as lirilumab.
[00297] In some embodiments, an immuno-oncology agent is an agent that inhibits or depletes macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WOl 1/70024, WOl 1/107553, WOl 1/131407, W013/87699, W013/119716, WO13/132044) or FPA-008 (WOl 1/140249; W013169264; WO14/036357).
[00298] In some embodiments, an immuno-oncology agent is selected from agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct immune suppressive pathways within the tumor microenvironment ( e.g ., block inhibitory receptor engagement (e.g, PD-Ll/PD-1 interactions), deplete or inhibit Tregs (e.g, using an anti-CD25 monoclonal antibody (e.g, daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell energy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.
[00299] In some embodiments, an immuno-oncology agent is a CTLA-4 antagonist. In some embodiments, a CTLA-4 antagonist is an antagonistic CTLA-4 antibody. In some embodiments, an antagonistic CTLA-4 antibody is YERVOY (ipilimumab) or tremelimumab.
[00300] In some embodiments, an immuno-oncology agent is a PD-1 antagonist. In some embodiments, a PD-1 antagonist is administered by infusion. In some embodiments, an immuno- oncology agent is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, a PD-1 antagonist is an antagonistic PD-1 antibody. In some embodiments, an antagonistic PD-1 antibody is OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MED 1-0680 (AMP-514; WO2012/145493). In some embodiments, an immuno-oncology agent may be pidilizumab (CT-
Oil). In some embodiments, an immuno-oncology agent is a recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgGl, called AMP -224. [00301] In some embodiments, an immuno-oncology agent is a PD-L1 antagonist. In some embodiments, a PD-L1 antagonist is an antagonistic PD-L1 antibody. In some embodiments, a PD-L1 antibody is MPDL3280A (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS- 936559 (W02007/005874), and MSB0010718C (WO2013/79174).
[00302] In some embodiments, an immuno-oncology agent is a LAG-3 antagonist. In some embodiments, a LAG-3 antagonist is an antagonistic LAG-3 antibody. In some embodiments, a LAG3 antibody is BMS-986016 (W010/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO009/44273).
[00303] In some embodiments, an immuno-oncology agent is a CD137 (4-1BB) agonist. In some embodiments, a CD137 (4-1BB) agonist is an agonistic CD137 antibody. In some embodiments, a CD137 antibody is urelumab or PF-05082566 (W012/32433).
[00304] In some embodiments, an immuno-oncology agent is a GITR agonist. In some embodiments, a GITR agonist is an agonistic GITR antibody. In some embodiments, a GITR antibody is BMS-986153, BMS-986156, TRX-518 (WO006/105021, W0009/009116), or MK- 4166 (WOl 1/028683).
[00305] In some embodiments, an immuno-oncology agent is an indoleamine (2,3)- dioxygenase (IDO) antagonist. In some embodiments, an IDO antagonist is selected from epacadostat (INCB024360, Incyte); indoximod (NLG-8189, NewLink Genetics Corporation); capmanitib (INC280, Novartis); GDC-0919 (Genentech/Roche); PF-06840003 (Pfizer); BMS:F001287 (Bristol-Myers Squibb); Phy906/KD108 (Phytoceutica); an enzyme that breaks down kynurenine (Kynase, Ikena Oncology, formerly known as Kyn Therapeutics); and NLG-919 (W009/73620, WO009/1156652, WOl 1/56652, W012/142237).
[00306] In some embodiments, an immuno-oncology agent is an 0X40 agonist. In some embodiments, an 0X40 agonist is an agonistic 0X40 antibody. In some embodiments, an 0X40 antibody is MEDI-6383 or MEDI-6469.
[00307] In some embodiments, an immuno-oncology agent is an OX40L antagonist. In some embodiments, an OX40L antagonist is an antagonistic 0X40 antibody. In some embodiments, an OX40L antagonist is RG-7888 (WO06/029879).
[00308] In some embodiments, an immuno-oncology agent is a CD40 agonist. In some embodiments, a CD40 agonist is an agonistic CD40 antibody. In some embodiments, an immuno- oncology agent is a CD40 antagonist. In some embodiments, a CD40 antagonist is an antagonistic CD40 antibody. In some embodiments, a CD40 antibody is lucatumumab or dacetuzumab. [00309] In some embodiments, an immuno-oncology agent is a CD27 agonist. In some embodiments, a CD27 agonist is an agonistic CD27 antibody. In some embodiments, a CD27 antibody is varlilumab.
[00310] In some embodiments, an immuno-oncology agent is MGA271 (to B7H3) (WO 11/109400).
[00311] In some embodiments, an immuno-oncology agent is abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, atezolimab, avelumab, blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab, indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, MED14736, MPDL3280A, nivolumab, obinutuzumab, ocaratuzumab, ofatumumab, olatatumab, pembrolizumab, pidilizumab, rituximab, ticilimumab, samalizumab, or tremelimumab.
[00312] In some embodiments, an immuno-oncology agent is an immunostimulatory agent. For example, antibodies blocking the PD-1 and PD-L1 inhibitory axis can unleash activated tumor- reactive T cells and have been shown in clinical trials to induce durable anti-tumor responses in increasing numbers of tumor histologies, including some tumor types that conventionally have not been considered immunotherapy sensitive. See, e.g ., Okazaki, T. et al. (2013) Nat. Immunol. 14, 1212-1218; Zou etal. (2016) Sci. Transl. Med. 8. The anti-PD-1 antibody nivolumab (OPDIVO®, Bristol-Myers Squibb, also known as ONO-4538, MDX1106 and BMS-936558), has shown potential to improve the overall survival in patients with RCC who had experienced disease progression during or after prior anti -angiogenic therapy.
[00313] In some embodiments, the immunomodulatory therapeutic specifically induces apoptosis of tumor cells. Approved immunomodulatory therapeutics which may be used in the present invention include pomalidomide (POMALYST®, Celgene); lenalidomide (REVLIMID®, Celgene); ingenol mebutate (PICATO®, LEO Pharma).
[00314] In some embodiments, an immuno-oncology agent is a cancer vaccine. In some embodiments, the cancer vaccine is selected from sipuleucel-T (PROVENGE®,
Dendreon/Valeant Pharmaceuticals), which has been approved for treatment of asymptomatic, or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer; and talimogene laherparepvec (IMLYGIC®, BioVex/Amgen, previously known as T-VEC), a genetically modified oncolytic viral therapy approved for treatment of unresectable cutaneous, subcutaneous and nodal lesions in melanoma. In some embodiments, an immuno-oncology agent is selected from an oncolytic viral therapy such as pexastimogene devacirepvec (PexaVec/JX-594, SillaJen/formerly Jennerex Biotherapeutics), a thymidine kinase- (TK-) deficient vaccinia virus engineered to express GM-CSF, for hepatocellular carcinoma (NCT02562755) and melanoma (NCT00429312); pelareorep (REOLYSIN®, Oncolytics Biotech), a variant of respiratory enteric orphan virus (reovirus) which does not replicate in cells that are not RAS -activated, in numerous cancers, including colorectal cancer (NCTO 1622543); prostate cancer (NCT01619813); head and neck squamous cell cancer (NCTO 1166542); pancreatic adenocarcinoma (NCT00998322); and non-small cell lung cancer (NSCLC) (NCT 00861627); enadenotucirev (NG-348, PsiOxus, formerly known as ColoAdl), an adenovirus engineered to express a full length CD80 and an antibody fragment specific for the T-cell receptor CD3 protein, in ovarian cancer (NCT02028117); metastatic or advanced epithelial tumors such as in colorectal cancer, bladder cancer, head and neck squamous cell carcinoma and salivary gland cancer (NCT02636036); ONCOS-102 (Targovax/formerly Oncos), an adenovirus engineered to express GM-CSF, in melanoma (NCT03003676); and peritoneal disease, colorectal cancer or ovarian cancer (NCT02963831); GL- ONC1 (GLV-lh68/GLV-lhl53, Genelux GmbH), vaccinia viruses engineered to express beta- galactosidase (beta-gal)/beta-glucoronidase or beta-gal/human sodium iodide symporter (hNIS), respectively, were studied in peritoneal carcinomatosis (NCT01443260); fallopian tube cancer, ovarian cancer (NCT 02759588); or CG0070 (Cold Genesys), an adenovirus engineered to express GM-CSF, in bladder cancer (NCT02365818).
[00315] In some embodiments, an immuno-oncology agent is selected from JX-929 (SillaJen/formerly Jennerex Biotherapeutics), a TK- and vaccinia growth factor-deficient vaccinia virus engineered to express cytosine deaminase, which is able to convert the prodrug 5- fluorocytosine to the cytotoxic drug 5-fluorouracil; TG01 and TG02 (Targovax/formerly Oncos), peptide-based immunotherapy agents targeted for difficult-to-treat RAS mutations; and TILT-123 (TILT Biotherapeutics), an engineered adenovirus designated: Ad5/3-E2F-delta24-hTNFa-IRES-
hIL20; and VSV-GP (ViraTherapeutics) a vesicular stomatitis virus (VSV) engineered to express the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV), which can be further engineered to express antigens designed to raise an antigen-specific CD8+ T cell response.
[00316] In some embodiments, an immuno-oncology agent is a T-cell engineered to express a chimeric antigen receptor, or CAR. The T-cells engineered to express such chimeric antigen receptor are referred to as a CAR-T cells.
[00317] CARs have been constructed that consist of binding domains, which may be derived from natural ligands, single chain variable fragments (scFv) derived from monoclonal antibodies specific for cell-surface antigens, fused to endodomains that are the functional end of the T-cell receptor (TCR), such as the CD3-zeta signaling domain from TCRs, which is capable of generating an activation signal in T lymphocytes. Upon antigen binding, such CARs link to endogenous signaling pathways in the effector cell and generate activating signals similar to those initiated by the TCR complex.
[00318] For example, in some embodiments the CAR-T cell is one of those described in U.S. Patent 8,906,682 (June et a/. ; hereby incorporated by reference in its entirety), which discloses CAR-T cells engineered to comprise an extracellular domain having an antigen binding domain (such as a domain that binds to CD 19), fused to an intracellular signaling domain of the T cell antigen receptor complex zeta chain (such as CD3 zeta). When expressed in the T cell, the CAR is able to redirect antigen recognition based on the antigen binding specificity. In the case of CD 19, the antigen is expressed on malignant B cells. Over 200 clinical trials are currently in progress employing CAR-T in a wide range of indications. [https://clinicaltrials.gov/ct2/results?term=chimeric+antigen+receptors&pg=l].
[00319] In some embodiments, an immunostimulatory agent is an activator of retinoic acid receptor-related orphan receptor g (RORyt). RORyt is a transcription factor with key roles in the differentiation and maintenance of Type 17 effector subsets of CD4+ (Thl7) and CD8+ (Tcl7) T cells, as well as the differentiation of IL-17 expressing innate immune cell subpopulations such as NK cells. In some embodiments, an activator of RORyt is LYC-55716 (Lycera), which is currently being evaluated in clinical trials for the treatment of solid tumors (NCT02929862).
[00320] In some embodiments, an immunostimulatory agent is an agonist or activator of a tolllike receptor (TLR). Suitable activators of TLRs include an agonist or activator of TLR9 such as
SD-101 (Dynavax). SD-101 is an immunostimulatory CpG which is being studied for B-cell, follicular and other lymphomas (NCT02254772). Agonists or activators of TLR8 which may be used in the present invention include motolimod (VTX-2337, VentiRx Pharmaceuticals) which is being studied for squamous cell cancer of the head and neck (NCT02124850) and ovarian cancer (NCT02431559).
[00321] Other immuno-oncology agents that can be used in the present invention include urelumab (BMS-663513, Bristol-Myers Squibb), an anti-CD137 monoclonal antibody; varlilumab (CDX-1127, Celldex Therapeutics), an anti-CD27 monoclonal antibody; BMS-986178 (Bristol- Myers Squibb), an anti-OX40 monoclonal antibody; lirilumab (IPH2102/BMS-986015, Innate Pharma, Bristol-Myers Squibb), an anti -KIR monoclonal antibody; monalizumab (IPH2201, Innate Pharma, AstraZeneca) an anti-NKG2A monoclonal antibody; andecaliximab (GS-5745, Gilead Sciences), an anti-MMP9 antibody; MK-4166 (Merck & Co.), an anti-GITR monoclonal antibody.
[00322] In some embodiments, an immunostimulatory agent is selected from elotuzumab, mifamurtide, an agonist or activator of a toll-like receptor, and an activator of RORyt.
[00323] In some embodiments, an immunostimulatory therapeutic is recombinant human interleukin 15 (rhIL-15). rbll.- l 5 has been tested in the clinic as a therapy for melanoma and renal cell carcinoma (NCT01021059 and NCT01369888) and leukemias (NCT02689453). In some embodiments, an immunostimulatory agent is recombinant human interleukin 12 (rhIL-12). In some embodiments, an IL-15 based immunotherapeutic is heterodimeric IL-15 (hetIL-15, Novartis/ Admune), a fusion complex composed of a synthetic form of endogenous IL-15 complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL15:sIL-15RA), which has been tested in Phase 1 clinical trials for melanoma, renal cell carcinoma, non-small cell lung cancer and head and neck squamous cell carcinoma (NCT02452268). In some embodiments, a recombinant human interleukin 12 (rhIL-12) is NM-IL-12 (Neumedicines, Inc.), NCT02544724, or NCT02542124.
[00324] In some embodiments, an immuno-oncology agent is selected from those descripted in Jerry L. Adams et al ., “Big opportunities for small molecules in immuno-oncology,” Cancer Therapy 2015, Vol. 14, pages 603-622, the content of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is selected from the examples
described in Table 1 of Jerry L. Adams et al. In some embodiments, an immuno-oncology agent is a small molecule targeting an immuno-oncology target selected from those listed in Table 2 of Jerry L. Adams et al. In some embodiments, an immuno-oncology agent is a small molecule agent selected from those listed in Table 2 of Jerry L. Adams et al.
[00325] In some embodiments, an immuno-oncology agent is selected from the small molecule immuno-oncology agents described in Peter L. Toogood, “Small molecule immuno-oncology therapeutic agents,” Bioorganic & Medicinal Chemistry Letters 2018, Vol. 28, pages 319-329, the content of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is an agent targeting the pathways as described in Peter L. Toogood. [00326] In some embodiments, an immuno-oncology agent is selected from those described in Sandra L. Ross et al., “Bispecific T cell engager (BITE® ) antibody constructs can mediate bystander tumor cell killing”, PLoS ONE 12(8): e0183390, the content of which is incorporated herein by reference in its entirety. In some embodiments, an immuno-oncology agent is a bispecific T cell engager (BITE®) antibody construct. In some embodiments, a bispecific T cell engager (BITE®) antibody construct is a CD19/CD3 bispecific antibody construct. In some embodiments, abispecific T cell engager (BITE®) antibody construct is an EGFR/CD3 bispecific antibody construct. In some embodiments, abispecific T cell engager (BITE®) antibody construct activates T cells. In some embodiments, a bispecific T cell engager (BITE®) antibody construct activates T cells, which release cytokines inducing upregulation of intercellular adhesion molecule 1 (ICAM-1) and FAS on bystander cells. In some embodiments, a bispecific T cell engager (BITE®) antibody construct activates T cells which result in induced bystander cell lysis. In some embodiments, the bystander cells are in solid tumors. In some embodiments, the bystander cells being lysed are in proximity to the BITE®-activated T cells. In some embodiment, the bystander cells comprises tumor-associated antigen (TAA) negative cancer cells. In some embodiment, the bystander cells comprise EGFR-negative cancer cells. In some embodiments, an immuno- oncology agent is an antibody which blocks the PD-L1/PD1 axis and/or CTLA4. In some embodiments, an immuno-oncology agent is an ex vivo expanded tumor-infiltrating T cell. In some embodiments, an immuno-oncology agent is a bispecific antibody construct or chimeric antigen receptors (CARs) that directly connect T cells with tumor-associated surface antigens (TAAs).
Exemplary Immune Checkpoint Inhibitors
[00327] In some embodiments, an immuno-oncology agent is an immune checkpoint inhibitor as described herein.
[00328] The term “checkpoint inhibitor” as used herein relates to agents useful in preventing cancer cells from avoiding the immune system of the patient. One of the major mechanisms of anti-tumor immunity subversion is known as “T-cell exhaustion,” which results from chronic exposure to antigens that has led to up-regulation of inhibitory receptors. These inhibitory receptors serve as immune checkpoints in order to prevent uncontrolled immune reactions. [00329] PD-1 and co-inhibitory receptors such as cytotoxic T-lymphocyte antigen 4 (CTLA-4, B and T Lymphocyte Attenuator (BTLA; CD272), T cell Immunoglobulin and Mucin domain-3 (Tim-3), Lymphocyte Activation Gene-3 (Lag-3; CD223), and others are often referred to as a checkpoint regulators. They act as molecular “gatekeepers” that allow extracellular information to dictate whether cell cycle progression and other intracellular signaling processes should proceed.
[00330] In some embodiments, an immune checkpoint inhibitor is an antibody to PD-1. PD-1 binds to the programmed cell death 1 receptor (PD-1) to prevent the receptor from binding to the inhibitory ligand PDL-1, thus overriding the ability of tumors to suppress the host anti -turn or immune response.
[00331] In one aspect, the checkpoint inhibitor is a biologic therapeutic or a small molecule. In another aspect, the checkpoint inhibitor is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof. In a further aspect, the checkpoint inhibitor inhibits a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof. In an additional aspect, the checkpoint inhibitor interacts with a ligand of a checkpoint protein selected from CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands or a combination thereof. In an aspect, the checkpoint inhibitor is an immunostimulatory agent, a T cell growth factor, an interleukin, an antibody, a vaccine or a combination thereof. In a further aspect, the interleukin is IL-7 or IL-15. In a specific
aspect, the interleukin is glycosylated IL-7. In an additional aspect, the vaccine is a dendritic cell (DC) vaccine.
[00332] Checkpoint inhibitors include any agent that blocks or inhibits in a statistically significant manner, the inhibitory pathways of the immune system. Such inhibitors may include small molecule inhibitors or may include antibodies, or antigen binding fragments thereof, that bind to and block or inhibit immune checkpoint receptors or antibodies that bind to and block or inhibit immune checkpoint receptor ligands. Illustrative checkpoint molecules that can be targeted for blocking or inhibition include, but are not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7- H4, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4 (belongs to the CD2 family of molecules and is expressed on all NK, gd, and memory CD8+ (ab) T cells), CD160 (also referred to as BY55), CGEN-15049, CHK 1 and CHK2 kinases, A2aR, and various B-7 family ligands. B7 family ligands include, but are not limited to, B7- 1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7- H4, B7-H5, B7-H6 and B7-H7. Checkpoint inhibitors include antibodies, or antigen binding fragments thereof, other binding proteins, biologic therapeutics, or small molecules, that bind to and block or inhibit the activity of one or more of CTLA-4, PDL1, PDL2, PD1, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD 160 and CGEN-15049. Illustrative immune checkpoint inhibitors include, but are not limited to, Tremelimumab (CTLA-4 blocking antibody), anti-OX40, PD-L1 monoclonal Antibody (Anti-B7-Hl; MEDI4736), MK-3475 (PD-1 blocker), Nivolumab (anti-PDl antibody), CT-011 (anti-PDl antibody), BY55 monoclonal antibody, AMP224 (anti-PDLl antibody), BMS- 936559 (anti-PDLl antibody), MPLDL3280A (anti-PDLl antibody), MSB0010718C (anti-PDLl antibody), and ipilimumab (anti-CTLA-4 checkpoint inhibitor). Checkpoint protein ligands include, but are not limited to PD-L1, PD-L2, B7-H3, B7- H4, CD28, CD86 and TIM-3.
[00333] In certain embodiments, the immune checkpoint inhibitor is selected from a PD-1 antagonist, a PD-L1 antagonist, and a CTLA-4 antagonist. In some embodiments, the checkpoint inhibitor is selected from the group consisting of nivolumab (OPDIVO®), ipilimumab (YERVOY®), and pembrolizumab (KEYTRUDA®). In some embodiments, the checkpoint inhibitor is selected from nivolumab (anti-PD-1 antibody, OPDIVO®, Bristol-Myers Squibb); pembrolizumab (anti-PD-1 antibody, KEYTRUDA®, Merck); ipilimumab (anti-CTLA-4
antibody, YERVOY®, Bristol-Myers Squibb); durvalumab (anti-PD-Ll antibody, IMFINZI®, AstraZeneca); and atezolizumab (anti-PD-Ll antibody, TECENTRIQ®, Genentech).
[00334] In some embodiments, the checkpoint inhibitor is selected from the group consisting of lambrolizumab (MK-3475), nivolumab (BMS-936558), pidilizumab (CT-011), AMP-224, MDX-1105, MEDI4736, MPDL3280A, BMS-936559, ipilimumab, lirlumab, IPH2101, pembrolizumab (KEYTRUDA®), and tremelimumab.
[00335] In some embodiments, an immune checkpoint inhibitor is REGN2810 (Regeneron), an anti-PD-1 antibody tested in patients with basal cell carcinoma (NCT03132636); NSCLC (NCT03088540); cutaneous squamous cell carcinoma (NCT02760498); lymphoma (NCT02651662); and melanoma (NCT03002376); pidilizumab (CureTech), also known as CT- 011, an antibody that binds to PD-1, in clinical trials for diffuse large B-cell lymphoma and multiple myeloma; avelumab (BAVENCIO®, Pfizer/Merck KGaA), also known as MSB0010718C), a fully human IgGl anti-PD-Ll antibody, in clinical trials for non-small cell lung cancer, Merkel cell carcinoma, mesothelioma, solid tumors, renal cancer, ovarian cancer, bladder cancer, head and neck cancer, and gastric cancer; or PDR001 (Novartis), an inhibitory antibody that binds to PD-1, in clinical trials for non-small cell lung cancer, melanoma, triple negative breast cancer and advanced or metastatic solid tumors. Tremelimumab (CP-675,206; Astrazeneca) is a fully human monoclonal antibody against CTLA-4 that has been in studied in clinical trials for a number of indications, including: mesothelioma, colorectal cancer, kidney cancer, breast cancer, lung cancer and non-small cell lung cancer, pancreatic ductal adenocarcinoma, pancreatic cancer, germ cell cancer, squamous cell cancer of the head and neck, hepatocellular carcinoma, prostate cancer, endometrial cancer, metastatic cancer in the liver, liver cancer, large B-cell lymphoma, ovarian cancer, cervical cancer, metastatic anaplastic thyroid cancer, urothelial cancer, fallopian tube cancer, multiple myeloma, bladder cancer, soft tissue sarcoma, and melanoma. AGEN-1884 (Agenus) is an anti-CTLA4 antibody that is being studied in Phase 1 clinical trials for advanced solid tumors (NCT02694822).
[00336] In some embodiments, a checkpoint inhibitor is an inhibitor of T-cell immunoglobulin mucin containing protein-3 (TIM-3). TIM-3 inhibitors that may be used in the present invention include TSR-022, LY3321367 and MBG453. TSR-022 (Tesaro) is an anti-TIM-3 antibody which is being studied in solid tumors (NCT02817633). LY3321367 (Eli Lilly) is an anti-TIM-3
antibody which is being studied in solid tumors (NCT03099109). MBG453 (Novartis) is an anti- TIM-3 antibody which is being studied in advanced malignancies (NCT02608268).
[00337] In some embodiments, a checkpoint inhibitor is an inhibitor of T cell immunoreceptor with Ig and ITIM domains, or TIGIT, an immune receptor on certain T cells and NK cells. TIGIT inhibitors that may be used in the present invention include BMS-986207 (Bristol-Myers Squibb), an anti-TIGIT monoclonal antibody (NCT02913313); OMP-313M32 (Oncomed); and anti-TIGIT monoclonal antibody (NCT03119428).
[00338] In some embodiments, a checkpoint inhibitor is an inhibitor of Lymphocyte Activation Gene-3 (LAG-3). LAG-3 inhibitors that may be used in the present invention include BMS- 986016 and REGN3767 and IMP321. BMS-986016 (Bristol-Myers Squibb), an anti-LAG-3 antibody, is being studied in glioblastoma and gliosarcoma (NCT02658981). REGN3767 (Regeneron), is also an anti-LAG-3 antibody, and is being studied in malignancies (NCT03005782). IMP321 (Immutep S.A.) is an LAG-3-Ig fusion protein, being studied in melanoma (NCT02676869); adenocarcinoma (NCT02614833); and metastatic breast cancer (NCT00349934).
[00339] Checkpoint inhibitors that may be used in the present invention include 0X40 agonists. 0X40 agonists that are being studied in clinical trials include PF-04518600/PF-8600 (Pfizer), an agonistic anti-OX40 antibody, in metastatic kidney cancer (NCT03092856) and advanced cancers and neoplasms (NCT02554812; NCT05082566); GSK3174998 (Merck), an agonistic anti-OX40 antibody, in Phase 1 cancer trials (NCT02528357); MEDI0562 (Medimmune/AstraZeneca), an agonistic anti-OX40 antibody, in advanced solid tumors (NCT02318394 and NCT02705482); MEDI6469, an agonistic anti-OX40 antibody (Medimmune/AstraZeneca), in patients with colorectal cancer (NCT02559024), breast cancer (NCT01862900), head and neck cancer (NCT02274155) and metastatic prostate cancer (NCT01303705); and BMS-986178 (Bristol- Myers Squibb) an agonistic anti-OX40 antibody, in advanced cancers (NCT02737475).
[00340] Checkpoint inhibitors that may be used in the present invention include CD137 (also called 4-1BB) agonists. CD137 agonists that are being studied in clinical trials include utomilumab (PF-05082566, Pfizer) an agonistic anti-CD137 antibody, in diffuse large B-cell lymphoma (NCT02951156) and in advanced cancers and neoplasms (NCT02554812 and NCT05082566); urelumab (BMS-663513, Bristol-Myers Squibb), an agonistic anti-CD137
antibody, in melanoma and skin cancer (NCT02652455) and glioblastoma and gliosarcoma (NCT02658981); and CTX-471 (Compass Therapeutics), an agonistic anti-CD137 antibody in metastatic or locally advanced malignancies (NCT03881488).
[00341] Checkpoint inhibitors that may be used in the present invention include CD27 agonists. CD27 agonists that are being studied in clinical trials include varlilumab (CDX-1127, Celldex Therapeutics) an agonistic anti-CD27 antibody, in squamous cell head and neck cancer, ovarian carcinoma, colorectal cancer, renal cell cancer, and glioblastoma (NCT02335918); lymphomas (NCT01460134); and glioma and astrocytoma (NCT02924038).
[00342] Checkpoint inhibitors that may be used in the present invention include glucocorticoid- induced tumor necrosis factor receptor (GITR) agonists. GITR agonists that are being studied in clinical trials include TRX518 (Leap Therapeutics), an agonistic anti-GITR antibody, in malignant melanoma and other malignant solid tumors (NCT01239134 and NCT02628574); GWN323 (Novartis), an agonistic anti-GITR antibody, in solid tumors and lymphoma (NCT 02740270); INCAGN01876 (Incyte/Agenus), an agonistic anti-GITR antibody, in advanced cancers (NCT02697591 and NCT03126110); MK-4166 (Merck), an agonistic anti-GITR antibody, in solid tumors (NCT02132754) and MEDI1873 (Medimmune/AstraZeneca), an agonistic hexameric GITR-ligand molecule with a human IgGl Fc domain, in advanced solid tumors (NCT02583165). [00343] Checkpoint inhibitors that may be used in the present invention include inducible T- cell co-stimulator (ICOS, also known as CD278) agonists. ICOS agonists that are being studied in clinical trials include MEDI-570 (Medimmune), an agonistic anti-ICOS antibody, in lymphomas (NCT02520791); GSK3359609 (Merck), an agonistic anti-ICOS antibody, in Phase 1 (NCT02723955); JTX-2011 (Jounce Therapeutics), an agonistic anti-ICOS antibody, in Phase 1 (NCT02904226).
[00344] Checkpoint inhibitors that may be used in the present invention include killer IgG-like receptor (KIR) inhibitors. KIR inhibitors that are being studied in clinical trials include lirilumab (IPH2102/BMS-986015, Innate Pharma/Bristol-Myers Squibb), an anti -KIR antibody, in leukemias (NCT01687387, NCT02399917, NCT02481297, NCT02599649), multiple myeloma (NCT02252263), and lymphoma (NCT01592370); IPH2101 (1-7F9, Innate Pharma) in myeloma (NCT01222286 and NCT01217203); and IPH4102 (Innate Pharma), an anti-KIR antibody that binds to three domains of the long cytoplasmic tail (KIR3DL2), in lymphoma (NCT02593045).
[00345] Checkpoint inhibitors that may be used in the present invention include CD47 inhibitors of interaction between CD47 and signal regulatory protein alpha (SIRPa). CD47/SIRPa inhibitors that are being studied in clinical trials include ALX-148 (Alexo Therapeutics), an antagonistic variant of (SIRPa) that binds to CD47 and prevents CD47/SIRPa-mediated signaling, in phase 1 (NCT03013218); TTI-621 (SIRPa-Fc, Trillium Therapeutics), a soluble recombinant fusion protein created by linking the N-terminal CD47-binding domain of SIRPa with the Fc domain of human IgGl, acts by binding human CD47, and preventing it from delivering its “do not eat” signal to macrophages, is in clinical trials in Phase 1 (NCT02890368 andNCT02663518); CC-90002 (Celgene), an anti-CD47 antibody, in leukemias (NCT02641002); and Hu5F9-G4 (Forty Seven, Inc.), in colorectal neoplasms and solid tumors (NCT02953782), acute myeloid leukemia (NCT02678338) and lymphoma (NCT02953509).
[00346] Checkpoint inhibitors that may be used in the present invention include CD73 inhibitors. CD73 inhibitors that are being studied in clinical trials include MEDI9447 (Medimmune), an anti-CD73 antibody, in solid tumors (NCT02503774); and BMS-986179 (Bristol-Myers Squibb), an anti-CD73 antibody, in solid tumors (NCT02754141).
[00347] Checkpoint inhibitors that may be used in the present invention include agonists of stimulator of interferon genes protein (STING, also known as transmembrane protein 173, or TMEM173). Agonists of STING that are being studied in clinical trials include MK-1454 (Merck), an agonistic synthetic cyclic dinucleotide, in lymphoma (NCT03010176); and ADU- S100 (MIW815, Aduro Biotech/Novartis), an agonistic synthetic cyclic dinucleotide, in Phase 1 (NCT02675439 and NCT03172936).
[00348] Checkpoint inhibitors that may be used in the present invention include CSF1R inhibitors. CSF1R inhibitors that are being studied in clinical trials include pexidartinib (PLX3397, Plexxikon), a CSF1R small molecule inhibitor, in colorectal cancer, pancreatic cancer, metastatic and advanced cancers (NCT02777710) and melanoma, non-small cell lung cancer, squamous cell head and neck cancer, gastrointestinal stromal tumor (GIST) and ovarian cancer (NCT02452424); and IMC-CS4 (LY3022855, Lilly), an anti-CSF-lR antibody, in pancreatic cancer (NCT03153410), melanoma (NCT03101254), and solid tumors (NCT02718911); and BLZ945 (4-[2((lR,2R)-2-hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine-2-
carboxylic acid methylamide, Novartis), an orally available inhibitor of CSF1R, in advanced solid tumors (NCT02829723).
[00349] Checkpoint inhibitors that can be used in the present invention include NKG2A receptor inhibitors. NKG2A receptor inhibitors that are being studied in clinical trials include monalizumab (IPH2201, Innate Pharma), an anti-NKG2A antibody, in head and neck neoplasms (NCT02643550) and chronic lymphocytic leukemia (NCT02557516).
[00350] In some embodiments, the immune checkpoint inhibitor is selected from nivolumab, pembrolizumab, ipilimumab, avelumab, durvalumab, atezolizumab, or pidilizumab.
EXEMPLIFICATION
[00351] The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon.
Example 1: SPR Assays
MEK-RAF binding assay
[00352] Compound effects on binding affinity of MEK to BRAF or CRAF are followed by surface plasmon resonance (SPR) with single-cycle kinetic analysis. GST-BRAF or GST-CRAF is immobilized onto a chip and increasing concentrations of His-tagged MEK1 are flowed over the sensor chip. 500 mM ATP is added to the running buffer. The dissociation constant for MEK1 binding to either BRAF or CRAF is calculated in the absence and presence of compound. Instruments are carried out on a BIACORE 8K instrument. Sensorgrams are double-reference and DMSO corrected. Data is fit to a single-cycle kinetic model.
MEK-KSR binding assay
[00353] Compound effects on binding affinity of MEK to KSR1 or KSR2 are followed by surface plasmon resonance (SPR) with single-cycle kinetic analysis. GST-KSR1 or GST-KSR2 is immobilized onto a chip and increasing concentrations of His-tagged MEKl are flowed over the sensor chip. 500 mM ATP is added to the running buffer. The dissociation constant for MEKl binding to either BRAF or CRAF is calculated in the absence and presence of compound. Instruments are carried out on a BIACORE 8K instrument. Sensorgrams are double-reference and DMSO corrected. Data is fit to a single-cycle kinetic model.
MEK1/CRAF Stabilization
[00354] Anti-GST antibodies were immobilized to CM5 chips by amine coupling (GST capture kits from Cytiva). 1 pg/mL GST-CRAF protein (AA 306-548, N-terminal GST fusion, Carna Biosciences, Inc) was captured on this surface with a contact time of 200 seconds at a flow rate of 5 pL/min. Capture buffer was lxPBS, pH 7.4, 10 mM MgCh, 1 mM DTT, 0.01% Tween-20 and 500 pM ATP. The capture level of CRAF was approximately 50 resonance units (RUs).
[00355] His-tagged MEK1 (± compound) was diluted in buffer containing 10 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM MgCh, 1 mM DTT, 0.01% Tween-20, 500 mM ATP and 1% DMSO. Running buffer was lxPBS, 10 mM MgCh, 1 mM DTT, 0.01% Tween-20, 500 mM ATP and 1% DMSO. MEKl was serially diluted three-fold from the top doses of 200 nM with 3 mM compound solution for a total of 5 doses. In each cycle, association time was 60 seconds and dissociation time was 600 seconds with an extra wash of 50% DMSO. Analyte binding was collected at 15°C with a flow rate of 30 pL/min.
[00356] The KD ratio is defined as the (KD of CRAF-MEKl binary complex)/(KD of ternary complex).
Example 2: Immunoprecipitation Assay
[00357] Immunoprecipitation experiments are performed by plating about 450,000 HCT116 cells per well in 6-well plates. Cells are plated for 48 h so as to reach approximately 70% confluency before transfection. Then, 24 h after transfection, cells are treated with vehicle (0.1% DMSO) or a compound (about 200 nM) for 1 h. Cells are washed twice in cold PBS and then transferred to a pre-chilled tube in 0.6 ml of PBS solution. Cells are spun at 1 ,800# in a cold centrifuge for 10 min, and supernatant is aspirated. To lyse cells, pellets are resuspended in NP-40 buffer (50 mM Tris pH 7.8, 100 mM NaCl, 0.5% (v/v) NP-40, 10% (v/v) glycerol, 1 mM EDTA) supplemented with protease and phosphatase inhibitor cocktail (Thermo Fisher, 78440) and incubated on ice for 30 min. Lysates are centrifuged for 20 min at 2,100#, and supernatants are collected. Cleared lysates are quantified using BCA reagent (Pierce, 23225), with BSA as a standard. Five micrograms of rabbit anti-MEKl antibody (Millipore-Sigma, 07-641), or rabbit IgG (Millipore Sigma, 12-370), is immobilized on 50 pi of Sepharose Protein A Resin (Thermo Fisher, 53139) and washed three times in 300 mΐ NP-40 buffer before initiating immunoprecipitations.
[00358] Next, for MEK1 immunoprecipitation, 250 pg of total cell lysate in a total volume of 0.6 ml is mixed with the pre-immobilized anti-MEKl antibody pre-conjugated to Protein A resin. Samples are incubated at 4 °C on an end-over-end rotator for 4 h, followed by three washes in 0.6 ml volume of NP-40 buffer. Next, proteins are denatured and released from resin by the addition of 80 pi volume of lx SDS sample buffer. Samples are boiled at 90 °C for 2 min, spun, and then applied to a 4-12% bis-tris glycine gel (Bio-Rad, 3450125) run in MOPS-SDS buffer (Thermo Fisher, NPOOOl) for 60 min at 150 V. Gels are then transferred onto nitrocellulose in 20% methanol in Tris-glycine buffer (95 V, 250 A). Transfers are confirmed using Ponceau red and then analyzed by western blot. Signals for MEK, Flag-tagged proteins, BRAF, and GAPDH are detected by enhanced chemiluminescence on a ChemDoc XRS+ imaging system (Biorad).
Example 3: Biological Assay for Inhibiting Mouse Xenograft Tumor Growth [00359] Exemplary compounds having MEK inhibitory activity can be tested, alone or in combination with a second anti-cancer agent, such as a TEAD inhibitor or an ERK5 inhibitor, for ability to inhibit tumor growth in patient-derived mouse xenograft models of pancreatic cancer and lung cancer. Assay procedures are described below.
Procedures for Patient-Derived Mouse Xenograft (PDX) Tumor Growth Assay [00360] Balb/c mice (6-8 weeks old) are inoculated subcutaneously in the right flank with a primary human tumor xenograft model tumor fragment (2-3 mm3 in diameter) for tumor development. In one study, mice are inoculated with a human lung adenocarcinoma tumor model (MSCLC, ADC model LU6424) that harbors a BRAF mutation (LU6424); in a second study, mice are inoculated with a human pancreatic tumor model (adenosquamous carcinoma model PA6258) with a K-Ras G12D mutation (PA6258). When mean tumor volume reaches approximately 150- 200 mm3, animals are randomly allocated to appropriate treatment groups. Mice are treated with one of the following: (1) Vehicle control, (2) Exemplary MEK inhibitor alone, (3) Second anticancer agent alone, or (4) Combination of MEK inhibitor and second anti-cancer agent. Tumors are measured twice per week using calipers.
Example 4: Biological Assays pERK HTRF assay
Assay Principle:
[00361] Human AsPc-1 cells or HCT-116 cells are seeded in 384-well culture plates and grown overnight. Cells are pretreated with compound (10-pt titration) for 4 hrs. Then, cell lysates are prepared and assayed for levels of phosphorylated ERK1/2 using a homogeneous TR-FRET assay.
3D CTG viability assay
Assay Principle:
CellTiter-Glo 3D cell viability assay is intended for determining cell viability in 3D cell spheroids. The assay reagent penetrates large spheroids and has increased lytic capacity. It measures ATP as an indicator of viability and generates a luminescent readout. Cell Titer-Glo 3D cell viability assay kit Promega G9683 was used.
Generic protocol for NANOBRET
[00362] The protein: protein interaction of MEK1 and BRAF, MEK1 and CRAF, MEK1 and KSR1, and MEK1 and KSR2 are evaluated using a NANOBRET assay (Promega, Inc. Madison, Wisconsin). The full length open reading frames of each gene pair are either N-terminally or C- terminally fused with the open reading frames of either the NANOLUC® or HALOTAG® coding sequences. Once the vectors are synthesized, empiric evaluation of tag location for each pair determines the optimum signal window. The appropriate NANOLUC® and HALOTAG® chimeric gene fusions are transfected into HEK293 cells (or other cell lines) and cultured in white 96- or 384-well plates suitable for tissue culture and signal evaluation. Ikena compounds are dispensed to the transfected, live cells along with the necessary positive and negative controls. At discrete times the NANOBRET™ NANOLUC® substrate is added and donor and acceptor signals are measured on the Envision Multimode (or other capable instrument). Protein: protein interaction is evaluated by calculating the NANOBRET™ ratio by subtracting the NANOBRET™ ratios of the control samples from the experimental samples. Additionally, expression of these chimeric gene fusions in mammalian, bacterial or yeast protein expression systems can yield recombinant protein that can be used in an in vitro biochemical assay.
MEK1 Kinase Assay Protocol Assay Principle:
It is a coupled assay which includes inactive ERK activation by MEK1 and phosphorylation of ULIGHT-MBP substrate. The phosphorylated substrate captured by an Eu-anti-phospho-substrate antibody, which brings the Eu chelate donor and FLIGHT acceptor dyes into close proximity. Upon excitation at 340 nm, the Eu chelate transfers its energy to the FLIGHT dye, resulting in a fluorescent light emission at 665 nm.
HCT116 ERK/pERK in-cell western assay
[00363] The In-Cell Western (ICW) Assay is a quantitative immunofluorescence assay performed in microplates (optimized for 96- or 384-well format) that combines the specificity of Western blotting with the replicability and throughput of ELISA.
[00364] In-Cell Western Assays are also called cytoblots, cell-based ELISA, In-Cell ELISA (ICE), and FACE (Fast Activated Cell-based ELISA). With In-Cell Western Assays, you can:
• Detect proteins in fixed and permeabilized cultured cells using target-specific primary antibodies and IRDYE® secondary antibodies
• Quantify two targets at 700 nm and 800 nm, using spectrally-distinct infrared dye conjugates
• Quickly, accurately measure relative protein levels in many samples
• Detect proteins in situ in a relevant cellular context
[00365] Tables 2 and 3 show the activity of selected compounds in the assays described above. The compound numbers correspond to the compound numbers in Table 1. The activity is classified as A-D, wherein A represents IC50 < 100 nM; B represents 100 nM < IC50 < 1 uM; C represents 1 < IC50 < 10 uM; and D represents IC50 >10 uM.
Table 2.
Table 3.
[00366] Table 4 shows the activity of selected compounds in the assays described above. The compound numbers correspond to the compound numbers in Table 1. The activity is classified as A-D, wherein A represents IC50 < 100 nM; B represents 100 nM < IC50 < 1 uM; C represents 1 < IC50 < 10 uM; and D represents IC50 >10 uM. The CRaf/MEK SPR: KD Ratio is classified as A- D, wherein A represents KD Ratio < 0.5; B represents 0.5 < KD Ratio < 1; C represents 1 < KD Ratio < 5; and D represents KD Ratio >5.
Table 4.
Example 5: Synthesis of Certain Compounds
General synthesis scheme
[00367] A general synthesis scheme for compounds as described herein is provided above. Additionally, synthesis procedures for certain exemplary compounds are provided below.
1-21
Step 1: /V-[2-(Dimethylamino)ethyl|sulfamoyl chloride
[00368] To a solution of sulfuryl chloride (1.53 g, 11.34 mmol, 1.13 mL, 1 eq) in DCM (50 mL) was added a solution of N',N'-dimethylethane- 1,2-diamine (1 g, 11.34 mmol, 1.24 mL, 1 eq) and Et3N (1.15 g, 11.34 mmol, 1.58 mL, 1 eq) in DCM (5 mL) dropwise under N2 atmosphere at
-40—50 °C. The mixture was stirred under N2 atmosphere at -50 °C for 5 minutes to yield N-\2- (dimethylamino)ethyl]sulfamoyl chloride (75 g, crude) as a white suspension liquid, which was used in the next step without further purification.
Step 2: 3-Cyclopropyl-l-[3-[2-(dimethylamino)ethylsulfamoylamino]phenyl]-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione
[00369] To a solution of l-(3-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (60 mg, 104.65 pmol, 100% purity, 1 eq) and Et3N (72.70 mg, 718.46 pmol, 0.1 mL, 6.87 eq) in DCM (10 mL) was added N-\2- (dimethylamino)ethyl]sulfamoyl chloride (6 g, 32.14 mmol, N/A purity, 307.17 eq) at 15 °C. The mixture was stirred at 15 °C for 5 minutes. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime Cl 8 150*30mm*5um; mobile phase: [water (0.05% NH3H2O+10mM NH4HC03)-ACN]; B%: 48%- 78%, 10 min) and lyophilized to yield 3 -cyclopropyl- 1 -[3 -[2-
(dimethylamino)ethylsulfamoylamino]phenyl]-5-(2-fluoro-4-iodo-anilino)-6, 8-dimethyl- pyrido[4,3-d]pyrimidine-2,4,7-trione (14.69 mg, 19.82 pmol, 18.9% yield, 97.6% purity) as a white solid. 1HNMR (500 MHz, CD3OD) d ppm 7.68 (dd, J= 1.8, 10.1 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 7.45-7.38 (m, 1H), 7.26-7.20 (m, 2H), 7.08 (d, J= 7.8 Hz, 1H), 6.88 (t, J= 8.5 Hz, 1H), 3.22 (s, 3H), 3.12 (t, J= 6.9 Hz, 2H), 2.73 (tt, 7= 3.8, 7.2 Hz, 1H), 2.51 (t, J = 6.9 Hz, 2H), 2.28 (s, 6H), 1.42 (s, 3H), 1.10-1.05 (m, 2H), 0.80-0.75 (m, 2H); ES-LCMS m/z 724.0 [M+H]+.
1-41 & 1-42
Step 1: tert- Butyl /V-[2-(chlorosulfonylamino)ethyl]carbamate
[00370] To a solution of sulfuryl chloride (850 mg, 6.30 mmol, 629.63 pL, 1.01 eq) and Et3N (1.89 g, 18.73 mmol, 2.61 mL, 3 eq) in DCM (50 mL) was added a solution of /er/-butyl N-( 2- aminoethyl)carbamate (1 g, 6.24 mmol, 980.39 pL, 1 eq) in DCM (5 mL) dropwise under N2 atmosphere at -40—50 °C. The mixture was stirred under N2 atmosphere at -40—50 °C for 5 minutes to yield /er/-butyl A-[2-(chlorosulfonylamino)ethyl]carbamate (75 g, crude) as colorless liquid, which was used in the next step without further purification.
Step 2: tert- Butyl /V-[2-[[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7- trioxo-pyrido[4,3-d]pyrimidin-l-yl]phenyl]sulfamoylamino]ethyl]carbamate
[00371] To a solution of l-(3-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (90 mg, 156.97 pmol, 100% purity, 1 eq) and Et3N (145.40 mg, 1.44 mmol, 0.2 mL, 9.15 eq) in DCM (20 mL) was added ter/-butyl N-[2- (chlorosulfonylamino)ethyl]carbamate (10 g, 38.65 mmol, N/A purity, 246.23 eq). The mixture was stirred at 15 °C for 10 minutes. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 3/4, Rf = 0.48) to yield the desired compound (100 mg). 50 mg of the desired compound (100 mg) was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (lOmM NH4HC03)-ACN]; B%: 50%-80%, 10 min) and lyophilized to yield ter/-butyl /V-[2-[[3-[3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-l- yl]phenyl]sulfamoylamino]ethyl]carbamate (16.07 mg, 20.07 pmol, 12.8% yield, 99.4% purity) as a white solid. ¾ NMR (500 MHz, CD3OD) d ppm 7.58 (dd, J= 1.8, 10.1 Hz, 1H), 7.49 (d, 7 = 8.2 Hz, 1H), 7.31 (t, J= 8.1 Hz, 1H), 7.17 (s, 1H), 7.13 (dd, J= 1.4, 8.1 Hz, 1H), 7.00-6.95 (m, 1H), 6.78 (t, J= 8.5 Hz, 1H), 3.13 (s, 3H), 3.03-2.98 (m, 2H), 2.97-2.92 (m, 2H), 2.64 (tt, J =
3.8, 7.2 Hz, 1H), 1.33 (s, 9H), 1.32 (s, 3H), 1.02-0.96 (m, 2H), 0.71-0.66 (m, 2H); ES-LCMS m/z 796.1 [M+H]+.
Step 3 : l-[3-(2-Aminoethylsulfamoylamino)phenyl]-3-cyclopropyl-5-(2-fluoro-4-iodo- anilino)-6, 8-dim ethyl-pyrido [4, 3-d] pyrimidine-2, 4, 7-trione
[00372] To a solution of ter/-butyl /V-[2-[[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-l-yl]phenyl]sulfamoylamino]ethyl]carbamate (50 mg, 62.84 pmol, N/A purity, 1 eq) in DCM (2 mL) was added TFA (3.08 g, 27.01 mmol, 2 mL, 429.83 eq). The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water (0.05%NH3H20+10mM NH4HCO3)- ACN]; B%: 45%-75%, 10 min) and lyophilized to yield l-[3-(2- aminoethylsulfamoylamino)phenyl]-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6, 8-dimethyl- pyrido[4,3-d]pyrimidine-2,4,7-trione (16.78 mg, 23.94 umol, 38.09% yield, 99.223% purity) was obtained as a white solid. 1HNMR (500 MHz, CD3OD) d ppm 7.68 (dd, J= 1.8,
10.1 Hz, 1H), 7.59 (d, J= 8.4 Hz, 1H), 7.41 (t, J= 8.0 Hz, 1H), 7.28-7.25 (m, 1H), 7.25-7.22 (m, 1H), 7.08-7.04 (m, 1H), 6.88 (t, J= 8.5 Hz, 1H), 3.22 (s, 3H), 3.06 (t, J= 6.1 Hz, 2H), 2.76-2.70 (m, 3H), 1.41 (s, 3H), 1.10-1.05 (m, 2H), 0.80-0.76 (m, 2H); ES-LCMS m/z 696.0 [M+H]+.
1-24
Step 1: 3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-l-(3-hydroxyphenyl)-6,8- dimethylpyrido[4,3-</|pyrimidine-2,4,7(l//,3//,6//)-trione
[00373] An aqueous solution o
µmol, 2 eq) in H2O (1 mL) was added to a solution of 1-(3-ainophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (40 mg, 69.76 µmol, 100.0% purity, 1 eq) in H2SO4 (0.25 mL) and H2O (0.5 mL) at 0 °C. The reaction mixture was stirred for 30 minutes. AcOH (2 mL) was added. The reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was concentrated under reduced pressure to remove most acetic acid. The residue was added addition sat aq NaHCO3 until pH 7 and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (PE/EtOAc = 1/1, Rf = 0.4) to yield 3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-1-(3-hydroxyphenyl)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (35 mg, 55.45 µmol, 79.5% yield, 91.0% purity) as a white solid.1H NMR (500 MHz, CDCl3) δ ppm 11.30 (s, 1H), 7.53 (d, J = 9.3 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.29 (s, 1H), 6.84 (d, J = 7.8 Hz, 2H), 6.80 (s, 1H), 6.70 (t, J = 8.0 Hz, 1H), 5.59 (s, 1H), 3.21 (s, 3H), 2.75 (s, 1H), 1.44 (s, 3H), 1.16-1.10 (m, 2H), 0.86 (d, J = 16.8 Hz, 2H); ES-LCMS m/z 574.8 [M+H]+. Step 2: 3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl methylsulfamate
[00374] To a solution of 3-cy
phenyl)amino)-1-(3- hydroxyphenyl)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (25 mg, 55.45 µmol, 79.5% yield, 91.0% purity, 1 eq) in DCM (1 mL) was added N-methylsulfamoyl chloride (4.62 mg, 35.65 µmol, 0.9 eq) and Et3N (12.02 mg, 118.83 µmol, 16.54 µL, 3 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was acidified by the addition of 0.1 N HCl and extracted with EtOAc (20 mL x 3). The organic layer was washed with brine (20 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um;mobile phase: [water (0.05% NH3H2O + 10mM NH4HCO3)-ACN]; B%: 55%-85%, 10 min) and lyophilized to give desired compound (20 mg, purity 60.0%) as a white solid, which was further purified by preparative TLC (PE/EtOAc = 1/1, Rf = 0.38) to yield 3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)- 6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl methylsulfamate (8.34 mg, 12.50 µmol, 31.6% yield, 100.0% purity) as a white solid.1H NMR (500 MHz, CDCl3) δ ppm 11.28 (s, 1H), 7.53 (dd, J = 1.7, 9.6 Hz, 1H), 7.49-7.45 (m, 2H), 7.34- 7.29 (m, 2H), 7.25 (d, J = 2.3 Hz, 1H), 6.72 (t, J = 8.3 Hz, 1H), 4.80 (s, 1H), 3.21 (s, 3H), 2.96- 2.91 (m, 3H), 2.80-2.71 (m, 1H), 1.40 (s, 3H), 1.16-1.11 (m, 2H), 0.83-0.77 (m, 2H); ES-LCMS m/z 668.0 [M+H]+. I-25
Pd/CH2
mL) was added Pd/C (1 g, 10.98 mmol, 10.0% purity, 1.00 eq) under Ar2 atmosphere. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (30 psi) at 25 °C for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.37) to yield 2-methylbenzene-1,3- diamine (800 mg, 6.35 mmol, 57.9% yield, 97.0% purity) as a gray solid.1H NMR (400 MHz, CDCl3) δ ppm 7.67-7.15 (m, 1H), 6.89-6.81 (m, 2H), 6.22 (d, J = 7.8 Hz, 4H), 1.99 (s, 3H). Step 2: [3-Cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7-trioxo-pyrido[2,3- d]pyrimidin-5-yl] 4-methylbenzenesulfonate
[00376] To a solution of 3-cyclo
odo-phenyl)-5-hydroxy-6,8-dimethyl- pyrido[2,3-d]pyrimidine-2,4,7-trione (800 mg, 1.66 mmol, 100.0% purity, 1 eq) in MeCN (35 mL) was added 4-methylbenzenesulfonyl chloride (479.74 mg, 2.52 mmol, 1.52 eq) and Et3N (581.30 mg, 5.74 mmol, 799.58 µL, 3.47 eq). The mixture was stirred under N2 atmosphere at 15 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 2/1, Rf = 0.3) to yield [3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl- 2,4,7-trioxo-pyrido[2,3-d]pyrimidin-5-yl] 4-methylbenzenesulfonate (620 mg, 924.04 µmol, 55.8% yield, 95.0% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 11.28 (s, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7.47 (s, 2H), 7.37-7.29 (m, 2H), 7.26-7.23 (m, 1H), 6.72 (t, J = 7.2 Hz, 1H), 4.95 (s, 1H), 3.21 (s, 3H), 2.93 (s, 3H), 2.74 (s, 1H), 1.40 (s, 3H), 1.27 (s, 2H), 1.14 (d, J = 6.1 Hz, 2H); ES-LCMS m/z 638.0 [M+H]+. Step 3: 5-(3-Amino-2-methyl-anilino)-3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8- dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione
[00377] To a solution of [3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] 4-methylbenzenesulfonate (220 mg, 327.89 µmol, 95.0% purity, 1 eq) in DMA (2 mL) was added 2-methylbenzene-1,3-diamine (123.89 mg, 983.66 µmol, 97.0% purity, 3 eq) and 2,6-LUTIDINE (105.40 mg, 983.66 µmol, 114.56 µL, 3 eq). The mixture was stirred under microwave at 180 °C for 2 h. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water (0.05% HCl)-ACN];B%: 46%-76%, 10 min) and lyophilized to yield 5-(3-amino-2-methyl-anilino)-3- cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione (58 mg, 88.65 µmol, 27.0% yield, 95.4% purity, HCl) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 10.16 (s, 1H), 7.70-7.59 (m, 2H), 7.14 (d, J = 7.8 Hz, 2H), 7.08-6.77 (m, 1H), 6.67(d, J = 6.1 Hz, 1H), 2.97 (s, 3H), 2.78 (s, 1H), 2.55 (s, 3H), 1.60 (s, 3H), 1.18 (d, J = 5.6 Hz, 2H), 0.83 (s, 2H); ES-LCMS m/z 588.1 [M+H]+. Step 4: 3-Cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-5-[2-methyl-3- (methylsulfamoylamino)anilino]pyrido[2,3-d]pyrimidine-2,4,7-trione [00378] To a solution of 5-(3-a
-cyclopropyl-1-(2-fluoro-4-iodo- phenyl)-6,8-dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione (50 mg, 76.42 µmol, 95.4% purity, 1 eq, HCl) in DCM (1 mL) was added N-methylsulfamoyl chloride (8.91 mg, 68.78 µmol, 0.9 eq) and TEA (38.66 mg, 382.11 µmol, 53.18 µL, 5 eq). The mixture was stirred under N2
atmosphere at 5°C for 1 h. The residue was added addition sat. aq. NaHCO3 until pH 7 and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by prep- TLC (SiO2, PE/EtOAc = 1/1, Rf = 0.38) to yield 3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8- dimethyl-5-[2-methyl-3-(methylsulfamoylamino)anilino]pyrido[2,3-d]pyrimidine-2,4,7-trione (50 mg, 70.19 µmol, 91.9% yield, 95.5% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 10.11 (s, 1H), 7.63 (d, J = 9.5 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 6.95 (s, 1H), 6.67 (d, J = 7.6 Hz, 1H), 6.25 (s, 1H), 4.50 (s, 1H), 4.12 (s, 1H), 2.96 (s, 3H), 2.85 (s, 1H), 2.79 (s, 3H), 2.74 (d, J = 4.6 Hz, 3H), 1.54 (s, 3H), 1.18 (d, J = 6.1 Hz, 2H), 0.83 (d, J = 5.4 Hz, 2H); ES-LCMS m/z 681.0 [M+H]+. Step 5: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[2-methyl-3- (methylsulfamoylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione [00379] To a solution of 3-c
enyl)-6,8-dimethyl-5-[2-methyl- 3-(methylsulfamoylamino)anilino]pyrido[2,3-d]pyrimidine-2,4,7-trione (30 mg, 42.11µmol, 95.5% purity, 1 eq) in THF (1 mL) was added a drop of NaOMe/MeOH (28 wt %, 42.11 µmol, 1 eq). The mixture was stirred at 25 °C for 1 h. The residue was added AcOH until pH to 7 and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(0.05%HCl)-ACN]; B%: 50%-70%,10 min) and lyophilized to yield a product, which was added addition sat aq NaHCO3 until pH = 7 and extracted with EtOAc (20 mL x 3), then the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield 3-cyclopropyl-5-(2-
fluoro-4-iodo-anilino)-6,8-dimethyl-1-[2-methyl-3-(methylsulfamoylamino)phenyl]pyrido[4,3- d]pyrimidine-2,4,7-trione (10.19 mg, 14.66 µmol, 34.8% yield, 97.9% purity) as a white solid. 1H NMR (400 MHz, CD3OD) δ ppm 7.70-7.63 (m, 1H), 7.55 (J = 8.4, 12.8 Hz, 2H), 7.28 (J = 7.8 Hz, 1H), 7.06 (d, J = 7.1 Hz, 1H), 6.86 (t, J = 8.6 Hz, 1H), 3.20 (s, 3H), 2.74-2.69 (m, 1H), 2.67 (s, 3H), 2.24 (s, 3H), 1.27 (s, 3H), 1.07 (d, J = 7.1 Hz, 2H), 0.89-0.76 (m, 2H); ES-LCMS m/z 681.0 [M+H]+. I-29
pyrido[4,3-d]pyrimidin-1-yl]phenyl]-3-(methylsulfamoyl)urea [00380] To a solution of 1
2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (200 mg, 348.82 ^mol, 1 eq) in THF (20 mL) was added N-(oxomethylene)sulfamoyl chloride (100 mg, 706.55 ^mol, 61.35 ^L, 2.03 eq) under N2 atmosphere at -60 °C. The mixture was stirred under N2 atmosphere at -60~ -20 °C for 0.5 h. MeNH2 (235 mg, 3.48 mmol, 100% purity, 9.98 eq, HCl) and Et3N (352.97 mg, 3.49 mmol, 485.52 ^L, 10 eq) was added. The mixture was warmed to 25 °C slowly and stirred at 25 °C for 1 h. The reaction mixture was concentrated under reduced pressure to yield a residue which was
purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water (0.05%HCl)-ACN]; B%: 50%-70%, 10 min) and lyophilized. The residue was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um;mobile phase: [water (0.05%NH3H2O+10mM NH4HCO3)-ACN]; B%: 25%-55%, 10 min) and lyophilized to yield 1- [3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin- 1-yl]phenyl]-3-(methylsulfamoyl)urea (18.94 mg, 25.86 ^mol, 7.4% yield, 96.9% purity) as a white solid.1H NMR (400 MHz, CD3OD) δ ppm 7.70-7.52 (m, 3H), 7.40 (d, J = 4.6 Hz, 2H), 7.08 (d, J = 3.2 Hz, 1H), 6.86 (t, J = 8.6 Hz, 1H), 3.20 (s, 3H), 2.75-2.65 (m, 4H), 1.40 (s, 3H), 1.10-1.00 (m, 2H), 0.80-0.70(m, 2H); ES-LCMS m/z 710.0 [M+H]+. I-44
Step 1: N-[3-[6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-3,7-dimethyl-2,5-dioxo-pyrano[3,2- c]pyridin-8-yl]-2-methyl-phenyl]acetamide [00381] To a stirred solution of 8
henyl)-6-cyclopropyl-4-(2-fluoro-4- iodo-anilino)-3,7-dimethyl-pyrano[3,2-c]pyridine-2,5-dione (20 mg, 31.50 µmol, 90.0% purity, 1 eq) and TEA (9.56 mg, 94.51 µmol, 13.15 µL, 3 eq) in DCM (2 mL) was added acetyl chloride (4.95 mg, 63.01 µmol, 4.50 µL, 2 eq). The reaction mixture was stirred at 0 °C for 1 h under N2
atmosphere. The reaction mixture was quenched by addition sat. aq. NaHCO3 (15 mL) at 0 °C and extracted with DCM (20 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative TLC (PE/EtOAc = 0/1, TLC: PE/EtOAc = 0/1, Rf = 0.45), followed by lyophilization to yield N-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-3,7- dimethyl-2,5-dioxo-pyrano[3,2-c]pyridin-8-yl]-2-methyl-phenyl]acetamide (13.71 mg, 22.31 µmol, 70.8% yield, 99.8% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.32 (s, 1H), 9.40 (s, 1H), 7.72 (d, J = 10.3 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.26 (t, J = 7.6 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.88 (t, J = 8.7 Hz, 1H), 3.04 (d, J = 4.2 Hz, 1H), 2.24 (s, 3H), 2.08 (s, 3H), 1.95 (s, 3H), 1.45 (s, 3H), 1.21 (d, J = 8.1 Hz, 2H), 0.97-0.88 (m, 2H); ES-LCMS m/z 614.0 [M+H]+. I-45
[00382] To a solution of 2-oxo-2
g, 339.70 mmol, 1 eq) in H2SO4 (80 mL) was added KNO3 (41.21 g, 407.64 mmol, 1.2 eq) at 0 °C. The mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into ice water (1.6 L) and extracted with EtOAc (400 mL x 3). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to yield 2-(3-nitrophenyl)-2-oxo-acetic acid (66 g, crude) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 8.70 (t, J = 1.8 Hz, 1H), 8.56 (td, J = 1.2, 8.2 Hz, 1H), 8.41-8.37 (m, 1H), 7.89 (t, J = 8.0 Hz, 1H). Step 2: Ethyl 2-(3-nitrophenyl)-2-oxo-acetate [00383] To a solution of 2-(3-n
cid (66 g, 338.24 mmol, 1 eq) in DMF (700 mL) was added K2CO3 (121.54 g, 879.42 mmol, 2.6 eq). After stirred at 20 °C for 2h, iodoethane (263.77 g, 1.69 mol, 135.26 mL, 5 eq) was added dropwise. The mixture was stirred at 20 °C for 16 h. The reaction mixture was poured into water (800 mL), extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 10/1, TLC: PE/EtOAc = 5/1, Rf = 0.45) to yield ethyl 2-(3-nitrophenyl)-2-oxo-acetate (35.5 g, 143.16 mmol, 42.3% yield, 90.0% purity) as a yellow oil.1H NMR (400 MHz, CDCl3) δ ppm 8.90 (s, 1H), 8.54-8.47 (m, 1H), 8.40 (d, J = 7.8 Hz, 1H), 7.75 (t, J = 7.9 Hz, 1H), 4.50 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.1 Hz, 3H). Step 3: Ethyl 3-[(2E)-2-[2-ethoxy-1-(3-nitrophenyl)-2-oxo-ethylidene]hydrazino]-3-oxo- propanoate
O O O N [00384] To a solution of et
e (22.5 g, 90.73 mmol, 1 eq) in EtOH (120 mL) was added H2SO4 (2.29 g, 23.33 mmol, 1.24 mL, 0.25 eq) and ethyl 3- hydrazino-3-oxo-propanoate (13.79 g, 94.36 mmol, 1.04 eq). The mixture was stirred at 90 °C for 2 h. The solvent was removed to yield a residue which was diluted with water (200 mL) and extracted with EtOAc (300 mL x 3). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to yield ethyl 3-[(2E)-2-[2-ethoxy-1-(3-nitrophenyl)-2-oxo-ethylidene]hydrazino]-3-oxo-propanoate (30 g, crude, E/Z mixture) as a yellow oil. ES-LCMS m/z 352.2 [M+H]+. Step 4: Ethyl 4-hydroxy-3-(3-nitrophenyl)-6-oxo-1H-pyridazine-5-carboxylate H N O N [00385] To a solution of eth
ophenyl)-2-oxo- ethylidene]hydrazino]-3-oxo-propanoate (30 g, 85.39 mmol, E/Z mixture, 1 eq) in DMF (300 mL) was added K2CO3 (6.49 g, 46.97 mmol, 0.55 eq). The mixture was stirred at 80 °C for 3 h. The mixture was cooled to ambient temperature and poured into 3N HCl (600 mL). The precipitated solid was collected by filtration to give a residue which was added MeOH (50 mL), and stirred at 15 °C for 2 h. The slurry was filtered, and the cake was rinsed with MeOH (3 x 3 mL). The solid was collected and dried in vacuo to yield ethyl 4-hydroxy-3-(3-nitrophenyl)-6- oxo-1H-pyridazine-5-carboxylate (8.3 g, 24.47 mmol, 28.7% yield, 90.0% purity) as a yellow solid.1H NMR (400MHz, DMSO-d6) δ ppm 13.23 (s, 1H), 8.58-8.53 (m, 1H), 8.30 (td, J = 1.2, 7.2 Hz, 1H), 8.15 (d, J = 8.1 Hz, 1H), 7.76 (t, J = 8.1 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H); ES-LCMS m/z 306.1 [M+H]+.
Step 5: Ethyl 2-allyl-5-hydroxy-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate [00386] To a solution of ethy
6-oxo-1H-pyridazine-5- carboxylate (3 g, 8.85 mmol, 1 eq) in DMF (40 mL) was added NaH (707.63 mg, 17.69 mmol, 60.0% purity, 2 eq) and stirred at 20 °C for 30 min. The solution was cooled to -10 °C, 3- bromoprop-1-ene (1.12 g, 9.29 mmol, 1.05 eq) was added dropwise. The reaction temperature was slowly warmed up to 20 °C and stirred at 20 °C for 1 h. The reaction mixture was quenched by addition water (60 mL) and extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield ethyl 2-allyl-5-hydroxy-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate (3 g, 7.82 mmol, 88.4% yield, 90.0% purity) as a yellow oil.1H NMR (400 MHz, DMSO-d6) δ ppm 8.57 (s, 1H), 8.30 (d, J = 1.5, 8.3 Hz, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.76 (t, J = 8.1 Hz, 1H), 5.98 (td, J = 5.5, 10.9, 16.8 Hz, 1H), 5.24-5.15 (m, 2H), 4.70 (d, J = 5.6 Hz, 2H), 4.30 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H); ES-LCMS m/z 346.0 [M+H]+. Step 6: Ethyl 2-allyl-5-chloro-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate [00387] To a solution of ethy
henyl)-3-oxo-pyridazine-4- carboxylate (3 g, 7.82 mmol, 1 eq) in DCM (40 mL) was added (COCl)2 (9.92 g, 78.19 mmol, 6.84 mL, 10 eq). The mixture was stirred at 35 °C for 3 h. The solvent was removed to yield ethyl 2-allyl-5-chloro-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate (3 g, crude) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 8.46 (t, J = 1.8 Hz, 1H), 8.37-8.33 (m, 1H), 7.91 (d, J
= 1.0, 7.8 Hz, 1H), 7.68 (t, J = 7.9 Hz, 1H), 6.01 (td, J = 6.2, 10.3, 16.9 Hz, 1H), 5.41-5.27 (m, 2H), 4.82 (d, J = 6.4 Hz, 2H), 4.49 (q, J = 7.2 Hz, 2H), 1.42 (t, J = 7.2 Hz, 3H); ES-LCMS m/z 364.1, 366.1 [M+H]+. Step 7: Ethyl 2-allyl-5-(methylamino)-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate [00388] To a solution of ethy
enyl)-3-oxo-pyridazine-4- carboxylate (3 g, 6.60 mmol, 1 eq) in DCM (30 mL) was added MeNH2 (13.66 g, 131.96 mmol, 30.0% purity, 20 eq) at 0 °C. The mixture was stirred at 0 °C for 5 h. The reaction mixture was quenched by addition water (50 mL) and extracted with EtOAc (60 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (PE/EtOAc = 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.24) to yield ethyl 2-allyl-5-(methylamino)-6-(3- nitrophenyl)-3-oxo-pyridazine-4-carboxylate (2.2 g, 5.53 mmol, 83.7% yield, 90.0% purity) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 8.38-8.32 (m, 1H), 8.29 (t, J = 1.7 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.83-7.76 (m, 1H), 6.24 (d, J = 5.1 Hz, 1H), 5.98-5.84 (m, 1H), 5.21- 5.07 (m, 2H), 4.56 (d, J = 5.6 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 2.66 (d, J = 5.1 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H); ES-LCMS m/z 359.1 [M+H]+. Step 8: 2-Allyl-5-(methylamino)-6-(3-nitrophenyl)pyridazin-3-one
[00389] To a solution of ethyl 2-allyl-5-(methylamino)-6-(3-nitrophenyl)-3-oxo-pyridazine-4- carboxylate (1.5 g, 3.77 mmol, 1 eq) in DMSO (20 mL) was added LiCl (3.19 g, 75.35 mmol, 20 eq). The mixture was stirred at 180 °C for 6 h. The mixture was diluted with water (40 mL) and extracted with EtOAc (60 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 1/2, TLC: PE/EtOAc = 1/2, Rf = 0.25) to yield 2-allyl-5-(methylamino)-6-(3-nitrophenyl)pyridazin-3-one (1.2 g, 3.35 mmol, 89.0% yield, 80.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 8.38 (d, J = 1.7 Hz, 1H), 8.34-8.29 (m, 1H), 7.85 (d, J = 7.6 Hz, 1H), 7.70 (t, J = 7.9 Hz, 1H), 6.09-5.94 (m, 1H), 5.86 (s, 1H), 5.28-5.17 (m, 2H), 4.73 (d, J = 4.6 Hz, 2H), 4.29 (s, 1H), 2.85-2.79 (m, 3H); ES-LCMS m/z 287.1 [M+H]+. Step 9: 6-Allyl-4-hydroxy-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione [00390] To a solution of 2-allyl-
itrophenyl)pyridazin-3-one (1.2 g, 3.35 mmol, 1 eq) in Ac2O (20 mL) was added 2-methylpropanedioic acid (1.19 g, 10.06 mmol, 3 eq). The mixture was stirred at 110 °C for 2 h. The solvent was removed to yield a residue which was purified by preparative TLC (PE/EtOAc = 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.40), followed by lyophilization to yield 6-allyl-4-hydroxy-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3- d]pyridazine-2,5-dione (1.1 g, 2.45 mmol, 73.0% yield, 82.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 8.50-8.27 (m, 2H), 7.83-7.60 (m, 2H), 6.10-5.92 (m, 1H), 5.39-5.31 (m, 2H), 4.86 (d, J = 6.1 Hz, 2H), 3.08 (s, 3H), 2.15 (s, 3H); ES-LCMS m/z 369.1 [M+H]+. Step 10: [6-Allyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin-4-yl] 4- methylbenzenesulfonate
[00391] To a solution of 6-allyl-
l-8-(3-nitrophenyl)pyrido[2,3- d]pyridazine-2,5-dione (1.1 g, 2.45 mmol, 1 eq) in ACN (20 mL) was added DIEA (1.58 g, 12.24 mmol, 2.13 mL, 5 eq) and 4-methylbenzenesulfonyl chloride (933.71 mg, 4.90 mmol, 2 eq). The mixture was stirred at 60 °C for 1 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (60 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.35) to yield [6- allyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin-4-yl] 4- methylbenzenesulfonate (1.2 g, 1.88 mmol, 76.9% yield, 82.0% purity) as a brown solid.1H NMR (400 MHz, CDCl3) δ ppm 8.41-8.30 (m, 2H), 7.97 (d, J = 8.3 Hz, 2H), 7.79-7.66 (m, 2H), 7.41 (d, J = 8.3 Hz, 2H), 6.10-5.94 (m, 1H), 5.40-5.22 (m, 2H), 4.84 (d, J = 6.1 Hz, 2H), 3.09 (s, 3H), 2.50 (s, 3H), 1.89 (s, 3H); ES-LCMS m/z 523.1 [M+H]+. Step 11: 6-Allyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3- d]pyridazine-2,5-dione [00392] To a solution of 2-flu
g, 2.73 mmol, 2.49 eq) in THF (10 mL) was added NaH (175.74 mg, 4.39 mmol, 60.0% purity, 4 eq) and stirred at 0 °C for 30 min, [6-allyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin-4-yl] 4-
methylbenzenesulfonate (700 mg, 1.10 mmol, 1 eq) was added at 0 °C. The reaction temperature was slowly warmed up to 25 °C and stirred at 25 °C for 3 h. The reaction mixture was quenched by addition water (30 mL) and extracted with EtOAc (40 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 3/1, TLC: PE/EtOAc = 3/1, Rf = 0.43) to yield 6-allyl-4-(2-fluoro-4-iodo- anilino)-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (150 mg, 217.08 µmol, 19.7% yield, 85.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 10.72 (s, 1H), 8.42-8.39 (m, 1H), 8.36 (td, J = 1.8, 7.8 Hz, 1H), 7.77-7.66 (m, 2H), 7.46 (dd, J = 1.8, 10.0 Hz, 1H), 7.38 (d, J = 8.7 Hz, 1H), 6.57 (t, J = 8.5 Hz, 1H), 6.04 (td, J = 6.1, 10.4, 16.9 Hz, 1H), 5.39-5.28 (m, 2H), 4.86 (d, J = 6.0 Hz, 2H), 3.08 (s, 3H), 1.82 (s, 3H); ES-LCMS m/z 588.0 [M+H]+. Step 10: 6-Allyl-8-(3-aminophenyl)-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-pyrido[2,3- d]pyridazine-2,5-dione [00393] To a solution of 6-all
)-1,3-dimethyl-8-(3- nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (130 mg, 188.14 µmol, 1 eq) in EtOH (1.5 mL) and H2O (1.5 mL) was added NH4Cl (100.64 mg, 1.88 mmol, 10 eq) and Fe (52.53 mg, 940.68 µmol, 5 eq). The mixture was stirred at 90 °C for 3 h. The reaction mixture was filtered to remove the insoluble. The filter liquor was concentrated under reduced pressure to give a residue which was purified by preparative HPLC (column: AgNO3_silica 150*25mm*15um; mobile phase: [Heptane-EtOH (0.1%NH3H2O)]; B%: 0%-80%, 9min), followed by lyophilization to yield 6-allyl-8-(3-aminophenyl)-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-pyrido[2,3-
d]pyridazine-2,5-dione (80.27 mg, 144.02 µmol, 76.6% yield, 100.0% purity) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.81 (s, 1H), 7.44 (d, J = 1.8, 10.1 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 6.84-6.70 (m, 3H), 6.53 (t, J = 8.5 Hz, 1H), 6.04 (td, J = 6.0, 10.5, 17.0 Hz, 1H), 5.37-5.24 (m, 2H), 4.85 (d, J = 4.9 Hz, 2H), 3.83 (s, 2H), 3.16 (s, 3H), 1.81 (s, 3H); ES-LCMS m/z 557.9 [M+H]+. I-46
[00394] To a solution of (3-nitrophe
onyl chloride (500 mg, 2.12 mmol, 1 eq) in THF (1 mL) was added DIEA (548.47 mg, 4.24 mmol, 739.17 µL, 2 eq) and MeNH2.EtOH (197.69 mg, 6.37 mmol, 212.18 µL, 3 eq). The mixture was stirred at 25 °C for 1 h. The mixture was quenched with water (30 mL) and extracted with DCM (30 mL x 3). The combined organic phase was washed with NaHCO3 (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 2/1, Rf = 0.4) to yield 4- methylbenzenesulfonate N-methyl-1-(3-nitrophenyl)methanesulfonamide (200 mg, 861.19 µmol,
40.6% yield, 99.1% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 8.32-8.20 (m, 2H), 7.79 (d, J = 7.6 Hz, 1H), 7.64-7.58 (m, 1H), 4.35 (s, 2H), 4.27-4.13 (m, 1H), 2.79 (d, J = 5.4 Hz, 3H). Step 2: 1-(3-Aminophenyl)-N-methylmethanesulfonamide [00395] To a solution of 4-methylb
N-methyl-1-(3- nitrophenyl)methanesulfonamide (200 mg, 861.19 µmol, 99.1%, 1 eq) in MeOH (2 mL) was added Pd/C (200 mg, 861.19 µmol, 10.0%, 1 eq) under N2 atmosphere. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25 °C for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to yield 1-(3-aminophenyl)-N-methyl-methanesulfonamide (180 mg, 853.90 µmol, 99.2% yield, 95.0% purity) as a yellow solid, which was used in the next step without further purification.1H NMR (500 MHz, CDCl3) δ ppm 7.22-7.17 (m, 1H), 7.17-7.14 (m, 1H), 6.75-6.73 (m, 2H), 6.71- 6.67 (m, 2H), 6.66-6.57 (m, 1H), 4.18 (s, 2H), 2.02 (s, 3H). Step 3: 1-(3-((3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)-N-methylmethanesulfonamide
[00396] To a solution of 1-(3-aminophenyl)-N-methyl-methanesulfonamide (150 mg, 711.58 µmol, 95.0%, 1.91 eq) in DMA (3 mL) was added 2,6-lutidine (119.77 mg, 1.12 mmol, 130.19 µL, 3 eq) and [3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7-trioxo-pyrido[2,3- d]pyrimidin-5-yl] 4-methylbenzenesulfonate (250 mg, 372.60 µmol, 90.0%, 1 eq). The mixture was stirred under microwave (2 bar) at 140 °C for 3 h. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water (HCl) - ACN]; B%: 46%-66%, 10 min) and lyophilized to yield a product, which was added addition sat aq NaHCO3 until pH = 7 and extracted with EtOAc (20 mL x 3), then the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield 1-(3- ((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)-N-methylmethanesulfonamide (45 mg, 58.55 µmol, 15.7% yield, 86.6% purity) as a yellow solid.1H NMR (500 MHz, CD3OD) δ ppm 7.85 (dd, J = 1.8, 9.5 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.22-7.14 (m, 2H), 7.08-6.99 (m, 2H), 4.33 (s, 2H), 2.95 (s, 3H), 2.82-2.76 (m, 1H), 2.69 (s, 3H), 1.67 (s, 3H), 1.16-1.09 (m, 2H), 0.81 (d, J = 2.6 Hz, 2H); ES-LCMS m/z 666.0 [M+H]+. Step 4: 1-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N-methylmethanesulfonamide
7- trioxo-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)-N- methylmethanesulfonamide (45 mg, 58.15 µmol, 86.0%, 1 eq) in THF (1 mL) was added a drop
of NaOMe/MeOH (20 wt%, 58.15 µmol, 1 eq). The mixture was stirred under N2 atmosphere at 25 °C for 1 h. The residue was added AcOH until pH = 7 and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um;mobile phase: [water( NH3H2O+NH4HCO3)-ACN]; B%: 53%-83%, 10 min) and lyophilized to yield 1-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl- 2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N- methylmethanesulfonamide (10.01 mg, 14.96 µmol, 25.7% yield, 99.4% purity) as a white solid. 1H NMR (400 MHz, CD3OD) δ ppm 7.66 (dd, J = 1.7, 10.3 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.51-7.47 (m, 2H), 7.43 (s, 1H), 7.39 (dd, J = 3.2, 5.6 Hz, 1H), 6.86 (t, J = 8.4 Hz, 1H), 4.37 (s, 2H), 3.20 (s, 3H), 2.76-2.69 (m, 1H), 2.67 (s, 3H), 1.34 (s, 3H), 1.08-1.03 (m, 2H), 0.81-0.74 (m, 2H); ES-LCMS m/z 666.1 [M+H]+. I-33
(methylsulfamoylamino)phenyl]pyrano[3,2-c]pyridine-2,5-dione
[00398] To a stirred solution of 8-(3-amino-2-methyl-phenyl)-6-cyclopropyl-4-(2-fluoro-4- iodo-anilino)-3,7-dimethyl-pyrano[3,2-c]pyridine-2,5-dione (50 mg, 70.01 µmol, 80% purity, 1 eq) and TEA (28.34 mg, 280.02 µmol, 38.98 µL, 4 eq) in DCM (2 mL) was added N- methylsulfamoyl chloride (18.14 mg, 140.01 µmol, N/A purity, 2 eq) at 0 °C. The reaction mixture was stirred at 0 °C for 5 h under N2 atmosphere. The reaction mixture was quenched by addition sat. aq. NaHCO3 (30 mL) at 0 °C and extracted with DCM (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um;mobile phase: [water(NH3H2O+NH4HCO3)-ACN];B%: 53%-83%,10min), followed by lyophilization to yield 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)- 3,7-dimethyl-8-[2-methyl-3-(methylsulfamoylamino)phenyl]pyrano[3,2-c]pyridine-2,5-dione (6.22 mg, 9.36 µmol, 13.4% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO- d6) δ ppm 11.30 (s, 1H), 8.82 (s, 1H), 7.71 (d, J = 1.7, 10.3 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.27 (t, J = 7.7 Hz, 1H), 7.14 (q, J = 4.9 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.87 (t, J = 8.7 Hz, 1H), 3.03 (s, 1H), 2.55 (d, J = 5.1 Hz, 3H), 2.20 (s, 3H), 2.03 (s, 3H), 1.43 (s, 3H), 1.23-1.17 (m, 2H), 0.96-0.84 (m, 2H); ES-LCMS m/z 665.0 [M+H]+. I-47 & I-48
[00399] To a mixture of (methyldisulfanyl)methane (5.07 g, 53.82 mmol, 4.83 mL, 1 eq) and AcOH (6.46 g, 107.64 mmol, 6.16 mL, 2 eq) was added sulfuryl chloride (21.79 g, 161.47 mmol, 16.14 mL, 3 eq) dropwise under N2 atmosphere at -20 °C. The mixture was stirred under N2 atmosphere at -20 °C for 2 h. The mixture was warmed to 20 °C slowly and stirred under N2 atmosphere at 20 °C for 1 h and at 35 °C for 1 h. The mixture was concentrated under reduced pressure to yield methanesulfinyl chloride (10.6 g, crude) as colorless oil, which was used in the next step without further purification.1H NMR (400 MHz, CDCl3) δ ppm 3.38 (s, 3H). Step 2: (S)-N-[3-[3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo- pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide and (R)-N-[3-[3-cyclopropyl-5-(2- fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1- yl]phenyl]methanesulfinamide [00400] To
-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (200 mg, 348.82 ^mol, 100% purity, 1 eq) and Et3N (363.50 mg, 3.59 mmol, 0.5 mL, 10.30 eq) in DCM (10 mL) was added methanesulfinyl chloride (200 mg, 2.03 mmol, N/A purity, 5.82 eq). The mixture was stirred at 25 °C for 0.5 h. TLC (PE/EtOAc = 2/3, Rf = 0.15) showed the starting material was almost consumed. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 0/1, TLC: PE/EtOAc = 2/3, Rf = 0.15) to yield N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo- pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide (200 mg, 91.9% purity) as a white solid. The product (160 mg) was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 40%-70%, 10 min) to give
desired compound as a white solid, which was further separated by SFC (column: DAICEL CHIRALCEL OD-H (250mm*30mm, 5um); mobile phase: [0.1% NH3H2O EtOH]; B%: 45%- 45%) to yield peak 1 and peak 2. Peak 1 was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 43%-73%, 11 min), followed by lyophilization to yield (S)-N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl- 2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide (13.75 mg, 20.91 ^mol, 9.0% yield, 96.6% purity, SFC: Rt = 4.554, ee = 100%, [α]27.8 D = -36.364 (MeOH, c = 0.011 g/100 mL)) as a white solid.1H NMR (400 MHz, CD3OD) δ ppm 7.66 (dd, J = 1.8, 10.1 Hz, 1H), 7.59-7.54 (m, 1H), 7.39 (t, J = 8.1 Hz, 1H), 7.17-7.08 (m, 2H), 7.05-7.00 (m, 1H), 6.86 (t, J = 8.5 Hz, 1H), 3.20 (s, 3H), 2.84 (s, 3H), 2.71 (tt, J = 3.8, 7.2 Hz, 1H), 1.40 (s, 3H), 1.10-1.00 (m, 2H), 0.79-0.70 (m, 2H); ES-LCMS m/z 636.1 [M+H]+. Peak 2 was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 40%-70%, 10 min) to give desired compound as a white solid, which was further separated by SFC (column: DAICEL CHIRALCEL OD-H (250mm*30mm,5um); mobile phase: [0.1% NH3H2O ETOH]; B%: 45%- 45%, min), followed by lyophilization to yield a residue which was purified by preparative HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water ( NH4HCO3)- ACN]; B%: 40%-70%, 11 min), followed by lyophilization to yield (R)-N-[3-[3-cyclopropyl-5- (2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1- yl]phenyl]methanesulfinamide (12.41 mg, 19.05 ^mol, 8.2% yield, 97.6% purity, SFC: Rt = 4.991, ee = 89.18%, [α]27.7D = +107.692 (MeOH, c = 0.013 g/100 mL)) as a white solid.1H NMR (400 MHz, CD3OD) δ ppm 7.66 (dd, J = 1.8, 10.2 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.17-7.10 (m, 2H), 7.02 (dd, J = 1.1, 8.0 Hz, 1H), 6.86 (t, J = 8.5 Hz, 1H), 3.20 (s, 3H), 2.84 (s, 3H), 2.71 (tt, J = 3.7, 7.2 Hz, 1H), 1.40 (s, 3H), 1.08-1.03 (m, 2H), 0.78-0.73 (m, 2H); ES-LCMS m/z 636.0 [M+H]+. I-49
[00401] To a solution of eth
6-oxo-1H-pyridazine-5- carboxylate (2.5 g, 7.37 mmol, 1 eq) in DCM (30 mL) was added (COCl)2 (935.60 mg, 7.37 mmol, 645.24 µL, 1 eq). The mixture was stirred at 35 °C for 3 h. The reaction mixture was quenched by addition water (30 mL) and extracted with DCM (40 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was added MeOH (5 mL), and stirred at 25 °C for 2 h. The slurry was filtered, and the cake was rinsed with PE (2 x 3 mL). The solid was collected and dried in vacuo to yield ethyl 4-chloro-3-(3-nitrophenyl)-6-oxo-1H-pyridazine-5- carboxylate (1.9 g, 5.69 mmol, 77.2% yield, 97.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 11.67 (s, 1H), 8.48 (s, 1H), 8.38 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H), 7.74-7.66 (m, 1H), 4.51 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H); ES-LCMS m/z 324.0, 326.0 [M+H]+.
Step 2: Ethyl 5-chloro-2-cyclopropyl-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate [00402] A mixture of ethyl 4
o-1H-pyridazine-5-carboxylate (1.4 g, 4.20 mmol, 1 eq), cyclopropylboronic acid (720.75 mg, 8.39 mmol, 2 eq), 2-(2- pyridyl)pyridine (1.64 g, 10.49 mmol, 2.5 eq), Na2CO3 (533.60 mg, 5.03 mmol, 1.2 eq) and Cu(OAc)2 (914.43 mg, 5.03 mmol, 1.2 eq) in DCE (20 mL) was degassed and purged with N2 for 3 times and the mixture was stirred at 70 °C for 24 h under N2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with DCM (60 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 3/1, TLC: PE/EtOAc = 3/1, Rf = 0.43) to yield ethyl 5-chloro-2- cyclopropyl-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate (400 mg, 989.69 µmol, 23.6% yield, 90.0% purity) as a yellow gum.1H NMR (500 MHz, CDCl3) δ ppm 8.42 (d, J = 1.8 Hz, 1H), 8.35 (td, J = 1.1, 8.3 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.70-7.65 (m, 1H), 4.51 (q, J = 7.1 Hz, 2H), 4.22 (t, J = 4.0, 7.6 Hz, 1H), 1.43 (t, J = 7.2 Hz, 3H), 1.22-1.16 (m, 2H), 1.13-1.06 (m, 2H); ES-LCMS m/z 364.0, 366.0 [M+H]+. Step 3: Ethyl 2-cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)-3-oxo-pyridazine-4- carboxylate [00403] To a solution of eth
nitrophenyl)-3-oxo-pyridazine-4- carboxylate (400 mg, 989.69 µmol, 1 eq) in DCM (3 mL) was added MeNH2 (1.02 g, 9.90 mmol, 30.0% purity, 10 eq) at 0 °C. The mixture was stirred at 20 °C for 2 h. The solvent was
removed to yield ethyl 2-cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)-3-oxo-pyridazine-4- carboxylate (300 mg, 669.74 µmol, 67.7% yield, 80.0% purity) as a yellow solid.1H NMR (500 MHz, CDCl3) δ ppm 8.33-8.30 (m, 2H), 7.79 (d, J = 7.6 Hz, 1H), 7.70-7.66 (m, 1H), 4.43 (q, J = 7.1 Hz, 2H), 4.02-3.95 (m, 1H), 2.69 (d, J = 5.3 Hz, 3H), 1.44 (t, J = 7.1 Hz, 2H), 1.46-1.42 (m, 1H), 1.03-0.94 (m, 4H); ES-LCMS m/z 359.1 [M+H]+. Step 4: 2-Cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)pyridazin-3-one [00404] To a solution of ethyl 2-
mino)-6-(3-nitrophenyl)-3-oxo- pyridazine-4-carboxylate (300 mg, 669.74 µmol, 1 eq) in DMSO (5 mL) was added LiCl (283.93 mg, 6.70 mmol, 10 eq). The mixture was stirred at 150 °C for 8 h. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 0/1, TLC: PE/EtOAc = 0/1, Rf = 0.15) to yield 2-cyclopropyl-5- (methylamino)-6-(3-nitrophenyl)pyridazin-3-one (200 mg, 628.74 µmol, 93.9% yield, 90.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 8.38-8.27 (m, 2H), 7.83 (d, J = 7.6 Hz, 1H), 7.73-7.66 (m, 1H), 5.92 (s, 1H), 4.03 (t, J = 3.9, 7.5 Hz, 1H), 2.83 (d, J = 3.4 Hz, 3H), 1.09-0.93 (m, 4H); ES-LCMS m/z 287.1 [M+H]+. Step 5: 6-Cyclopropyl-4-hydroxy-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine- 2,5-dione
[00405] To a solution of 2-cyclo
o)-6-(3-nitrophenyl)pyridazin-3-one (200 mg, 628.74 µmol, 1 eq) in Ac2O (3 mL) was added 2-methylpropanedioic acid (222.74 mg, 1.89 mmol, 152.56 µL, 3 eq). The mixture was stirred at 110 °C for 2 h. The solvent was removed to yield a residue which was purified by preparative TLC (PE/EtOAC = 3/1, TLC: PE/EtOAC = 3/1, Rf = 0.24) to yield 6-cyclopropyl-4-hydroxy-1,3-dimethyl-8-(3- nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (200 mg, 434.38 µmol, 69.1% yield, 80.0% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 12.80 (s, 1H), 8.37 (td, J = 2.2, 7.0 Hz, 1H), 8.33 (d, J = 1.5 Hz, 1H), 7.72-7.68 (m, 2H), 4.16-4.09 (m, 1H), 3.06 (s, 3H), 2.16 (s, 3H), 1.20-1.15 (m, 2H), 1.15-1.09 (m, 2H); ES-LCMS m/z 369.0 [M+H]+. Step 6: [6-Cyclopropyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin-4- yl] 4-methylbenzenesulfonate [00406] To a solution of 6-cyclo
dimethyl-8-(3-nitrophenyl)pyrido[2,3- d]pyridazine-2,5-dione (200 mg, 434.38 µmol, 1 eq) in DCM (8 mL) was added DIEA (561.40 mg, 4.34 mmol, 756.61 µL, 10 eq) and 4-methylbenzenesulfonyl chloride (414.06 mg, 2.17 mmol, 5 eq). The mixture was stirred at 50 °C for 12 h. The solvent was removed to yield a residue which was purified by preparative TLC (PE/EtOAC = 3/1, TLC: PE/EtOAC = 3/1, Rf = 0.24) to yield [6-cyclopropyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin- 4-yl] 4-methylbenzenesulfonate (200 mg, 371.27 µmol, 85.5% yield, 97.0% purity) as a yellow
solid.1H NMR (400 MHz, CDCl3) δ ppm 8.38-8.30 (m, 2H), 7.98 (d, J = 8.3 Hz, 2H), 7.77-7.63 (m, 2H), 7.41 (d, J = 8.0 Hz, 2H), 4.22-4.06 (m, 1H), 3.08 (s, 3H), 2.49 (s, 3H), 1.85 (s, 3H), 1.12-1.01 (m, 4H); ES-LCMS m/z 523.1 [M+H]+. Step 7: 6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3- d]pyridazine-2,5-dione [00407] To a solution of 2-fluo
mg, 1.11 mmol, 3 eq) in THF (3 mL) was added NaH (89.10 mg, 2.23 mmol, 60.0% purity, 6 eq) and stirred at 0 °C for 30 min, then [6-cyclopropyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin-4-yl] 4- methylbenzenesulfonate (200 mg, 371.27 µmol, 1 eq) was added at 0 °C. The reaction temperature was slowly warmed up to 25 °C and stirred at 25 °C for 1 h. The reaction mixture was quenched by addition water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative TLC (PE/EtOAC = 1/1, TLC: PE/EtOAC = 1/1, Rf = 0.35) to yield 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3- dimethyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (100 mg, 156.64 µmol, 42.2% yield, 92.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 10.78 (s, 1H), 8.44- 8.27 (m, 2H), 7.75-7.65 (m, 2H), 7.46 (d, J = 1.8, 10.0 Hz, 1H), 7.37 (d, J = 8.5 Hz, 1H), 6.56 (t, J = 8.5 Hz, 1H), 4.10-4.01 (m, 1H), 3.07 (s, 3H), 1.82 (s, 3H), 1.19-1.07 (m, 4H); ES-LCMS m/z 588.0 [M+H]+. Step 8: 8-(3-Aminophenyl)-6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl- pyrido[2,3-d]pyridazine-2,5-dione
[00408] To a solution of 6-cyc
o-anilino)-1,3-dimethyl-8-(3- nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (100 mg, 156.64 µmol, 1 eq) in EtOH (1.5 mL), H2O (1.5 mL) and THF (1.5 mL) was added NH4Cl (83.79 mg, 1.57 mmol, 10 eq) and Fe (43.74 mg, 783.19 µmol, 5 eq). The mixture was stirred at 90 °C for 3 h. The reaction mixture was filtered to remove the insoluble. The filter liquor was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water(NH3H2O+NH4HCO3)-ACN]; B%: 64%-94%,10min), followed by lyophilization to yield 8-(3-aminophenyl)-6-cyclopropyl-4-(2-fluoro-4-iodo- anilino)-1,3-dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (55.23 mg, 99.09 µmol, 63.3% yield, 100.0% purity) as a yellow solid.1H NMR (400MHz, CD3OD) δ ppm 7.55 (d, J = 1.8, 10.3 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 6.82 (d, J = 1.5, 8.0 Hz, 1H), 6.79-6.76 (m, 1H), 6.71 (d, J = 7.7 Hz, 1H), 6.64 (t, J = 8.6 Hz, 1H), 4.04 (t, J = 3.9, 7.5 Hz, 1H), 3.13 (s, 3H), 1.76 (s, 3H), 1.17-1.11 (m, 2H), 1.07-0.99 (m, 2H); ES-LCMS m/z 558.0 [M+H]+. I-50
Step 1: N-[3-[6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-2,5-dioxo-pyrido[2,3- d]pyridazin-8-yl]phenyl]acetamide
F I [00409] To a solution of 8-(3-
l-4-(2-fluoro-4-iodo-anilino)-1,3- dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (20 mg, 35.88 µmol, 1 eq) in DCM (3 mL) was added acetyl chloride (5.63 mg, 71.77 µmol, 5.12 µL, 2 eq) and TEA (14.52 mg, 143.53 µmol, 19.98 µL, 4 eq). The mixture was stirred at 25 °C for 1 h. The solvent was removed to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water(NH3H2O+NH4HCO3)-ACN]; B%: 55%-85%,10min), followed by lyophilization to yield N-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-2,5-dioxo- pyrido[2,3-d]pyridazin-8-yl]phenyl]acetamide (7.96 mg, 13.28 µmol, 37.0% yield, 100.0 purity) as a yellow solid.1H NMR (400 MHz, CD3OD) δ ppm 7.76 (s, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 1.7, 10.3 Hz, 1H), 7.49-7.40 (m, 2H), 7.20 (d, J = 7.6 Hz, 1H), 6.64 (t, J = 8.6 Hz, 1H), 4.05 (t, J = 3.8, 7.5 Hz, 1H), 3.09 (s, 3H), 2.14 (s, 3H), 1.76 (s, 3H), 1.17-1.09 (m, 2H), 1.09-1.00 (m, 2H); ES-LCMS m/z 600.0 [M+H]+. I-20
Step 1: 6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-8-[3- (methylsulfamoylamino)phenyl]pyrido[2,3-d]pyridazine-2,5-dione
[00410] To a solution of 8-(3
4-(2-fluoro-4-iodo-anilino)-1,3- dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (20 mg, 35.88 µmol, 1 eq) in DCM (2 mL) was added TEA (3.63 mg, 35.88 µmol, 4.99 µL, 1 eq) and N-methylsulfamoyl chloride (9.30 mg, 71.77 µmol, 2 eq). The mixture was stirred at 0 °C for 1 h. The solvent was removed to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water(NH3H2O+NH4HCO3)-ACN]; B%: 51%-81%,10min), followed by lyophilization to yield 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-8-[3- (methylsulfamoylamino)phenyl]pyrido[2,3-d]pyridazine-2,5-dione (7.62 mg, 11.46 µmol, 31.9% yield, 97.9% purity) as a yellow solid.1H NMR (400 MHz, CD3OD) δ ppm 7.55 (d, J = 1.8, 10.3 Hz, 1H), 7.49-7.40 (m, 2H), 7.33-7.26 (m, 2H), 7.18 (d, J = 7.6 Hz, 1H), 6.65 (t, J = 8.6 Hz, 1H), 4.05 (t, J = 3.9, 7.5 Hz, 1H), 3.09 (s, 3H), 2.61 (s, 3H), 1.77 (s, 3H), 1.18-1.10 (m, 2H), 1.09- 0.99 (m, 2H); ES-LCMS m/z 651.0 [M+H]+. I-31
dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione
[00411] A mixture of [3-cyclopr
-phenyl)-6,8-dimethyl-2,4,7-trioxo- pyrido[2,3-d]pyrimidin-5-yl] 4-methylbenzenesulfonate (400 mg, 564.78 µmol, 90.0%, 1 eq), 1H-indol-4-amine (111.96 mg, 847.17 µmol, 1.5 eq), Xphos Pd G2 (24.30 mg, 28.24 µmol, 0.05 eq) and Xphos (29.62 mg, 62.13 µmol, 0.11 eq) in 1,4-dioxane (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred under N2 atmosphere at 130 °C for 6 h. The mixture was duilted with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phase was concentrated in vacuum to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.26) to yield 5-((1H-indol-4-yl)amino)-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8- dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (230 mg, 346.51 µmol, 61.4% yield, 90.0% purity) as a green solid.1H NMR (500 MHz, DMSO-d6) δ ppm 11.21 (s, 1H), 10.45 (s, 1H), 7.95 (dd, J = 1.8, 9.5 Hz, 1H), 7.74 (dd, J = 1.7, 8.4 Hz, 1H), 7.34 (t, J = 2.7 Hz, 1H), 7.28 (t, J = 8.1 Hz, 1H), 7.13 (d, J = 8.1 Hz, 1H), 7.02 (t, J = 7.8 Hz, 1H), 6.46-6.38 (m, 2H), 2.75 (s, 3H), 2.70-2.65 (m, 1H), 2.07 (s, 3H), 1.02-0.98 (m, 2H), 0.69-0.64 (m, 2H); ES-LCMS m/z 598.0 [M+H]+. Step 2: 3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-1-(1H-indol-4-yl)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione
[00412] To a solution of 5-((1H
opropyl-1-(2-fluoro-4-iodophenyl)- 6,8-dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (100 mg, 150.66 µmol, 90.0%, 1 eq) was added a drop of NaOMe/MeOH (20 wt %, 58.15 µmol, 1 eq) in THF (2 mL). The mixture was stirred at 25 °C for 2 h. The residue was added AcOH until pH 7 and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.3) to yield 3- cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-1-(1H-indol-4-yl)-6,8-dimethylpyrido[4,3- d]pyrimidine-2,4,7(1H,3H,6H)-trione (40 mg, 56.92 µmol, 37.8% yield, 85.0%) as a green solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.29 (s, 1H), 11.12 (s, 1H), 7.84-7.73 (m, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 2.6 Hz, 1H), 7.12 (t, J = 7.8 Hz, 1H), 7.01- 6.88 (m, 2H), 6.22 (s, 1H), 3.07 (s, 3H), 2.68-2.62 (m, 1H), 2.07 (s, 3H), 0.96-0.93 (m, 2H), 0.75-0.64 (m, 2H); ES-LCMS m/z 598.0 [M+H]+. Step 3: 1-(1-Acetyl-1H-indol-4-yl)-3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione
[00413] To a solution of 3-cyc
ophenyl)amino)-1-(1H-indol-4-yl)- 6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (20 mg, 28.46 µmol, 85.0%, 1 eq) in DCM (2 mL) was added Ac2O (2.91 mg, 28.46 µmol, 2.67 µL, 1 eq) and DMAP (10.43 mg, 85.37 µmol, 3 eq). The mixture was stirred at 0 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue which was by preparative HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; B%: 55%-85%, 10 min) and lyophilized to yield 1-(1-acetyl-1H-indol-4-yl)-3-cyclopropyl-5-((2- fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (9.66 mg, 15.03 µmol, 52.8% yield, 99.5%) as a white solid.1H NMR (400 MHz, CD3OD) δ ppm 8.48 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 3.9 Hz, 1H), 7.66 (d, J = 10.3 Hz, 1H), 7.58 (d, J = 8.3 Hz, 1H), 7.40 (t, J = 8.2 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 6.88 (t, J = 8.6 Hz, 1H), 6.55 (d, J = 3.9 Hz, 1H), 3.20 (s, 3H), 2.73 (s, 1H), 2.69 (s, 3H), 1.11 (s, 3H), 1.07 (d, J = 5.6 Hz, 2H), 0.80 (d, J = 3.9 Hz, 2H); ES-LCMS m/z 640.1 [M+H]+. I-51 & I-52
trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N- methylmethanesulfonimidamide and (R)-N'-(3-(3-cyclopropyl-5-((2-fluoro-4-
iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin- 1(2H)-yl)phenyl)-N-methylmethanesulfonimidamide [00414] To
-dimethyl-2,4,7- trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide (100 mg, 135.81 ^mol, 86.3% purity, 1 eq), MeNH2 (32 mg, 473.95 ^mol, 100% purity, 3.49 eq, HCl) and t-BuOK (1 M, 1 mL, 7.36 eq) in MeCN (20 mL) was added NCS (25 mg, 187.22 ^mol, 1.38 eq) under N2 atmosphere at 25 °C. The mixture was stirred under N2 atmosphere at 25 °C for 12 h. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 0/1, TLC: PE/EtOAc = 1/2, Rf = 0.20). The desired fraction was concentrated under reduced pressure to yield a residue which was separated by SFC (column: (s,s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [0.1%NH3H2O/MeOH]; B%: 60%-60%) to yield peak 1 and peak 2. Peak 1 was concentrated under reduced pressure to yield a residue which was dissolved in MeCN (10 mL) and water (10 mL) and lyophilized to yield (S)-N'-(3-(3-cyclopropyl-5-((2-fluoro-4- iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)- yl)phenyl)-N-methylmethanesulfonimidamide (5.32 mg, 8.01 ^mol, 5.9% yield, 100.0% purity, SFC: Rt = 5.680, ee = 100%, [ ^]29.3 D = -5.26 (MeOH, c = 0.114 g/100 mL)).1H NMR (500 MHz, CD3OD) δ ppm 7.67 (dd, J = 1.8, 10.1 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.06 (s, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.87 (t, J = 8.5 Hz, 1H), 3.22 (s, 3H), 3.12 (s, 3H), 2.74-2.72 (m, 1H), 2.70 (s, 3H), 1.43 (s, 3H), 1.10-1.05 (m, 2H), 0.79-0.75 (m, 2H); ES-LCMS m/z 665.1 [M+H]+. Peak 2 was concentrated under reduced pressure to yield a residue which was dissolved in MeCN (10 mL) and water (10 mL) and lyophilized to yield (R)-
N'-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N-methylmethanesulfonimidamide (5.85 mg, 8.80 ^mol, 6.5% yield, 100.0% purity, SFC: Rt = 6.804, ee = 100%, [ ^]29.4D = +18.28 (MeOH, c = 0.186 g/100 mL)) as a white solid.1H NMR (500 MHz, CD3OD) δ ppm 7.67 (dd, J = 1.8, 10.1 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.33-7.28 (m, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.06 (s, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.87 (t, J = 8.5 Hz, 1H), 3.22 (s, 3H), 3.12 (s, 3H), 2.75-2.72 (m, 1H), 2.70 (s, 3H), 1.43 (s, 3H), 1.10-1.05 (m, 2H), 0.79-0.75 (m, 2H); ES-LCMS m/z 665.0 [M+H]+. I-54
Step 1: 3-Cyclopropyl-1-(1,1-dioxido-3-oxo-2,3-dihydrobenzo[d]isothiazol-6-yl)-5-((2-fluoro- 4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione [00415] To a solution of [3-cy
o-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] 4-methylbenzenesulfonate (200 mg, 307.49 µmol, 98.0%, 1 eq) in DMF (3 mL) was added Cs2CO3 (200.37 mg, 614.98 µmol, 2.5 eq) and 6-amino-1,1-
dioxo-1,2-benzothiazol-3-one (121.89 mg, 614.98 µmol, 2 eq). The mixture was stirred at 130 °C for 6 h. The mixture was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um;mobile phase: [water (HCl)-ACN];B%: 44%-64%, 10 min) and lyophilized to yield 3-cyclopropyl-1-(1,1-dioxido-3-oxo-2,3-dihydrobenzo[d]isothiazol-6-yl)-5-((2-fluoro-4- iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (6.74 mg, 9.69 µmol, 3.15% yield, 95.4% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 11.42 (s, 1H), 8.00 (s, 1H), 7.67 (s, 1H), 7.60 (s, 2H), 7.44-7.35 (m, 2H), 7.01 (s, 1H), 3.41 (s, 3H), 2.84- 2.75 (m, 1H), 1.53 (s, 3H), 1.31-1.12 (m, 2H), 0.91-0.79 (m, 2H); ES-LCMS m/z 664.0 [M+H]+. I-22
Step 1: 1-(5-Aminopyridin-3-yl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione [00416] To a solution of [3-cyc
do-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] 4-methylbenzenesulfonate (250 mg, 384.36 µmol, 98.0%, 1 eq) in DMF (5 mL) was added pyridine-3,5-diamine (50.33 mg, 461.24 µmol, 1.2 eq) and 2,6- LUTIDINE (102.96 mg, 960.91 µmol, 111.91 µL, 2.5 eq). The mixture was stirred under N2 atmosphere at 140 °C for 6 h. The reaction mixture was diluted with H2O (20 mL), extracted
with DCM:IPA (3:1, 30 ml) and the organic layer was concentrated under reduced pressure to yield 1-(5-aminopyridin-3-yl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (150 mg, 261.17 µmol, 68.0% yield, 100.0% purity) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 8.08-7.93 (m, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.26 (d, J = 18.1 Hz, 2H), 7.19-7.09 (m, 1H), 6.85 (s, 1H), 6.51 (s, 1H), 6.48 (s, 1H), 4.89 (s, 1H), 2.83 (s, 3H), 2.37-2.25 (m, 1H), 1.79 (s, 3H), 0.96 (s, 2H), 0.57 (d, J = 14.7 Hz, 2H); ES-LCMS m/z 575.1 [M+H]+. Step 2: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[5- (methylsulfamoylamino)-3-pyridyl]pyrido[4,3-d]pyrimidine-2,4,7-trione [00417] To a solution of 1-(
opyl-5-((2-fluoro-4- iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (95 mg, 165.41 µmol, 100.0%, 1 eq) in DCM (5 mL) was added N-methylsulfamoyl chloride (32.15 mg, 248.11 µmol, N/A, 1.5 eq) and TEA (50.21 mg, 496.22 µmol, 69.07 µL, 3 eq). The mixture was stirred under N2 atmosphere at 0 °C for 3 h. The reaction mixture was diluted with H2O (20 mL), extracted with DCM (30 mL x 3) and the organic layer was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um;mobile phase: [water(NH3H2O + NH4HCO3)-ACN];B%: 20%-50%, 10 min) and lyophilized to yield 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[5- (methylsulfamoylamino)-3-pyridyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (16.52 mg, 24.67 µmol, 14.9% yield, 99.7% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 7.99 (ddd, J = 1.6, 4.9, 9.3 Hz, 1H), 7.76 ( d, J = 8.3 Hz, 1H), 7.38-7.26 (m, 2H), 7.18-7.04 (m, 2H), 6.05 (d,
J = 15.5 Hz, 2H), 5.47 (s, 1H), 2.82 (d, J = 2.1 Hz, 3H), 2.39-2.35 (m, 3H), 2.33 (d, J = 1.8 Hz, 1H), 1.77 (d, J = 1.9 Hz, 3H), 1.00-0.91 (m, 2H), 0.58 (s, 2H); ES-LCMS m/z 668.0 [M+H]+. I-41 and I-42
[00418] To a solution of sulfuryl
0 mmol, 629.63 ^L, 1.01 eq) and Et3N (1.89 g, 18.73 mmol, 2.61 mL, 3 eq) in DCM (50 mL) was added a solution of tert-butyl N-(2- aminoethyl)carbamate (1 g, 6.24 mmol, 980.39 ^L, 1 eq) in DCM (5 mL) dropwise under N2 atmosphere at -40~-50 °C. The mixture was stirred under N2 atmosphere at -40~-50 °C for 5 minutes to yield tert-butyl N-[2-(chlorosulfonylamino)ethyl]carbamate (75 g, crude) as colorless liquid, which was used in the next step without further purification. Step 2: tert-Butyl N-[2-[[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7- trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]sulfamoylamino]ethyl]carbamate
[00419] To a solution o
luoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (90 mg, 156.97 ^mol, 100% purity, 1 eq) and Et3N (145.40 mg, 1.44 mmol, 0.2 mL, 9.15 eq) in DCM (20 mL) was added tert-butyl N-[2- (chlorosulfonylamino)ethyl]carbamate (10 g, 38.65 mmol, N/A purity, 246.23 eq). The mixture was stirred at 15 °C for 10 minutes. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 3/4, Rf = 0.48) to yield the desired compound (100 mg).50 mg of the desired compound (100 mg) was purified by preparative HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 50%-80%, 10 min) and lyophilized to yield tert-butyl N-[2-[[3-[3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1- yl]phenyl]sulfamoylamino]ethyl]carbamate (16.07 mg, 20.07 ^mol, 12.8% yield, 99.4% purity) as a white solid.1H NMR (500 MHz, CD3OD) δ ppm 7.58 (dd, J = 1.8, 10.1 Hz, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.31 (t, J = 8.1 Hz, 1H), 7.17 (s, 1H), 7.13 (dd, J = 1.4, 8.1 Hz, 1H), 7.00-6.95 (m, 1H), 6.78 (t, J = 8.5 Hz, 1H), 3.13 (s, 3H), 3.03-2.98 (m, 2H), 2.97-2.92 (m, 2H), 2.64 (tt, J = 3.8, 7.2 Hz, 1H), 1.33 (s, 9H), 1.32 (s, 3H), 1.02-0.96 (m, 2H), 0.71-0.66 (m, 2H); ES-LCMS m/z 796.1 [M+H]+. Step 3: 1-[3-(2-Aminoethylsulfamoylamino)phenyl]-3-cyclopropyl-5-(2-fluoro-4-iodo- anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione
[00420] To a solution o
-fluoro-4-iodo-anilino)-6,8- dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]sulfamoylamino]ethyl]carbamate (50 mg, 62.84 ^mol, N/A purity, 1 eq) in DCM (2 mL) was added TFA (3.08 g, 27.01 mmol, 2 mL, 429.83 eq). The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water (0.05%NH3H2O+10mM NH4HCO3)- ACN]; B%: 45%-75%, 10 min) and lyophilized to yield 1-[3-(2- aminoethylsulfamoylamino)phenyl]-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl- pyrido[4,3-d]pyrimidine-2,4,7-trione (16.78 mg, 23.94 umol, 38.09% yield, 99.223% purity) was obtained as a white solid.1H NMR (500 MHz, CD3OD) δ ppm 7.68 (dd, J = 1.8, 10.1 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.41 (t, J = 8.0 Hz, 1H), 7.28-7.25 (m, 1H), 7.25-7.22 (m, 1H), 7.08-7.04 (m, 1H), 6.88 (t, J = 8.5 Hz, 1H), 3.22 (s, 3H), 3.06 (t, J = 6.1 Hz, 2H), 2.76-2.70 (m, 3H), 1.41 (s, 3H), 1.10-1.05 (m, 2H), 0.80-0.76 (m, 2H); ES-LCMS m/z 696.0 [M+H]+. I-47 and I-48
Step 1: Methanesulfinyl chloride
[00421] To a mixture of (methyldisulfan
hane (5.07 g, 53.82 mmol, 4.83 mL, 1 eq) and AcOH (6.46 g, 107.64 mmol, 6.16 mL, 2 eq) was added sulfuryl chloride (21.79 g, 161.47 mmol, 16.14 mL, 3 eq) dropwise under N2 atmosphere at -20 °C. The mixture was stirred under N2 atmosphere at -20 °C for 2 h. The mixture was warmed to 20 °C slowly and stirred under N2 atmosphere at 20 °C for 1 h and at 35 °C for 1 h. The mixture was concentrated under reduced pressure to yield methanesulfinyl chloride (10.6 g, crude) as colorless oil, which was used in the next step without further purification.1H NMR (400 MHz, CDCl3) δ ppm 3.38 (s, 3H). Step 2: (S)-N-[3-[3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo- pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide and (R)-N-[3-[3-cyclopropyl-5-(2- fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1- yl]phenyl]methanesulfinamide [00422] To
-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (200 mg, 348.82 ^mol, 100% purity, 1 eq) and Et3N (363.50 mg, 3.59 mmol, 0.5 mL, 10.30 eq) in DCM (10 mL) was added methanesulfinyl chloride (200 mg, 2.03 mmol, N/A purity, 5.82 eq). The mixture was stirred at 25 °C for 0.5 h. TLC (PE/EtOAc = 2/3, Rf = 0.15) showed the starting material was almost consumed. The reaction mixture was concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 0/1, TLC: PE/EtOAc = 2/3, Rf = 0.15) to yield N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo- pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide (200 mg, 91.9% purity) as a white
solid. The product (160 mg) was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water ( NH4HCO3)-ACN]; B%: 40%-70%, 10 min) to give desired compound as a white solid, which was further separated by SFC (column: DAICEL CHIRALCEL OD-H (250mm*30mm, 5um); mobile phase: [0.1% NH3H2O EtOH]; B%: 45%- 45%) to yield peak 1 and peak 2. Peak 1 was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 43%-73%, 11 min), followed by lyophilization to yield (S)-N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl- 2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]methanesulfinamide (13.75 mg, 20.91 ^mol, 9.0% yield, 96.6% purity, SFC: Rt = 4.554, ee = 100%, [α]27.8D = -36.364 (MeOH, c = 0.011 g/100 mL)) as a white solid.1H NMR (400 MHz, CD3OD) δ ppm 7.66 (dd, J = 1.8, 10.1 Hz, 1H), 7.59-7.54 (m, 1H), 7.39 (t, J = 8.1 Hz, 1H), 7.17-7.08 (m, 2H), 7.05-7.00 (m, 1H), 6.86 (t, J = 8.5 Hz, 1H), 3.20 (s, 3H), 2.84 (s, 3H), 2.71 (tt, J = 3.8, 7.2 Hz, 1H), 1.40 (s, 3H), 1.10-1.00 (m, 2H), 0.79-0.70 (m, 2H); ES-LCMS m/z 636.1 [M+H]+. Peak 2 was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 40%-70%, 10 min) to give desired compound as a white solid, which was further separated by SFC (column: DAICEL CHIRALCEL OD-H (250mm*30mm,5um); mobile phase: [0.1% NH3H2O ETOH]; B%: 45%- 45%, min), followed by lyophilization to yield a residue which was purified by preparative HPLC (column: Welch Xtimate C18150*25mm*5um; mobile phase: [water ( NH4HCO3)- ACN]; B%: 40%-70%, 11 min), followed by lyophilization to yield (R)-N-[3-[3-cyclopropyl-5- (2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1- yl]phenyl]methanesulfinamide (12.41 mg, 19.05 ^mol, 8.2% yield, 97.6% purity, SFC: Rt = 4.991, ee = 89.18%, [α]27.7D = +107.692 (MeOH, c = 0.013 g/100 mL)) as a white solid.1H NMR (400 MHz, CD3OD) δ ppm 7.66 (dd, J = 1.8, 10.2 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.17-7.10 (m, 2H), 7.02 (dd, J = 1.1, 8.0 Hz, 1H), 6.86 (t, J = 8.5 Hz, 1H), 3.20 (s, 3H), 2.84 (s, 3H), 2.71 (tt, J = 3.7, 7.2 Hz, 1H), 1.40 (s, 3H), 1.08-1.03 (m, 2H), 0.78-0.73 (m, 2H); ES-LCMS m/z 636.0 [M+H]+. I-55
(methylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione [00423] To a solution of 1-(3-a
yl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (100 mg, 174.41 ^mol, 100% purity, 1 eq) in THF (5 mL) was added NaH (40 mg, 1.00 mmol, 60% purity, 5.73 eq). The mixture was stirred at 25 °C for 0.5 h. MeI (30 mg, 211.36 ^mol, 13.16 ^L, 1.21 eq) was added. The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched with H2O (20 mL) and extracted with EtOAc (20 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(HCl)-ACN]; B%: 49%-69%, 10 min) and lyophilized to yield 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- (methylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (6 mg, 9.87 ^mol, 5.7% yield, 96.6% purity) as an off-white solid.1H NMR (500 MHz, CD3OD) δ ppm 7.68 (dd, J = 1.8, 10.2 Hz, 1H), 7.66-7.62 (m, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.50 (t, J = 1.9 Hz, 1H), 7.47-7.40 (m, 2H), 6.90 (t, J = 8.5 Hz, 1H), 3.22 (s, 3H), 3.10 (s, 3H), 2.74 (tt, J = 3.7, 7.2 Hz, 1H), 1.37 (s, 3H), 1.11-1.06 (m, 2H), 0.81-0.76 (m, 2H); ES-LCMS m/z 588.1 [M+H]+.
Step 2: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- [methyl(methylsulfamoyl)amino]phenyl]-2,4,7-trioxo-pyrido[4,3-d]pyrimidine [00424] To a solution of 3-cycl
-anilino)-6,8-dimethyl-1-[3- (methylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (5 mg, 8.22 ^mol, 96.6% purity, 1 eq) and DIEA (22.26 mg, 172.23 ^mol, 30 ^L, 20.95 eq) in DCM (5 mL) was added N- methylsulfamoyl chloride (10 mg, 77.18 ^mol, 9.39 eq) at 0 °C. The mixture was stirred at 0 °C for 10 minutes. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(HCl)-ACN]; B%: 54%-74%, 10 min) and lyophilized to yield 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- [methyl(methylsulfamoyl)amino]phenyl]-2,4,7-trioxo-pyrido[4,3-d]pyrimidine (1.58 mg, 2.28 ^mol, 27.8% yield, 98.3% purity) as a white solid.1H NMR (500 MHz, CD3OD) δ ppm 11.24 (s, 1H), 7.68 (dd, J = 1.3, 10.3 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.53-7.48 (m, 2H), 7.48-7.44 (m, 1H), 7.34-7.25 (m, 1H), 6.88 (dt, J = 2.5, 8.5 Hz, 1H), 3.27 (s, 3H), 3.22 (d, J = 2.9 Hz, 3H), 2.73 (tt, J = 3.7, 7.2 Hz, 1H), 2.65 (s, 3H), 1.39 (s, 3H), 1.13-1.02 (m, 2H), 0.83-0.75 (m, 2H); ES- LCMS m/z 680.9 [M+H]+. I-82
ethyl- pyrido[2,3-d]pyrimidine-2,4,7-trione [00425] To a solution of [3-c
o-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (300 mg, 482.70 μmol, 99.0%, 1 eq) in DMF (2 mL) was added 2,6-lutidine (155.17 mg, 1.45 mmol, 168.66 μL, 3 eq) and benzene-1,4-diamine (78.30 mg, 724.05 μmol, 1.5 eq). The mixture was stirred at 60 °C for 2 h. The reaction mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (PE/EtOAc = 2/1, TLC: PE/EtOAc = 2/1, Rf = 0.20) to yield tert-butyl 5-(4-aminoanilino)- 3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione (200 mg, 327.89 μmol, 67.9% yield, 94.0% purity) as a brown solid.1H NMR (400 MHz,
DMSO-d6) δ ppm 10.16-10.03 (m, 1H), 8.04-7.87 (m, 1H), 7.77-7.60 (m, 1H), 7.32-7.13 (m, 1H), 6.85-6.65 (m, 2H), 6.63-6.45 (m, 2H), 5.24-4.99 (m, 2H), 2.73-2.67 (m, 3H), 1.51-1.34 (m, 3H), 1.09-0.89 (m, 2H), 0.76-0.56 (m, 2H); ES-LCMS m/z 574.1 [M+H]+. Step 2: tert-Butyl 1-(4-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl- pyrido[4,3-d]pyrimidine-2,4,7-trione [00426] A mixture of 5-(4-amin
1-(2-fluoro-4-iodo-phenyl)-6,8- dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione (100 mg, 163.95 μmol, 1 eq) and NaOMe/MeOH (163.95 μmol, 11 μL, 30.0%, 1 eq) in THF (0.3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 25 °C for 1 h under N2 atmosphere. The reaction mixture was quenched by addition AcOH (0.1 mL), and then diluted with H2O (20 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (DCM/MeOH = 10/1, TLC: DCM/MeOH= 10/1, Rf = 0.80) to yield tert-butyl 1-(4-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (90 mg, 67.50 μmol, 41.2% yield, 43.0% purity) as a yellow solid. ES-LCMS m/z 574.0 [M+H]+. Step 3: tert-Butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[4- (methylsulfamoylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione
[00427] To a solution of 1
opropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (43.00 mg, 75.00 μmol, 1 eq) in DCM (1 mL) was added TEA (15.18 mg, 149.99 μmol, 20.88 μL, 2 eq) and N-methylsulfamoyl chloride (9.72 mg, 75.00 μmol, 1 eq). The mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water (FA)-ACN]; B%: 56%-76%, 12 min), followed by lyophilization to yield tert-butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-1-[4-(methylsulfamoylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (8.77 mg, 13.16 μmol, 17.6% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.23-10.93 (m, 1H), 10.00-9.81 (m, 1H), 7.90-7.70 (m, 1H), 7.59-7.52 (m, 1H), 7.50-7.44 (m, 1H), 7.29-7.23 (m, 2H), 7.22-7.15 (m, 2H), 6.99-6.82 (m, 1H), 3.12-3.01 (m, 3H), 2.63-2.57 (m, 1H), 2.47-2.44 (m, 3H), 1.22 (s, 3H), 0.99-0.91 (m, 2H), 0.72-0.57 (m, 2H); ES-LCMS m/z 667.0 [M+H]+. I-83
3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate [00428] To a solution of 3-cyclop
odo-phenyl)-5-hydroxy-6,8-dimethyl- pyrido[2,3-d]pyrimidine-2,4,7-trione (3.2 g, 6.62 mmol, 1 eq) and 2,6-lutidine (1.21 g, 11.26 mmol, 1.31 mL, 1.7 eq) in DCM (20 mL) was added dropwise trifluoromethylsulfonyl trifluoromethanesulfonate (3.74 g, 13.24 mmol, 2.19 mL, 2 eq) at 0 °C over 30 min. And then, the mixture was stirred at 25 °C under N2 atmosphere for 12 h. The reaction mixture was successively with the saturated aqueous NaHCO3(40 mL x 3), 1N HCl (40 mL x 3) and extracted with DCM (50 mL x 3). The organic layer was washed with brine (50 mL x 3) and dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from EtOAc/DCM = 100/1 to 8/1, TLC: PE/EtOAc = 1/1, Rf
= 0.3) to yield 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (4 g, 6.43 mmol, 97.1% yield, 98.9% purity) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 7.95 (dd, J = 1.8, 9.4 Hz, 1H), 7.72 (dd, J = 1.3, 8.4 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 2.76 (s, 3H), 2.71-2.65 (m, 1H), 2.01 (s, 3H), 1.08-0.98 (m, 2H), 0.68-0.58 (m, 2H); ES-LCMS m/z 615.9 [M+H]+. Step 2: Methyl 2-chlorosulfonyl-5-nitro-benzoate [00429] To a solution of methyl 2-am
enzoate (5 g, 25.49 mmol, 1 eq) in HCl (12 M, 80 mL, 37.66 eq) was added a solution of NaNO2 (1.76 g, 25.49 mmol, 1 eq) in H2O (5 mL) dropwise at 0 °C. The mixture was stirred at 0 °C for 15 min and a solution of NaHSO3 (23.9 g, 229.67 mmol, 9.01 eq) in H2O (50 mL) was added, followed by CuSO4 (406.83 mg, 2.55 mmol, 0.1 eq) at 0 °C, the mixture was stirred at 0 °C for 45 min. The mixture was diluted with water (100 mL) and extracted with EtOAc (80 mL x 3). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 5/1, TLC: PE/EtOAc = 3/1, Rf = 0.51) to yield methyl 2-chlorosulfonyl-5- nitro-benzoate (5.6 g, 18.02 mmol, 70.7% yield, 90.0% purity) as a yellow solid.1H NMR (500 MHz, CDCl3) δ ppm 8.58 (d, J = 2.3 Hz, 1H), 8.54 (d, J = 2.3, 8.7 Hz, 1H), 8.40 (d, J = 8.7 Hz, 1H), 4.06 (s, 3H). Step 3: 5-Nitro-1,1-dioxo-1,2-benzothiazol-3-one
[00430] A mixture of methyl 2-chlorosulfonyl-5-nitro-benzoate (5.6 g, 18.02 mmol, 90.0%, 1 eq) in NH3.H2O (54.60 g, 436.23 mmol, 60 mL, 28.0% purity, 24.21 eq) was stirred at 25 °C for 16 h. TLC (PE/EtOAc = 1/1, Rf = 0.04) indicated the starting material was consumed completely and one new spot formed. The mixture was adjusted pH to 2 with HCl (12 M) diluted with water (150 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield 5-nitro-1,1-dioxo-1,2-benzothiazol-3-one (3.7 g, 14.59 mmol, 80.9% yield, 90.0% purity) as a yellow solid.1H NMR (500 MHz, CDCl3) δ ppm 8.88 (d, J = 2.0 Hz, 1H), 8.76 (d, J = 2.0, 8.4 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H). Step 4: 5-Amino-1,1-dioxo-1,2-benzothiazol-3-one [00431] To a solution of Pd/C (3 g, 1
% purity, 1 eq) in THF (50 mL) was added 5-nitro-1,1-dioxo-1,2-benzothiazol-3-one (3.7 g, 14.59 mmol, 90.0%, 1 eq) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25 °C for 12 h. The reaction mixture was filtered and the filter was concentrated to yield a residue which was added EtOAc/MeOH (10/1, 10 mL), and stirred at 25 °C for 2 h. The slurry was filtered, and the cake was rinsed with EtOAc (2 x 3 mL). The solid was collected and dried in vacuo to yield 5-amino-1,1-dioxo-1,2-benzothiazol-3-one (2.8 g, 13.42 mmol, 91.9% yield, 95.0% purity) as a yellow solid.1H NMR (500 MHz, DMSO-d6) δ ppm 7.67 (d, J = 8.4 Hz, 1H), 7.02-6.90 (m, 2H). Step 5: 3-Cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-5-[(1,1,3-trioxo-1,2- benzothiazol-5-yl)amino]pyrido[2,3-d]pyrimidine-2,4,7-trione
[00432] To a solution of 5-a
ol-3-one (134.81 mg, 646.16 µmol, 95.0%, 2.01 eq) in DMF (3 mL) was added NaH (51.44 mg, 1.29 mmol, 60.0% purity, 4 eq) and stirred at 0 °C for 30 min, [3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (200 mg, 321.47 µmol, 98.9%, 1 eq) was added at 0 °C. The reaction temperature was slowly warmed up to 25 °C and stirred at 25 °C for 3 h. The reaction mixture was quenched by addition water (40 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water(NH3H2O+NH4HCO3)-ACN]; B%: 28%-58%,10min), followed by lyophilization to yield 3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-5-[(1,1,3-trioxo-1,2-benzothiazol-5- yl)amino]pyrido[2,3-d]pyrimidine-2,4,7-trione (25 mg, 37.68 µmol, 11.7% yield, 100.0% purity) as a white solid.1H NMR (500 MHz, CD3OD) δ ppm 7.93 (d, J = 8.1 Hz, 1H), 7.84 (s, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.66 (d, J = 10.2 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 6.89 (t, J = 8.5 Hz, 1H), 3.21 (s, 3H), 2.76-2.68 (m, 1H), 1.34 (s, 3H), 1.10-1.01 (m, 2H), 0.81-0.73 (m, 2H); ES-LCMS m/z 663.9 [M+H]+. Step 6: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-(1,1,3-trioxo-1,2- benzothiazol-5-yl)pyrido[4,3-d]pyrimidine-2,4,7-trione
[00433] To a solution of 3-cyclopropyl-l-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-5-[(l,l,3- trioxo-l,2-benzothiazol-5-yl)amino]pyrido[2,3-d]pyrimidine-2,4,7-trione (20 mg, 30.15 pmol, 1 eq) in THF (0.5 mL) was added NaOMe (5.82 mg, 30.15 pmol, 28.0% purity, 1 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous NaiSCL, filtered and concentrated under reduced pressure to give a residue which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water(NH3H20+NH4HC03)-ACN]; B%: 29%-59%, lOmin), followed by lyophilization to yield 3 -cy cl opropyl-5-(2-fluoro-4-iodo-anilino)-6, 8-dimethyl- 1 -( 1 , 1 ,3 -trioxo- 1 ,2- benzothiazol-5-yl)pyrido[4,3-d]pyrimidine-2,4,7-trione (2.99 mg, 4.46 pmol, 14.8% yield,
99.0% purity) as a white solid. 1HNMR (500 MHz, CDCh) d ppm 11.06 (s, 1H), 7.80 (d, J= 7.9 Hz, 1H), 7.73 (s, 1H), 7.60 (d, J= 8.1 Hz, 1H), 7.47 (d, J= 10.4 Hz, 1H), 7.42 (d, J= 8.5 Hz, 1H), 6.70 (t, J= 8.3 Hz, 1H), 3.07 (s, 3H), 2.64 (s, 1H), 1.18 (s, 3H), 1.02 (d, 7= 6.1 Hz, 2H), 0.70 (s, 2H); ES-LCMS m/z 663.9 [M+H]+.
[00434] 1-102
Step 1: tert-Butyl N-[3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7-trioxo- pyrido[2,3-d]pyrimidin-5-yl]amino]-1-bicyclo[1.1.1]pentanyl]carbamate [00435] To a solution of N-[3
do-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesµLfonate (300 mg, 482.70 µmol, 99.0%, 1 eq) in DMF (8 mL) was added 2,6-lutidine (155.17 mg, 1.45 mmol, 168.66 µL, 3 eq) and tert- butyl N-(3-amino-1-bicyclo[1.1.1]pentanyl)carbamate (143.55 mg, 724.05 µmol, 1.5). The mixture was stirred at 60 °C for 2 h. The reaction mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with
brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (PE/EtOAc = 2/1, TLC: PE/EtOAc = 2/1, Rf = 0.20) to yield tert-butyl N-[3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl]amino]-1-bicyclo[1.1.1]pentanyl]carbamate (200 mg, 292.4 µmol, 60.6% yield, 97.0% purity) as a white solid.1H NMR (500 MHz, DMSO-d6) δ ppm 8.64 (s, 1H), 8.02-7.87 (m, 1H), 7.76-7.63 (m, 1H), 7.54 (s, 1H), 7.25-7.13 (m, 1H), 2.74-2.67 (m, 3H), 2.67-2.61 (m, 1H), 2.18-2.07 (m, 6H), 1.99-1.93 (m, 3H), 1.43-1.31 (m, 9H), 1.08-0.94 (m, 2H), 0.73-0.59 (m, 2H); ES-LCMS m/z 664.5 [M+H]+. Step 2: tert-Butyl N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo- pyrido[4,3-d]pyrimidin-1-yl]-1-bicyclo[1.1.1]pentanyl]carbamate
[00436] A mixture of N-[3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl]amino]-1-bicyclo[1.1.1]pentanyl]carbamate (100 mg, 146.20 µmol, 97.0%, 1 eq) and NaOMe/MeOH (19.40 mg, 20 µL, 30.0%, 1.00 eq) in THF (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 25 °C for 1 h under N2 atmosphere. The reaction mixture was quenched by addition CH3COOH (0.1 mL), and then diluted with H2O (20 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue, which was purified by preparative TLC (PE/EtOAc = 3/1, TLC: PE/EtOAc = 3/1, Rf = 0.30) to yield tert-butyl N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)- 6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]-1-bicyclo[1.1.1]pentanyl]carbamate (50
mg, 67.8 µmol, 46.4% yield, 90.0% purity) as a white solid.1H NMR (500 MHz, DMSO-d6) δ ppm 10.36-10.16 (m, 1H), 7.83-7.68 (m, 1H), 7.65-7.55 (m, 1H), 7.54-7.48 (m, 1H), 6.96-6.82 (m, 1H), 3.08-3.06 (m, 3H), 2.59-2.54 (m, 3H), 2.44-2.39 (m, 2H), 2.23-2.18 (m, 2H), 2.03-2.01 (m, 3H), 1.39-1.35 (m, 9H), 0.93-0.84 (m, 2H), 0.63-0.39 (m, 2H); ES-LCMS m/z 664.0 [M+H]+. Step 3: tert-Butyl 1-(3-amino-1-bicyclo[1.1.1]pentanyl)-3-cyclopropyl-5-(2-fluoro-4-iodo- anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione [00437] To a solution of tert-b
.1.1]pentanyl)-3-cyclopropyl-5-(2- fluoro-4-iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (50 mg, 67.82 µmol, 90.0%, 1 eq) in DCM (1 mL) was added TFA (462.00 mg, 4.05 mmol, 0.3 mL, 59.74 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to yield a residue pressure to yield tert-butyl 1-(3-amino-1-bicyclo[1.1.1]pentanyl)-3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (30 mg, 44.29 µmol, 65.3% yield, 100.0% purity, TFA) was obtained as a white solid which was used in the next step without further purification.1H NMR (500 MHz, DMSO-d6) δ ppm 10.31 (s, 1H), 8.69 (s, 2H), 7.76 (dd, J=1.8, 10.2 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H), 6.90 (t, J=8.5 Hz, 1H), 3.06 (s, 3H), 2.65- 2.62 (m, 1H), 2.52-2.51 (m, 6H), 2.01 (s, 3H), 0.94-0.85 (m, 2H), 0.67-0.34 (m, 2H); ES-LCMS m/z 564.1 [M+H]+. Step 3: tert-Butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- (methylsµLfamoylamino)-1-bicyclo[1.1.1]pentanyl]pyrido[4,3-d]pyrimidine-2,4,7-trione
[00438] To a solution of 1-(3-a
anyl)-3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (30 mg, 44.29 µmol, 100.0%, 1 eq, TFA) in DCM (4 mL) was added TEA (10.78 mg, 106.50 µmol, 14.82 µL, 2 eq) and N- methylsµLfamoyl chloride (6.90 mg, 53.25 µmol, 1 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to yield a residue pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water (FA)-ACN]; B%: 51%-71%, 12 min), followed by lyophilization to yield product, followed by lyophilization to yield tert-butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-1-[3-(methylsulfamoylamino)-1-bicyclo[1.1.1]pentanyl]pyrido[4,3-d]pyrimidine-2,4,7- trione (12.23 mg, 18.63 µmol, 42.1% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 10.26 (s, 1H), 7.85 (s, 1H), 7.76 (dd, J = 1.8, 10.3 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 6.88 (t, J = 8.6 Hz, 1H), 6.76 (q, J = 5.0 Hz, 1H), 3.06 (s, 3H), 2.57-2.54 (m, 1H), 2.52 (s, 1H), 2.42 (d, J = 5.0 Hz, 6H), 2.23 (s, 3H), 2.02 (s, 3H), 0.88 (s, 2H), 0.67-0.32 (m, 2H); ES- LCMS m/z 657.0 [M+H]+. I-103
rioxo- pyrido[2,3-d]pyrimidin-5-yl]amino]azetidine-1-carboxylate [00439] To a solution of [3-cyc
o-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (400 mg, 642.95 ^mol, 98.9% purity, 1 eq) and tert-butyl 3-aminoazetidine-1-carboxylate (221.46 mg, 1.29 mmol, 2 eq) in 1,4- dioxane (8 mL) was added Cs2CO3 (628.45 mg, 1.93 mmol, 3 eq). The mixture was stirred at 40 °C for 3 h. TLC (petroleum ether: EtOAc=1:1, Rf = 0.4) showed that new point was formed and start material was consumed completely. The reaction mixture was quenched by addition of H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative TLC (PE/EtOAc = 1/1.5, TLC: PE/EtOAc = 1/1, Rf = 0.40) to yield tert-butyl 3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7-trioxo-
pyrido[2,3-d]pyrimidin-5-yl]amino]azetidine-1-carboxylate (150 mg, 223.55 ^mol, 34.8% yield, 95.0% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 9.19 (d, J = 6.4 Hz, 1H), 7.61 (dd, J = 8.8, 15.6 Hz, 2H), 6.89 (t, J = 8.0 Hz, 1H), 4.56-4.46 (m, 1H), 4.27 (td, J = 8.4, 13.2 Hz, 2H), 3.92 (dt, J = 5.2, 9.2 Hz, 2H), 2.89 (s, 3H), 2.79-2.71 (m, 1H), 2.04 (s, 3H), 1.46 (s, 9H), 1.22-1.15 (m, 2H), 0.86-0.78 (m, 2H); ES-LCMS m/z 638.0 [M+H]+. Step 2: tert-Butyl 3-[[3-(cyclopropylcarbamoyl)-2-(2-fluoro-4-iodo-anilino)-1,5-dimethyl-6- oxo-4-pyridyl]amino]azetidine-1-carboxylate and tert-butyl 3-[3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]azetidine-1-carboxylate [00440] To a s
o ut on o NaO e ( 3. mg, 7 .5 mo , 0.5 m , 30% purity, 1 eq) in THF (30 mL) was added tert-butyl 3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl]amino]azetidine-1-carboxylate (50 mg, 74.52 ^mol, 95% purity, 1 eq) at 0 °C. The mixture was stirred at 0 °C for 1 h. TLC (petroleum ether: EtOAc=3:1, Rf = 0.7) showed that new point was formed and start material was consumed completely. The reaction mixture was quenched by addition of AcOH (1 mL) and stirred at 0 °C for 10 min. The mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (PE/EtOAc = 2/1 , TLC: PE/EtOAc = 3/1, Rf = 0.70) to yield tert-butyl 3-[[3- (cyclopropylcarbamoyl)-2-(2-fluoro-4-iodo-anilino)-1,5-dimethyl-6-oxo-4- pyridyl]amino]azetidine-1-carboxylate (20 mg, 31.07 ^mol, 41.7% yield, 95.0% purity) and tert- butyl 3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3- d]pyrimidin-1-yl]azetidine-1-carboxylate (20 mg, 29.81 ^mol, 40.0% yield, 95.0% purity) as a
white solid.1H NMR (500 MHz, CDCl3) δ ppm 10.87 (s, 1H), 7.50 (dd, J = 1.5, 9.5 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 6.68 (t, J = 8.5 Hz, 1H), 4.75 (quin, J=6.5 Hz, 1H), 4.26 - 4.15 (m, 4H), 3.19 - 3.12 (m, 3H), 2.71 (tt, J=4.0, 7.0 Hz, 1H), 2.03 (s, 3H), 1.43 (s, 9H), 1.10 (q, J = 7.0 Hz, 2H), 0.73-0.67 (m, 2H); 1H NMR (500 MHz, CDCl3) δ ppm 8.83 (s, 1H), 7.42 (dd, J = 2.0, 10.0 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 2.0 Hz, 1H), 6.35 (t, J = 8.5 Hz, 1H), 4.61 (d, J = 10.0 Hz, 1H), 4.21 (dd, J = 8.0, 9.0 Hz, 2H), 3.73 (dd, J = 5.0, 9.5 Hz, 2H), 3.25 (s, 3H), 2.74 (dt, J = 3.5, 7.0 Hz, 1H), 2.08 (s, 3H), 2.04 (s, 3H), 1.44 (s, 9H), 0.80-0.75 (m, 2H), 0.38-0.32 (m, 2H); ES-LCMS m/z 612.1 [M+H]+; ES-LCMS m/z 638.0 [M+H]+. Step 3: 1-(Azetidin-3-yl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-pyrido[4,3- d]pyrimidine-2,4,7-trione [00441] To a solution of tert-bu
-fluoro-4-iodo-anilino)-6,8-dimethyl- 2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]azetidine-1-carboxylate (20 mg, 29.81 ^mol, 95.0% purity, 1 eq) in DCM (5 mL) was added TFA (1.54 g, 13.51 mmol, 1 mL). The mixture was stirred at 25 °C for 1 h. The mixture was concentrated to yield 1-(azetidin-3-yl)-3-cyclopropyl-5- (2-fluoro-4-iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (16 mg, 28.29 ^mol, 94.9% yield, 95.0% purity) as a white solid, which was used directly in the next step without further purification. ES-LCMS m/z 538.0 [M+H]+. Step 4: 3-[3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3- d]pyrimidin-1-yl]-N-methyl-azetidine-1-sulfonamide
[00442] To a solution of 1-(aze
5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (16 mg, 28.29 ^mol, 95% purity, 1 eq) in DCM (5 mL) was added Et3N (8.59 mg, 84.86 ^mol, 11.81 ^L, 3 eq) and N-methylsulfamoyl chloride (3.67 mg, 28.29 ^mol, 1 eq) under N2 atmosphere at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched by addition of H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by preparative HPLC (column: Welch Xtimate C18150 * 25 mm * 5 ^m; mobile phase: [water( NH4HCO3)-ACN]; B%: 36%-66%,11min) to yield 3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)- 6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]-N-methyl-azetidine-1-sulfonamide (6.76 mg, 10.47 ^mol, 37.0% yield, 100.0% purity) as a white solid.1H NMR (500 MHz, CD3OD) δ ppm 7.64 (d, J = 10.0 Hz, 1H), 7.55 (d, J = 8.5 Hz, 1H), 6.84 (t, J = 8.5 Hz, 1H), 4.95 (d, J = 7.5 Hz, 1H), 4.08 (quin, J = 8.0 Hz, 4H), 3.18 (s, 3H), 2.72-2.67 (m, 4H), 2.05 (s, 3H), 1.03 (q, J = 7.0 Hz, 2H), 0.68-0.62 (m, 2H); ES-LCMS m/z 630.9 [M+H]+. I-109
o-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate [00443] To a solution of 3-cyclop
odo-phenyl)-5-hydroxy-6,8-dimethyl- pyrido[2,3-d]pyrimidine-2,4,7-trione (5 g, 10.35 mmol, 1 eq) and 2,6-lutidine (1.88 g, 17.59 mmol, 2.05 mL, 1.7 eq) in DCM (35 mL) was added dropwise trifluoromethylsulfonyl trifluoromethanesulfonate (5.84 g, 20.69 mmol, 3.41 mL, 2 eq) at 0 °C over 30 min. The mixture was stirred at 25 °C for 12 h under N2 atmosphere. The reaction mixture was quenched with the saturated aqueous NaHCO3 (40 mL x 3), extracted with DCM (50 mL x 3). The organic layer was washed with 1N HCl (40 mL x 3) and brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from EtOAc/DCM = 100/1 to 8/1, TLC: PE/EtOAc = 1/1, Rf = 0.3) to yield 3- cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (4 g, 6.43 mmol, 97.1% yield,
98.9% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 7.95 (dd, J = 1.2, 9.5 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 2.76 (s, 3H), 2.70-2.66 (m, 1H), 2.01 (s, 3H), 1.08-0.98 (m, 2H), 0.62 (t, J = 11.9 Hz, 2H); ES-LCMS m/z 615.9 [M+H]+. Step 2: tert-Butyl (3-((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo- 1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)cyclobutyl)carbamate [00444] A mixture of 3-cyclo
nyl)-6,8-dimethyl-2,4,7-trioxo- 1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (350 mg, 563.15 µmol, 99.0%, 1 eq), tert-butyl N-(3-aminocyclobutyl)carbamate (115.38 mg, 619.46 µmol, 1.1 eq) and Cs2CO3 (550.45 mg, 1.69 mmol, 3 eq) in DMF (5 mL) was stirred at 40 °C for 1 h, then the mixture was stirred under N2 atmosphere at 25 °C for 4 h. The reaction mixture was diluted with H2O (30 mL), extracted with EtOAc (40 mL x 3), and washed with brine (40 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by prep-TLC (SiO2, PE/EtOAc = 1/1, Rf = 0.3) to yield tert-butyl (3- ((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)cyclobutyl)carbamate (200 mg, 255.42 µmol, 45.4% yield, 83.2% purity) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 9.07 (d, J = 6.6 Hz, 1H), 7.88 (d, J = 9.3 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.16- 7.11 (m, 1H), 4.27 (d, J = 6.4 Hz, 1H), 3.87-3.41 (m, 1H), 2.62 (s, 3H), 2.35-2.09 (m, 4H), 1.95 (s, 3H), 1.93 (s, 1H), 1.34 (s, 9H), 0.99 (s, 2H), 0.65 (s, 2H); ES-LCMS m/z 652.1 [M+H]+. Step 3: tert-Butyl (3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7- trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)cyclobutyl)carbamate
[00445] To a solution of tert-b
2-fluoro-4-iodophenyl)-6,8- dimethyl-2,4,7-trioxo-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5- yl)amino)cyclobutyl)carbamate (150 mg, 191.57 µmol, 83.2%, 1 eq) in THF (30 mL) was added NaOMe/MeOH (191.57 µmol, 0.25 mL, 30%, 1 eq) at 0 °C under N2 atmosphere. The mixture was stirred under N2 atmosphere at 25 °C for 0.5 h. The residue was added the CH3COOH to pH = 7 and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield the residue which was purified by prep-TLC (SiO2, PE/EtOAc = 1:1, Rf1 = 0.3) to yield tert-butyl(3-(3-cyclopropyl-5-((2- fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin- 1(2H)-yl)cyclobutyl)carbamate (30 mg, 32.56 µmol, 17.0% yield, 70.7% purity) as a yellow solid.1H NMR (500 MHz, CDCl3) δ ppm 10.99-10.67 (m, 1H), 7.51 (d, J = 9.6 Hz, 1H), 7.45- 7.41 (m, 1H), 6.68-6.61 (m, 1H), 4.09-3.93 (m, 1H), 3.76 (s, 3H), 3.53-3.41 (m, 1H), 3.17 (s, 3H), 3.12-2.99 (m, 1H), 2.79-2.70 (m, 2H), 2.48-2.24 (m, 2H), 1.45 (s, 9H), 1.18-1.07 (m, 2H), 0.92-0.86 (m, 2H); ES-LCMS m/z 652.1 [M+H]+. [00446] Step 4: 1-(3-Aminocyclobutyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)- 6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione
I F [00447] To a solution of tert-bu
2-fluoro-4-iodophenyl)amino)-6,8- dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)cyclobutyl)carbamate (30 mg, 32.56 µmol, 70.7%, 1 eq) in DCM (2 mL) was added TFA (616.00 mg, 5.40 mmol, 0.4 mL, 165.94 eq). The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was diluted with H2O (10 mL), extracted with DCM (30 mL x 3) and washed with brine (30 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield 1-(3-aminocyclobutyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3- d]pyrimidine-2,4,7(1H,3H,6H)-trione (30 mg, 31.56 µmol, 96.9% yield, 70.0% purity, TFA) as yellow oil, which was used in the next step without further purification.1H NMR (500 MHz, CD3OD) δ ppm 7.62 (d, J = 10.5 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 6.87-6.74 (m, 1H), 5.33 (s, 2H), 4.16 (d, J = 7.0 Hz, 1H), 3.43 (d, J = 1.5 Hz, 1H), 3.16 (s, 3H), 2.72 (s, 2H), 2.64 (s, 1H), 2.28-2.18 (m, 2H), 1.27 (s, 3H), 1.04-0.99 (m, 2H), 0.90-0.88 (m, 2H); ES-LCMS m/z 552.1 [M+H]+. Step 5: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- (methylsulfamoylamino)cyclobutyl]pyrido[4,3-d]pyrimidine-2,4,7-trione
[00448] To a solution of 1-(3-a
ropyl-5-((2-fluoro-4- iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (30 mg, 31.56 µmol, 70.0%, 1 eq, TFA) in DCM (2 mL) was added TEA (9.58 mg, 94.68 µmol, 13.18 µL, 3 eq) and N-methylsulfamoyl chloride (4.50 mg, 34.72 µmol, 1.1 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was diluted with H2O (20 mL), extracted with DCM (20 mL x 3). The organic layer was concentrated under reduced pressure, which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(NH4HCO3)-ACN]; B%: 45%-70%, 11 min) and lyophilized to yield 3-cyclopropyl-5-(2- fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3-(methylsulfamoylamino)cyclobutyl]pyrido[4,3- d]pyrimidine-2,4,7-trione (3.13 mg, 4.81 µmol, 15.3% yield, 99.1% purity) as a yellow solid.1H NMR (500 MHz, CD3OD) δ ppm 7.64 (dd, J = 1.8, 10.0 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 6.82 (t, J = 8.5 Hz, 1H), 4.29-4.20 (m, 1H), 3.51-3.47 (m, 1H), 3.18 (s, 3H), 2.87-2.82 (m, 2H), 2.67 (td, J = 3.4, 7.1 Hz, 1H), 2.58 (s, 3H), 2.44-2.37 (m, 2H), 2.08 (s, 3H), 1.05-0.98 (m, 2H), 0.66- 0.62 (m, 2H); ES-LCMS m/z 645.0 [M+H]+. [00449] I-111 O I F O OTf NH NH
Step 1: 3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-5-((1-oxoisoindolin-5- yl)amino)pyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione [00450] To a solution of [3-c
-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (200 mg, 321.80 µmol, 99.0%, 1 eq) in DMF (3 mL) was added 5-aminoisoindolin-1-one (47.68 mg, 321.80 µmol, 1 eq) and Cs2CO3 (314.54 mg, 965.39 µmol, 3 eq). The mixture was stirred at 60 °C for 3 h. The reaction mixture was diluted with H2O (30 mL), extracted with DCM (40 mL x 3) and the organic layer was concentrated under reduced pressure, which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um;mobile phase: [water(NH3H2O+NH4HCO3)-ACN]; B%: 40%-70%, 10 min) and lyophilized to yield 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8- dimethyl-5-((1-oxoisoindolin-5-yl)amino)pyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (120 mg, 193.09 µmol, 60.0% yield, 98.7% purity) as a white solid.1H NMR (500 MHz, DMSO-d6) δ ppm 7.90-7.83 (m, 1H), 7.73-7.63 (m, 1H), 7.45 (d, J = 8.9 Hz, 1H), 6.79-6.62 (m, 2H), 6.06 (d, J = 6.6 Hz, 2H), 4.70-4.56 (m, 2H), 4.46 (d, J = 15.9 Hz, 1H), 3.38 (s, 3H), 2.52 (s, 1H), 2.50 (s, 3H), 2.07 (d, J = 1.5 Hz, 1H), 0.94-0.83 (m, 2H), 0.67-0.45 (m, 2H); ES-LCMS m/z 614.0 [M+H]+. Step 2: 3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-1-(1-oxoisoindolin-5- yl)pyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione
[00451] To a solution of 3-cycl
ophenyl)-6,8-dimethyl-5-((1- oxoisoindolin-5-yl)amino)pyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (30 mg, 48.27 µmol, 98.7%, 1 eq) in THF (30 mL) was added MeONa/MeOH (48.27 µmol, 0.1 mL, 30%, 1 eq) at 0°C under N2 atmosphere. The resulting mixture was stirred under N2 atmosphere at 25°C for 20 min. The residue was added the CH3COOH to pH = 7 and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure, which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um;mobile phase: [water(TFA)-ACN]; B%: 38%-58%, 12 min) and lyophilized to yield 3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-1-(1-oxoisoindolin-5- yl)pyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (3.84 mg, 6.26 µmol, 13.0% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.01 (s, 1H), 8.46 (s, 1H), 7.87 (dd, J = 1.5, 9.4 Hz, 1H), 7.70-7.63 (m, 2H), 7.27-7.22 (m, 1H), 7.21-7.17 (m, 2H), 4.34 (s, 2H), 3.11 (s, 3H), 2.33 (d, J = 1.8 Hz, 1H), 1.29 (s, 3H), 0.95 (d, J = 7.0 Hz, 2H), 0.67-0.57 (m, 2H); ES-LCMS m/z 613.9 [M+H]+. Synthesis of 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- [methyl(methylsulfamoyl)amino]phenyl]-2,4,7-trioxo-pyrido[4,3-d]pyrimidine (I-55)
Step 1 : 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-l-[3- (methylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione
[00452] To a solution of l-(3-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (100 mg, 174.41 pmol, 100% purity, 1 eq) in THF (5 mL) was added NaH (40 mg, 1.00 mmol, 60% purity, 5.73 eq). The mixture was stirred at 25 °C for 0.5 h. Mel (30 mg, 211.36 pmol, 13.16 pL, 1.21 eq) was added. The mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched with LLO (20 mL) and extracted with EtOAc (20 mL x 3). The organic layer was dried over NaiSCL, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(HCl)-ACN]; B%: 49%-69%, 10 min) and lyophilized to yield 3 -cyclopropyl-5 -(2-fluoro-4-iodo-anilino)-6, 8-dimethyl- 1 -[3-
(methylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (6 mg, 9.87 pmol, 5.7% yield, 96.6% purity) as an off-white solid. 1HNMR (500 MHz, CD3OD) d ppm 7.68 (dd, J= 1.8, 10.2 Hz,
1H), 7.66-7.62 (m, 1H), 7.60 (d, J= 8.4 Hz, 1H), 7.50 (t, J= 1.9 Hz, 1H), 7.47-7.40 (m, 2H),
6.90 (t, J= 8.5 Hz, 1H), 3.22 (s, 3H), 3.10 (s, 3H), 2.74 (tt, J= 3.7, 7.2 Hz, 1H), 1.37 (s, 3H), 1.11-1.06 (m, 2H), 0.81-0.76 (m, 2H); ES-LCMS m/z 588.1 [M+H]+.
Step 2: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-l-[3- [methyl(methylsulfamoyl)amino]phenyl]-2,4,7-trioxo-pyrido[4,3-d]pyrimidine
[00453] To a solution of 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-l-[3- (methylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (5 mg, 8.22 pmol, 96.6% purity, 1 eq) and DIEA (22.26 mg, 172.23 pmol, 30 pL, 20.95 eq) in DCM (5 mL) was added N- methylsulfamoyl chloride (10 mg, 77.18 pmol, 9.39 eq) at 0 °C. The mixture was stirred at 0 °C for 10 minutes. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (30 mL x 3). The organic layer was dried over NaiSCL, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(HCl)-ACN]; B%: 54%-74%, 10 min) and lyophilized to yield 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-l-[3- [methyl(methylsulfamoyl)amino]phenyl]-2,4,7-trioxo-pyrido[4,3-d]pyrimidine (1.58 mg, 2.28 pmol, 27.8% yield, 98.3% purity) as a white solid. ¾ NMR (500 MHz, CD3OD) d ppm 11.24 (s, 1H), 7.68 (dd, J= 1.3, 10.3 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 7.53-7.48 (m, 2H), 7.48-7.44 (m, 1H), 7.34-7.25 (m, 1H), 6.88 (dt, J= 2.5, 8.5 Hz, 1H), 3.27 (s, 3H), 3.22 (d, J= 2.9 Hz, 3H), 2.73
(tt, J= 3.7, 7.2 Hz, 1H), 2.65 (s, 3H), 1.39 (s, 3H), 1.13-1.02 (m, 2H), 0.83-0.75 (m, 2H); ES- LCMS m/z 680.9 [M+H]+.
Synthesis of tert- Butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-l-[3- (methylspLfamoylamino)-l-bicyclo [1.1.1] pentanyl] pyrido [4,3-d\ pyrimidine-2, 4, 7-trione (I-
102)
Step 1: tert- Butyl /V-[3-[[3-cyclopropyl-l-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7-trioxo- pyrido[2,3-d]pyrimidin-5-yl]amino]-l-bicyclo[l.l.l]pentanyl]carbamate
[00454] To a solution of N-[3
y p py do-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesµlfonate (300 mg, 482.70 µmol, 99.0%, 1 eq) in DMF (8 mL) was added 2,6-lutidine (155.17 mg, 1.45 mmol, 168.66 µL, 3 eq) and tert- butyl N-(3-amino-1-bicyclo[1.1.1]pentanyl)carbamate (143.55 mg, 724.05 µmol, 1.5). The mixture was stirred at 60 °C for 2 h. The reaction mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (PE/EtOAc = 2/1, TLC: PE/EtOAc = 2/1, Rf = 0.20) to yield tert-butyl N-[3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl]amino]-1-bicyclo[1.1.1]pentanyl]carbamate (200 mg, 292.4 µmol, 60.6% yield, 97.0% purity) as a white solid.1H NMR (500 MHz, DMSO-d6) δ ppm 8.64 (s, 1H), 8.02-7.87 (m, 1H), 7.76-7.63 (m, 1H), 7.54 (s, 1H), 7.25-7.13 (m, 1H), 2.74-2.67 (m, 3H), 2.67-2.61 (m, 1H), 2.18-2.07 (m, 6H), 1.99-1.93 (m, 3H), 1.43-1.31 (m, 9H), 1.08-0.94 (m, 2H), 0.73-0.59 (m, 2H); ES-LCMS m/z 664.5 [M+H]+. Step 2: tert-Butyl N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo- pyrido[4,3-d]pyrimidin-1-yl]-1-bicyclo[1.1.1]pentanyl]carbamate
[00455] A mixture of N-[3-[[3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl]amino]-1-bicyclo[1.1.1]pentanyl]carbamate (100 mg, 146.20 µmol, 97.0%, 1 eq) and NaOMe/MeOH (19.40 mg, 20 µL, 30.0%, 1.00 eq) in THF (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 25 °C for 1 h under N2 atmosphere. The reaction mixture was quenched by addition CH3COOH (0.1 mL), and then diluted with H2O (20 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue, which was purified by preparative TLC (PE/EtOAc = 3/1, TLC: PE/EtOAc = 3/1, Rf = 0.30) to yield tert-butyl N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)- 6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]-1-bicyclo[1.1.1]pentanyl]carbamate (50 mg, 67.8 µmol, 46.4% yield, 90.0% purity) as a white solid.1H NMR (500 MHz, DMSO-d6) δ ppm 10.36-10.16 (m, 1H), 7.83-7.68 (m, 1H), 7.65-7.55 (m, 1H), 7.54-7.48 (m, 1H), 6.96-6.82 (m, 1H), 3.08-3.06 (m, 3H), 2.59-2.54 (m, 3H), 2.44-2.39 (m, 2H), 2.23-2.18 (m, 2H), 2.03-2.01 (m, 3H), 1.39-1.35 (m, 9H), 0.93-0.84 (m, 2H), 0.63-0.39 (m, 2H); ES-LCMS m/z 664.0 [M+H]+. Step 3: tert-Butyl 1-(3-amino-1-bicyclo[1.1.1]pentanyl)-3-cyclopropyl-5-(2-fluoro-4-iodo- anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione
[00456] To a solution of tert-b
.1.1]pentanyl)-3-cyclopropyl-5-(2- fluoro-4-iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (50 mg, 67.82 µmol, 90.0%, 1 eq) in DCM (1 mL) was added TFA (462.00 mg, 4.05 mmol, 0.3 mL, 59.74 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to yield a residue pressure to yield tert-butyl 1-(3-amino-1-bicyclo[1.1.1]pentanyl)-3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (30 mg, 44.29 µmol, 65.3% yield, 100.0% purity, TFA) was obtained as a white solid which was used in the next step without further purification.1H NMR (500 MHz, DMSO-d6) δ ppm 10.31 (s, 1H), 8.69 (s, 2H), 7.76 (dd, J=1.8, 10.2 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H), 6.90 (t, J=8.5 Hz, 1H), 3.06 (s, 3H), 2.65- 2.62 (m, 1H), 2.52-2.51 (m, 6H), 2.01 (s, 3H), 0.94-0.85 (m, 2H), 0.67-0.34 (m, 2H); ES-LCMS m/z 564.1 [M+H]+. Step 3: tert-Butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- (methylsµLfamoylamino)-1-bicyclo[1.1.1]pentanyl]pyrido[4,3-d]pyrimidine-2,4,7-trione
[00457] To a solution of 1-(3-a
y . . p tanyl)-3-cyclopropyl-5-(2-fluoro-4- iodo-anilino)-6,8-dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (30 mg, 44.29 µmol, 100.0%, 1 eq, TFA) in DCM (4 mL) was added TEA (10.78 mg, 106.50 µmol, 14.82 µL, 2 eq) and N- methylsµLfamoyl chloride (6.90 mg, 53.25 µmol, 1 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to yield a residue pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water (FA)-ACN]; B%: 51%-71%, 12 min), followed by lyophilization to yield product, followed by lyophilization to yield tert-butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-1-[3-(methylsulfamoylamino)-1-bicyclo[1.1.1]pentanyl]pyrido[4,3-d]pyrimidine-2,4,7- trione (12.23 mg, 18.63 µmol, 42.1% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 10.26 (s, 1H), 7.85 (s, 1H), 7.76 (dd, J = 1.8, 10.3 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 6.88 (t, J = 8.6 Hz, 1H), 6.76 (q, J = 5.0 Hz, 1H), 3.06 (s, 3H), 2.57-2.54 (m, 1H), 2.52 (s, 1H), 2.42 (d, J = 5.0 Hz, 6H), 2.23 (s, 3H), 2.02 (s, 3H), 0.88 (s, 2H), 0.67-0.32 (m, 2H); ES- LCMS m/z 657.0 [M+H]+. Synthesis of 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- (methylsulfamoylamino)cyclobutyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (I-109)
O OH O OTf NHBoc N N Step 1: 7,8-
hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate [00458] To a solution of 3-cyclop
odo-phenyl)-5-hydroxy-6,8-dimethyl- pyrido[2,3-d]pyrimidine-2,4,7-trione (5 g, 10.35 mmol, 1 eq) and 2,6-lutidine (1.88 g, 17.59 mmol, 2.05 mL, 1.7 eq) in DCM (35 mL) was added dropwise trifluoromethylsulfonyl
trifluoromethanesulfonate (5.84 g, 20.69 mmol, 3.41 mL, 2 eq) at 0 °C over 30 min. The mixture was stirred at 25 °C for 12 h under N2 atmosphere. The reaction mixture was quenched with the saturated aqueous NaHCO3 (40 mL x 3), extracted with DCM (50 mL x 3). The organic layer was washed with 1N HCl (40 mL x 3) and brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from EtOAc/DCM = 100/1 to 8/1, TLC: PE/EtOAc = 1/1, Rf = 0.3) to yield 3- cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (4 g, 6.43 mmol, 97.1% yield, 98.9% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 7.95 (dd, J = 1.2, 9.5 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 2.76 (s, 3H), 2.70-2.66 (m, 1H), 2.01 (s, 3H), 1.08-0.98 (m, 2H), 0.62 (t, J = 11.9 Hz, 2H); ES-LCMS m/z 615.9 [M+H]+. Step 2: tert-Butyl (3-((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo- 1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)cyclobutyl)carbamate [00459] A mixture of 3-cyclo
nyl)-6,8-dimethyl-2,4,7-trioxo- 1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (350 mg, 563.15 µmol, 99.0%, 1 eq), tert-butyl N-(3-aminocyclobutyl)carbamate (115.38 mg, 619.46 µmol, 1.1 eq) and Cs2CO3 (550.45 mg, 1.69 mmol, 3 eq) in DMF (5 mL) was stirred at 40 °C for 1 h, then the mixture was stirred under N2 atmosphere at 25 °C for 4 h. The reaction mixture was diluted with H2O (30 mL), extracted with EtOAc (40 mL x 3), and washed with brine (40 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by prep-TLC (SiO2, PE/EtOAc = 1/1, Rf = 0.3) to yield tert-butyl (3- ((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8-
hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)cyclobutyl)carbamate (200 mg, 255.42 µmol, 45.4% yield, 83.2% purity) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 9.07 (d, J = 6.6 Hz, 1H), 7.88 (d, J = 9.3 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.16- 7.11 (m, 1H), 4.27 (d, J = 6.4 Hz, 1H), 3.87-3.41 (m, 1H), 2.62 (s, 3H), 2.35-2.09 (m, 4H), 1.95 (s, 3H), 1.93 (s, 1H), 1.34 (s, 9H), 0.99 (s, 2H), 0.65 (s, 2H); ES-LCMS m/z 652.1 [M+H]+. Step 3: tert-Butyl (3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7- trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)cyclobutyl)carbamate I F [00460] To a solution of tert-bu
2-fluoro-4-iodophenyl)-6,8- dimethyl-2,4,7-trioxo-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5- yl)amino)cyclobutyl)carbamate (150 mg, 191.57 µmol, 83.2%, 1 eq) in THF (30 mL) was added NaOMe/MeOH (191.57 µmol, 0.25 mL, 30%, 1 eq) at 0 °C under N2 atmosphere. The mixture was stirred under N2 atmosphere at 25 °C for 0.5 h. The residue was added the CH3COOH to pH = 7 and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield the residue which was purified by prep-TLC (SiO2, PE/EtOAc = 1:1, Rf1 = 0.3) to yield tert-butyl(3-(3-cyclopropyl-5-((2- fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin- 1(2H)-yl)cyclobutyl)carbamate (30 mg, 32.56 µmol, 17.0% yield, 70.7% purity) as a yellow solid.1H NMR (500 MHz, CDCl3) δ ppm 10.99-10.67 (m, 1H), 7.51 (d, J = 9.6 Hz, 1H), 7.45- 7.41 (m, 1H), 6.68-6.61 (m, 1H), 4.09-3.93 (m, 1H), 3.76 (s, 3H), 3.53-3.41 (m, 1H), 3.17 (s, 3H), 3.12-2.99 (m, 1H), 2.79-2.70 (m, 2H), 2.48-2.24 (m, 2H), 1.45 (s, 9H), 1.18-1.07 (m, 2H), 0.92-0.86 (m, 2H); ES-LCMS m/z 652.1 [M+H]+.
Step 4: 1-(3-Aminocyclobutyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione [00461] To a solution of tert-bu
2-fluoro-4-iodophenyl)amino)-6,8- dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)cyclobutyl)carbamate (30 mg, 32.56 µmol, 70.7%, 1 eq) in DCM (2 mL) was added TFA (616.00 mg, 5.40 mmol, 0.4 mL, 165.94 eq). The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was diluted with H2O (10 mL), extracted with DCM (30 mL x 3) and washed with brine (30 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield 1-(3-aminocyclobutyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3- d]pyrimidine-2,4,7(1H,3H,6H)-trione (30 mg, 31.56 µmol, 96.9% yield, 70.0% purity, TFA) as yellow oil, which was used in the next step without further purification.1H NMR (500 MHz, CD3OD) δ ppm 7.62 (d, J = 10.5 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 6.87-6.74 (m, 1H), 5.33 (s, 2H), 4.16 (d, J = 7.0 Hz, 1H), 3.43 (d, J = 1.5 Hz, 1H), 3.16 (s, 3H), 2.72 (s, 2H), 2.64 (s, 1H), 2.28-2.18 (m, 2H), 1.27 (s, 3H), 1.04-0.99 (m, 2H), 0.90-0.88 (m, 2H); ES-LCMS m/z 552.1 [M+H]+. Step 5: 3-Cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3- (methylsulfamoylamino)cyclobutyl]pyrido[4,3-d]pyrimidine-2,4,7-trione
[00462] To a solution of 1-(3-a
ropyl-5-((2-fluoro-4- iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (30 mg, 31.56 µmol, 70.0%, 1 eq, TFA) in DCM (2 mL) was added TEA (9.58 mg, 94.68 µmol, 13.18 µL, 3 eq) and N-methylsulfamoyl chloride (4.50 mg, 34.72 µmol, 1.1 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was diluted with H2O (20 mL), extracted with DCM (20 mL x 3). The organic layer was concentrated under reduced pressure, which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(NH4HCO3)-ACN]; B%: 45%-70%, 11 min) and lyophilized to yield 3-cyclopropyl-5-(2- fluoro-4-iodo-anilino)-6,8-dimethyl-1-[3-(methylsulfamoylamino)cyclobutyl]pyrido[4,3- d]pyrimidine-2,4,7-trione (3.13 mg, 4.81 µmol, 15.3% yield, 99.1% purity) as a yellow solid.1H NMR (500 MHz, CD3OD) δ ppm 7.64 (dd, J = 1.8, 10.0 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 6.82 (t, J = 8.5 Hz, 1H), 4.29-4.20 (m, 1H), 3.51-3.47 (m, 1H), 3.18 (s, 3H), 2.87-2.82 (m, 2H), 2.67 (td, J = 3.4, 7.1 Hz, 1H), 2.58 (s, 3H), 2.44-2.37 (m, 2H), 2.08 (s, 3H), 1.05-0.98 (m, 2H), 0.66- 0.62 (m, 2H); ES-LCMS m/z 645.0 [M+H]+. Synthesis of 3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-1-(1- oxoisoindolin-5-yl)pyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (I-116)
Step 1: 3-Cyclo
y y , y indolin-5- yl)amino)pyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione [00463] To a solution of [3-c
-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (200 mg, 321.80 µmol, 99.0%, 1 eq) in DMF (3 mL) was added 5-aminoisoindolin-1-one (47.68 mg, 321.80 µmol, 1 eq) and Cs2CO3 (314.54 mg, 965.39 µmol, 3 eq). The mixture was stirred at 60 °C for 3 h. The reaction mixture was diluted with H2O (30 mL), extracted with DCM (40 mL x 3) and the organic layer was concentrated under reduced pressure, which was purified by preparative HPLC (column:
Boston Prime C18150*30mm*5um;mobile phase: [water(NH3H2O+NH4HCO3)-ACN]; B%: 40%-70%, 10 min) and lyophilized to yield 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8- dimethyl-5-((1-oxoisoindolin-5-yl)amino)pyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (120 mg, 193.09 µmol, 60.0% yield, 98.7% purity) as a white solid.1H NMR (500 MHz, DMSO-d6) δ ppm 7.90-7.83 (m, 1H), 7.73-7.63 (m, 1H), 7.45 (d, J = 8.9 Hz, 1H), 6.79-6.62 (m, 2H), 6.06 (d, J = 6.6 Hz, 2H), 4.70-4.56 (m, 2H), 4.46 (d, J = 15.9 Hz, 1H), 3.38 (s, 3H), 2.52 (s, 1H), 2.50 (s, 3H), 2.07 (d, J = 1.5 Hz, 1H), 0.94-0.83 (m, 2H), 0.67-0.45 (m, 2H); ES-LCMS m/z 614.0 [M+H]+. Step 2: 3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-1-(1-oxoisoindolin-5- yl)pyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione [00464] To a solution of 3-cycl
ophenyl)-6,8-dimethyl-5-((1- oxoisoindolin-5-yl)amino)pyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (30 mg, 48.27 µmol, 98.7%, 1 eq) in THF (30 mL) was added MeONa/MeOH (48.27 µmol, 0.1 mL, 30%, 1 eq) at 0°C under N2 atmosphere. The resulting mixture was stirred under N2 atmosphere at 25°C for 20 min. The residue was added the CH3COOH to pH = 7 and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure, which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um;mobile phase: [water(TFA)-ACN]; B%: 38%-58%, 12 min) and lyophilized to yield 3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-1-(1-oxoisoindolin-5- yl)pyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (3.84 mg, 6.26 µmol, 13.0% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.01 (s, 1H), 8.46 (s, 1H), 7.87
(dd, J = 1.5, 9.4 Hz, 1H), 7.70-7.63 (m, 2H), 7.27-7.22 (m, 1H), 7.21-7.17 (m, 2H), 4.34 (s, 2H), 3.11 (s, 3H), 2.33 (d, J = 1.8 Hz, 1H), 1.29 (s, 3H), 0.95 (d, J = 7.0 Hz, 2H), 0.67-0.57 (m, 2H); ES-LCMS m/z 613.9 [M+H]+. Synthesis of 1-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7- trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N- methylmethanesulfonamide (I-46) Step
[00465] To a solution of (3-nit chloride (500 mg, 2.12 mmol, 1 eq) in THF (1 mL) was added DIEA (
548.47 mg, 4.24 mmol, 739.17 µL, 2 eq) and MeNH2.EtOH (197.69 mg, 6.37 mmol, 212.18 µL, 3 eq). The mixture was stirred at 25 °C for 1 h. The mixture was quenched with water (30 mL) and extracted with DCM (30 mL x 3). The combined organic phase was washed with NaHCO3 (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 2/1, Rf = 0.4) to yield 4- methylbenzenesulfonate N-methyl-1-(3-nitrophenyl)methanesulfonamide (200 mg, 861.19 µmol, 40.6% yield, 99.1% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 8.32-8.20 (m,
2H), 7.79 (d, J = 7.6 Hz, 1H), 7.64-7.58 (m, 1H), 4.35 (s, 2H), 4.27-4.13 (m, 1H), 2.79 (d, J = 5.4 Hz, 3H). Step 2: 1-(3-Aminophenyl)-N-methylmethanesulfonamide [00466] To a solution of 4-methylb
N-methyl-1-(3- nitrophenyl)methanesulfonamide (200 mg, 861.19 µmol, 99.1%, 1 eq) in MeOH (2 mL) was added Pd/C (200 mg, 861.19 µmol, 10.0%, 1 eq) under N2 atmosphere. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25 °C for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to yield 1-(3-aminophenyl)-N-methyl-methanesulfonamide (180 mg, 853.90 µmol, 99.2% yield, 95.0 % purity) as a yellow solid, which was used in the next step without further purification.1H NMR (500 MHz, CDCl3) δ ppm 7.22-7.17 (m, 1H), 7.17-7.14 (m, 1H), 6.75-6.73 (m, 2H), 6.71- 6.67 (m, 2H), 6.66-6.57 (m, 1H), 4.18 (s, 2H), 2.02 (s, 3H). Step 3: 1-(3-((3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)-N-methylmethanesulfonamide
[00467] To a solution of 1-(3-aminophenyl)-N-methyl-methanesulfonamide (150 mg, 711.58 µmol, 95.0%, 1.91 eq) in DMA (3 mL) was added 2,6-lutidine (119.77 mg, 1.12 mmol, 130.19 µL, 3 eq) and [3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-2,4,7-trioxo-pyrido[2,3- d]pyrimidin-5-yl] 4-methylbenzenesulfonate (250 mg, 372.60 µmol, 90.0%, 1 eq). The mixture was stirred under microwave (2 bar) at 140 °C for 3 h. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water (HCl) - ACN]; B%: 46%-66%, 10 min) and lyophilized to yield a product, which was added addition sat aq NaHCO3 until pH = 7 and extracted with EtOAc (20 mL x 3), then the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield 1-(3- ((3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-1,2,3,4,7,8- hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)-N-methylmethanesulfonamide (45 mg, 58.55 µmol, 15.7% yield, 86.6% purity) as a yellow solid.1H NMR (500 MHz, CD3OD) δ ppm 7.85 (dd, J = 1.8, 9.5 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.22-7.14 (m, 2H), 7.08-6.99 (m, 2H), 4.33 (s, 2H), 2.95 (s, 3H), 2.82-2.76 (m, 1H), 2.69 (s, 3H), 1.67 (s, 3H), 1.16-1.09 (m, 2H), 0.81 (d, J = 2.6 Hz, 2H); ES-LCMS m/z 666.0 [M+H]+. Step 4: 1-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N-methylmethanesulfonamide
7- trioxo-1,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl)amino)phenyl)-N- methylmethanesulfonamide (45 mg, 58.15 µmol, 86.0%, 1 eq) in THF (1 mL) was added a drop Page 211 of 262 396661-032WO (190374)
of NaOMe/MeOH (20 wt%, 58.15 µmol, 1 eq). The mixture was stirred under N2 atmosphere at 25 °C for 1 h. The residue was added AcOH until pH = 7 and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18 150*30mm*5um;mobile phase: [water( NH3H2O+NH4HCO3)-ACN]; B%: 53%-83%, 10 min) and lyophilized to yield 1-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl- 2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)-N- methylmethanesulfonamide (10.01 mg, 14.96 µmol, 25.7% yield, 99.4% purity) as a white solid. 1H NMR (400 MHz, CD3OD) δ ppm 7.66 (dd, J = 1.7, 10.3 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.51-7.47 (m, 2H), 7.43 (s, 1H), 7.39 (dd, J = 3.2, 5.6 Hz, 1H), 6.86 (t, J = 8.4 Hz, 1H), 4.37 (s, 2H), 3.20 (s, 3H), 2.76-2.69 (m, 1H), 2.67 (s, 3H), 1.34 (s, 3H), 1.08-1.03 (m, 2H), 0.81-0.74 (m, 2H); ES-LCMS m/z 666.1 [M+H]+. Synthesis of 6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-3,7-dimethyl-8-[2-methyl-3- (methylsulfamoylamino)phenyl]pyrano[3,2-c]pyridine-2,5-dione (I-33) I F I F
Step 1: 6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-3,7-dimethyl-8-[2-methyl-3- (methylsulfamoylamino)phenyl]pyrano[3,2-c]pyridine-2,5-dione
[00469] To a stirred solution of 8-(3-amino-2-methyl-phenyl)-6-cyclopropyl-4-(2-fluoro-4- iodo-anilino)-3,7-dimethyl-pyrano[3,2-c]pyridine-2,5-dione (50 mg, 70.01 µmol, 80% purity, 1 eq) and TEA (28.34 mg, 280.02 µmol, 38.98 µL, 4 eq) in DCM (2 mL) was added N- methylsulfamoyl chloride (18.14 mg, 140.01 µmol, N/A purity, 2 eq) at 0 °C. The reaction mixture was stirred at 0 °C for 5 h under N2 atmosphere. The reaction mixture was quenched by addition sat. aq. NaHCO3 (30 mL) at 0 °C and extracted with DCM (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um;mobile phase: [water(NH3H2O+NH4HCO3)-ACN];B%: 53%-83%,10min), followed by lyophilization to yield 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)- 3,7-dimethyl-8-[2-methyl-3-(methylsulfamoylamino)phenyl]pyrano[3,2-c]pyridine-2,5-dione (6.22 mg, 9.36 µmol, 13.4% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO- d6) δ ppm 11.30 (s, 1H), 8.82 (s, 1H), 7.71 (d, J = 1.7, 10.3 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.27 (t, J = 7.7 Hz, 1H), 7.14 (q, J = 4.9 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.87 (t, J = 8.7 Hz, 1H), 3.03 (s, 1H), 2.55 (d, J = 5.1 Hz, 3H), 2.20 (s, 3H), 2.03 (s, 3H), 1.43 (s, 3H), 1.23-1.17 (m, 2H), 0.96-0.84 (m, 2H); ES-LCMS m/z 665.0 [M+H]+. Synthesis of tert-Butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[4- (methylsulfamoylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (I-82) O OTf NH NH2 2 N O HN
Step 1: tert-Butyl 5-(4-aminoanilino)-3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl- pyrido[2,3-d]pyrimidine-2,4,7-trione NH2 [00470] To a solution of [3-cy
p py o-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (300 mg, 482.70 μmol, 99.0%, 1 eq) in DMF (2 mL) was added 2,6-lutidine (155.17 mg, 1.45 mmol, 168.66 μL, 3 eq) and benzene-1,4-diamine (78.30 mg, 724.05 μmol, 1.5 eq). The mixture was stirred at 60 °C for 2 h. The reaction mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (PE/EtOAc = 2/1, TLC: PE/EtOAc = 2/1, Rf = 0.20) to yield tert-butyl 5-(4-aminoanilino)- 3-cyclopropyl-1-(2-fluoro-4-iodo-phenyl)-6,8-dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione (200 mg, 327.89 μmol, 67.9% yield, 94.0% purity) as a brown solid.1H NMR (400 MHz, DMSO-d6) δ ppm 10.16-10.03 (m, 1H), 8.04-7.87 (m, 1H), 7.77-7.60 (m, 1H), 7.32-7.13 (m, 1H), 6.85-6.65 (m, 2H), 6.63-6.45 (m, 2H), 5.24-4.99 (m, 2H), 2.73-2.67 (m, 3H), 1.51-1.34 (m, 3H), 1.09-0.89 (m, 2H), 0.76-0.56 (m, 2H); ES-LCMS m/z 574.1 [M+H]+. Step 2: tert-Butyl 1-(4-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl- pyrido[4,3-d]pyrimidine-2,4,7-trione
[00471] A mixture of 5-(4-amin
1-(2-fluoro-4-iodo-phenyl)-6,8- dimethyl-pyrido[2,3-d]pyrimidine-2,4,7-trione (100 mg, 163.95 μmol, 1 eq) and NaOMe/MeOH (163.95 μmol, 11 μL, 30.0%, 1 eq) in THF (0.3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 25 °C for 1 h under N2 atmosphere. The reaction mixture was quenched by addition AcOH (0.1 mL), and then diluted with H2O (20 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (DCM/MeOH = 10/1, TLC: DCM/MeOH= 10/1, Rf = 0.80) to yield tert-butyl 1-(4-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (90 mg, 67.50 μmol, 41.2% yield, 43.0% purity) as a yellow solid. ES-LCMS m/z 574.0 [M+H]+. Step 3: tert-Butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-1-[4- (methylsulfamoylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione I F
[00472] To a solution of 1-(4-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-pyrido[4,3-d]pyrimidine-2,4,7-trione (43.00 mg, 75.00 μmol, 1 eq) in DCM (1 mL) was added TEA (15.18 mg, 149.99 μmol, 20.88 μL, 2 eq) and N-methylsulfamoyl chloride (9.72 mg, 75.00 μmol, 1 eq). The mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched by addition H2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Prime C18150*30mm*5um; mobile phase: [water (FA)-ACN]; B%: 56%-76%, 12 min), followed by lyophilization to yield tert-butyl 3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8- dimethyl-1-[4-(methylsulfamoylamino)phenyl]pyrido[4,3-d]pyrimidine-2,4,7-trione (8.77 mg, 13.16 μmol, 17.6% yield, 100.0% purity) as a white solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.23-10.93 (m, 1H), 10.00-9.81 (m, 1H), 7.90-7.70 (m, 1H), 7.59-7.52 (m, 1H), 7.50-7.44 (m, 1H), 7.29-7.23 (m, 2H), 7.22-7.15 (m, 2H), 6.99-6.82 (m, 1H), 3.12-3.01 (m, 3H), 2.63-2.57 (m, 1H), 2.47-2.44 (m, 3H), 1.22 (s, 3H), 0.99-0.91 (m, 2H), 0.72-0.57 (m, 2H); ES-LCMS m/z 667.0 [M+H]+. Synthesis of 4-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-N-methyl-1H-indole-1-sulfonamide (I- 28)
Step 1: 5-((1H-Indol-4-yl)amino)-3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8- dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione [00473] To a solution of [3-cyclo
odo-phenyl)-6,8-dimethyl-2,4,7- trioxo-pyrido[2,3-d]pyrimidin-5-yl] trifluoromethanesulfonate (1.2 g, 1.92 mmol, 98.6%, 1 eq) in DMF (5 mL) was added 1H-indol-4-amine (254.15 mg, 1.92 mmol, 1 eq) and 2,6-LUTIDINE (618.14 mg, 5.77 mmol, 671.90 µL, 3 eq). The mixture was stirred under microwave at 60 °C for 8 h. The reaction mixture was diluted with H2O (30 mL), extracted with EtOAc (50 mL x 3), and washed with brine (40 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 100/1 to 1/1, TLC: PE/EtOAc = 1/1, Rf = 0.2) to yield 5-((1H-indol-4- yl)amino)-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimethylpyrido[2,3-d]pyrimidine- 2,4,7(1H,3H,8H)-trione (900 mg, 1.40 mmol, 72.9% yield, 93.0% purity) as a gray green solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.22 (s, 1H), 10.46 (s, 1H), 7.95 (d, J = 9.4 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.58-7.49 (m, 1H), 7.34 (d, J = 2.5 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.03-7.00 (m, 2H), 6.40 (d, J = 7.4 Hz, 1H), 2.75 (s, 3H), 2.67 (dd, J = 3.3, 6.8 Hz, 1H), 1.45 (s, 3H), 0.99 (d, J = 6.7 Hz, 2H), 0.67 (m, 2H); ES-LCMS m/z 598.0 [M+H]+. Step 2: 3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-1-(1H-indol-4-yl)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione
[00474] To a solution of 5-((1H
opropyl-1-(2-fluoro-4-iodophenyl)- 6,8-dimethylpyrido[2,3-d]pyrimidine-2,4,7(1H,3H,8H)-trione (500 mg, 701.82 µmol, 83.9%, 1 eq) in THF (30 mL) was added NaOMe/MeOH (701.82 µmol, 0.1 mL, 30.0%, 1 eq). The mixture was stirred under N2 atmosphere at 25 °C for 0.5 h. The residue was added the CH3COOH to pH = 7 and extracted with EtOAc (40 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (PE/EtOAc = 1/1, TLC: PE/EtOAC = 1/1, Rf = 0.3) to yield 3- cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-1-(1H-indol-4-yl)-6,8-dimethylpyrido[4,3- d]pyrimidine-2,4,7(1H,3H,6H)-trione (330 mg, 469.55 µmol, 66.9% yield, 85.0% purity) as a gray green solid.1H NMR (400 MHz, DMSO-d6) δ ppm 11.29 (s, 1H), 11.12 (s, 1H), 7.79 (dd, J = 1.7, 10.4 Hz, 1H), 7.59-7.52 (m, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 2.7 Hz, 1H), 7.12 (t, J = 7.8 Hz, 1H), 6.98-6.89 (m, 2H), 6.22 (s, 1H), 3.07 (s, 3H), 2.68-2.59 (m, 1H), 0.96 (s, 3H), 0.95-0.88 (m, 2H), 0.70 (d, J = 4.1 Hz, 2H); ES-LCMS m/z 598.0 [M+H]+. Step 3: 4-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-1H-indole-1-sulfonyl fluoride
[00475] To a solution of 3-cyc
ophenyl)amino)-1-(1H-indol-4-yl)- 6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (100 mg, 142.29 µmol, 85.0%, 1 eq) in DCM (4 mL) was added DIEA (110.34 mg, 853.73 µmol, 148.70 µL, 6 eq). The suspension was degassed under vacuum and purged with N2 several times. The mixture was stirred under F2O2S (15 Psi) at 25 °C for 24 h. The mixture was concentrated under reduced pressure to yield the residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(HCl)-ACN]; B%: 70%-90%, 10 min) and lyophilized to yield 4-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7- trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-1H-indole-1-sulfonyl fluoride (20 mg, 29.44 µmol, 20.7% yield, N/A purity) as a white solid. ES-LCMS m/z 679.9 [M+H]+. Step 4: 4-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-N-methyl-1H-indole-1-sulfonamide
[00476] To a solution of 4-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl- 2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-1H-indole-1-sulfonyl fluoride (20 mg, 29.44 µmol, N/A, 1 eq) in DMF (2 mL) was added DIEA (49.46 mg, 382.67 µmol, 66.65 µL, 13 eq) and methanamine;hydrochloride (39.75 mg, 588.73 µmol, 20 eq). The mixture was stirred at 80 °C for 12 h. The reaction mixture was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water(HCl)-ACN]; B%: 60%-80%, 10min) and lyophilized to yield 4-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7- trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-N-methyl-1H-indole-1-sulfonamide (2.51 mg, 3.64 µmol, 12.4% yield, 100.0% purity) as a white solid.1H NMR (500 MHz, CDCl3) δ ppm 11.37 (s, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.56-7.51 (m, 2H), 7.47 (d, J = 8.7 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 6.72 (t, J = 8.2 Hz, 1H), 6.46-6.31 (m, 1H), 4.88 (d, J = 5.0 Hz, 1H), 3.21 (s, 3H), 2.83-2.70 (m, 1H), 2.64 (d, J = 5.3 Hz, 3H), 1.27 (d, J = 6.1 Hz, 2H), 1.15 (s, 3H), 0.89-0.83 (m, 2H); ES-LCMS m/z 691.0 [M+H]+. Synthesis of (S)-N'-(3-(6-Cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-1,3-dimethyl-2,5- dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N- methylmethanesulfonimidamide & (R)-N'-(3-(6-Cyclopropyl-4-((2-fluoro-4- iodophenyl)amino)-1,3-dimethyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8- yl)phenyl)-N-methylmethanesulfonimidamide (I-119 & I-120)
Step 1: 2-(3-Nitrophenyl)-2-oxo-acetic acid
[00477] To a solution of 2-oxo-2-phenyl-acetic acid (51 g, 339.70 mmol, 1 eq ) in H2SO4 (80 mL) was added KNO3 (41.21 g, 407.64 mmol, 1.2 eq) at 0 °C. The mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into ice water (1.6 L) and extracted with EtOAc (400 mL x 3). The combined organic phases were washed with brine (300 mL), dried over anhydrous
Na2SO4, filtered and concentrated under reduced pressure to yield 2-(3-nitrophenyl)-2-oxo-acetic acid (66 g, crude) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ ppm 8.70 (t, J = 1.8 Hz, 1H), 8.56 (td, J = 1.2, 8.2 Hz, 1H), 8.41-8.37 (m, 1H), 7.89 (t, J = 8.0 Hz, 1H). Step 2: Ethyl 2-(3-nitrophenyl)-2-oxo-acetate O O2N O [00478] To a solution of 2-(3-n
cid (66 g, 338.24 mmol, 1 eq) in DMF (700 mL) was added K2CO3 (121.54 g, 879.42 mmol, 2.6 eq). After stirred at 20 °C for 2h, iodoethane (263.77 g, 1.69 mol, 135.26 mL, 5 eq) was added dropwise. The mixture was stirred at 20 °C for 16 h. The reaction mixture was poured into water (800 mL), extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 10/1, TLC: PE/EtOAc = 5/1, Rf = 0.45) to yield ethyl 2-(3-nitrophenyl)-2-oxo-acetate (35.5 g, 143.16 mmol, 42.3% yield, 90.0% purity) as a yellow oil.1H NMR (400MHz, CDCl3) δ ppm 8.90 (s, 1H), 8.54-8.47 (m, 1H), 8.40 (d, J = 7.8 Hz, 1H), 7.75 (t, J = 7.9 Hz, 1H), 4.50 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.1 Hz, 3H). Step 3: Ethyl 3-[(2E)-2-[2-ethoxy-1-(3-nitrophenyl)-2-oxo-ethylidene]hydrazino]-3-oxo- propanoate O O O N [00479] To a solution of et
e (22.5 g, 90.73 mmol, 1 eq) in EtOH (120 mL) was added H2SO4 (2.29 g, 23.33 mmol, 1.24 mL, 0.25 eq) and ethyl 3- hydrazino-3-oxo-propanoate (13.79 g, 94.36 mmol, 1.04 eq). The mixture was stirred at 90 °C for 2 h. The solvent was removed to yield a residue which was diluted with water (200 mL) and extracted with EtOAc (300 mL x 3). The combined organic phases were washed with brine (100
mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to yield ethyl 3-[(2E)-2-[2-ethoxy-1-(3-nitrophenyl)-2-oxo-ethylidene]hydrazino]-3-oxo-propanoate (30 g, crude, E/Z mixture) as a yellow oil. ES-LCMS m/z 352.2 [M+H]+. Step 4: Ethyl 4-hydroxy-3-(3-nitrophenyl)-6-oxo-1H-pyridazine-5-carboxylate [00480] To a solution of eth
ophenyl)-2-oxo- ethylidene]hydrazino]-3-oxo-propanoate (30 g, 85.39 mmol, E/Z mixture, 1 eq) in DMF (300 mL) was added K2CO3 (6.49 g, 46.97 mmol, 0.55 eq). The mixture was stirred at 80 °C for 3 h. The mixture was cooled to ambient temperature and poured into 3N HCl (600 mL). The precipitated solid was collected by filtration to give a residue which was added MeOH (50 mL), and stirred at 15 °C for 2 h. The slurry was filtered, and the cake was rinsed with MeOH (3 x 3 mL). The solid was collected and dried in vacuo to yield ethyl 4-hydroxy-3-(3-nitrophenyl)-6- oxo-1H-pyridazine-5-carboxylate (8.3 g, 24.47 mmol, 28.7% yield, 90.0% purity) as a yellow solid.1H NMR (400MHz, DMSO-d6) δ ppm 13.23 (s, 1H), 8.58-8.53 (m, 1H), 8.30 (td, J = 1.2, 7.2 Hz, 1H), 8.15 (d, J = 8.1 Hz, 1H), 7.76 (t, J = 8.1 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H); ES-LCMS m/z 306.1 [M+H]+. Step 5: Ethyl 4-chloro-3-(3-nitrophenyl)-6-oxo-1H-pyridazine-5-carboxylate [00481] To a solution of eth
6-oxo-1H-pyridazine-5- carboxylate (2.5 g, 7.37 mmol, 1 eq) in DCM (30 mL) was added (COCl)2 (935.60 mg, 7.37 mmol, 645.24 µL, 1 eq). The mixture was stirred at 35 °C for 3 h. The reaction mixture was quenched by addition water (30 mL) and extracted with DCM (40 mL x 3). The combined
organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was added MeOH (5 mL), and stirred at 25 °C for 2 h. The slurry was filtered, and the cake was rinsed with PE (2 x 3 mL). The solid was collected and dried in vacuo to yield ethyl 4-chloro-3-(3-nitrophenyl)-6-oxo-1H-pyridazine-5- carboxylate (1.9 g, 5.69 mmol, 77.2% yield, 97.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 11.67 (s, 1H), 8.48 (s, 1H), 8.38 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H), 7.74-7.66 (m, 1H), 4.51 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H); ES-LCMS m/z 324.0, 326.0 [M+H]+. Step 6: Ethyl 5-chloro-2-cyclopropyl-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate [00482] A mixture of ethyl
o-1H-pyridazine-5-carboxylate (1.4 g, 4.20 mmol, 1 eq), cyclopropylboronic acid (720.75 mg, 8.39 mmol, 2 eq), 2-(2- pyridyl)pyridine (1.64 g, 10.49 mmol, 2.5 eq), Na2CO3 (533.60 mg, 5.03 mmol, 1.2 eq) and Cu(OAc)2 (914.43 mg, 5.03 mmol, 1.2 eq) in 1,4-dioxane (20 mL) was degassed and purged with N2 for 3 times and the mixture was stirred at 70 °C for 24 h under N2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with DCM (60 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 3/1, TLC: PE/EtOAc = 3/1, Rf = 0.43) to yield ethyl 5-chloro-2-cyclopropyl-6-(3-nitrophenyl)-3-oxo-pyridazine-4-carboxylate (400 mg, 989.69 µmol, 23.6% yield, 90.0% purity) as a yellow gum.1H NMR (500 MHz, CDCl3) δ ppm 8.42 (d, J = 1.8 Hz, 1H), 8.35 (td, J = 1.1, 8.3 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.70-7.65 (m, 1H), 4.51 (q, J = 7.1 Hz, 2H), 4.22 (t, J = 4.0, 7.6 Hz, 1H), 1.43 (t, J = 7.2 Hz, 3H), 1.22-1.16 (m, 2H), 1.13-1.06 (m, 2H); ES-LCMS m/z 364.0, 366.0 [M+H]+.
Step 7: Ethyl 2-cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)-3-oxo-pyridazine-4- carboxylate [00483] To a solution of ethy
nitrophenyl)-3-oxo-pyridazine-4- carboxylate (400 mg, 989.69 µmol, 1 eq) in DCM (3 mL) was added MeNH2 (1.02 g, 9.90 mmol, 30.0% purity, 10 eq) at 0 °C. The mixture was stirred at 20 °C for 2 h. The solvent was removed to yield ethyl 2-cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)-3-oxo-pyridazine-4- carboxylate (300 mg, 669.74 µmol, 67.7% yield, 80.0% purity) as a yellow solid.1H NMR (500 MHz, CDCl3) δ ppm 8.33-8.30 (m, 2H), 7.79 (d, J = 7.6 Hz, 1H), 7.70-7.66 (m, 1H), 4.43 (q, J = 7.1 Hz, 2H), 4.02-3.95 (m, 1H), 2.69 (d, J = 5.3 Hz, 3H), 1.44 (t, J = 7.1 Hz, 2H), 1.46-1.42 (m, 1H), 1.03-0.94 (m, 4H); ES-LCMS m/z 359.1 [M+H]+. Step 8: 2-Cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)pyridazin-3-one [00484] To a solution of ethyl 2
mino)-6-(3-nitrophenyl)-3-oxo- pyridazine-4-carboxylate (300 mg, 669.74 µmol, 1 eq) in DMSO (5 mL) was added LiCl (283.93 mg, 6.70 mmol, 10 eq). The mixture was stirred at 150 °C for 8 h. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (40 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 0/1, TLC: PE/EtOAc = 0/1, Rf = 0.15) to yield 2-cyclopropyl-5- (methylamino)-6-(3-nitrophenyl)pyridazin-3-one (200 mg, 628.74 µmol, 93.9% yield, 90.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 8.38-8.27 (m, 2H), 7.83 (d, J = 7.6
Hz, 1H), 7.73-7.66 (m, 1H), 5.92 (s, 1H), 4.03 (t, J = 3.9, 7.5 Hz, 1H), 2.83 (d, J = 3.4 Hz, 3H), 1.09-0.93 (m, 4H); ES-LCMS m/z 287.1 [M+H]+. Step 9: 6-Cyclopropyl-4-hydroxy-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine- 2,5-dione [00485] To a solution of 2-cyclop
o)-6-(3-nitrophenyl)pyridazin-3-one (200 mg, 628.74 µmol, 1 eq) in Ac2O (3 mL) was added 2-methylpropanedioic acid (222.74 mg, 1.89 mmol, 152.56 µL, 3 eq). The mixture was stirred at 110 °C for 2 h. The solvent was removed to yield a residue which was purified by preparative TLC (PE/EtOAC = 3/1, TLC: PE/EtOAC = 3/1, Rf = 0.24) to yield 6-cyclopropyl-4-hydroxy-1,3-dimethyl-8-(3- nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (200 mg, 434.38 µmol, 69.1% yield, 80.0% purity) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 12.80 (s, 1H), 8.37 (td, J = 2.2, 7.0 Hz, 1H), 8.33 (d, J = 1.5 Hz, 1H), 7.72-7.68 (m, 2H), 4.16-4.09 (m, 1H), 3.06 (s, 3H), 2.16 (s, 3H), 1.20-1.15 (m, 2H), 1.15-1.09 (m, 2H); ES-LCMS m/z 369.0 [M+H]+. Step 10: [6-Cyclopropyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin- 4-yl] 4-methylbenzenesulfonate
[00486] To a solution of 6-cyclopropyl-4-hydroxy-1,3-dimethyl-8-(3-nitrophenyl)pyrido[2,3- d]pyridazine-2,5-dione (200 mg, 434.38 µmol, 1 eq) in DCM (8 mL) was added DIEA (561.40 mg, 4.34 mmol, 756.61 µL, 10 eq) and 4-methylbenzenesulfonyl chloride (414.06 mg, 2.17 mmol, 5 eq). The mixture was stirred at 50 °C for 12 h. The solvent was removed to yield a residue which was purified by preparative TLC (PE/EtOAC = 3/1, TLC: PE/EtOAC = 3/1, Rf = 0.24) to yield [6-cyclopropyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin- 4-yl] 4-methylbenzenesulfonate (200 mg, 371.27 µmol, 85.5% yield, 97.0% purity) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 8.38-8.30 (m, 2H), 7.98 (d, J = 8.3 Hz, 2H), 7.77-7.63 (m, 2H), 7.41 (d, J = 8.0 Hz, 2H), 4.22-4.06 (m, 1H), 3.08 (s, 3H), 2.49 (s, 3H), 1.85 (s, 3H), 1.12-1.01 (m, 4H); ES-LCMS m/z 523.1 [M+H]+. Step 11: 6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-8-(3- nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione [00487] To a solution of 2-fluo
mg, 1.11 mmol, 3 eq) in THF (3 mL) was added NaH (89.10 mg, 2.23 mmol, 60.0% purity, 6 eq) and stirred at 0 °C for 30 min, then [6-cyclopropyl-1,3-dimethyl-8-(3-nitrophenyl)-2,5-dioxo-pyrido[2,3-d]pyridazin-4-yl] 4- methylbenzenesulfonate (200 mg, 371.27 µmol, 1 eq) was added at 0 °C. The reaction temperature was slowly warmed up to 25 °C and stirred at 25 °C for 1 h. The reaction mixture was quenched by addition water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by preparative TLC (PE/EtOAC = 1/1, TLC: PE/EtOAC = 1/1, Rf = 0.35) to yield 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3- dimethyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (100 mg, 156.64 µmol, 42.2%
yield, 92.0% purity) as a yellow solid. ¾ NMR (400 MHz, CDCb) d ppm 10.78 (s, 1H), 8.44- 8.27 (m, 2H), 7.75-7.65 (m, 2H), 7.46 (d, J= 1.8, 10.0 Hz, 1H), 7.37 (d, J= 8.5 Hz, 1H), 6.56 (t, J= 8.5 Hz, 1H), 4.10-4.01 (m, 1H), 3.07 (s, 3H), 1.82 (s, 3H), 1.19-1.07 (m, 4H); ES-LCMS m/z 588.0 [M+H]+.
Step 12: 8-(3-Aminophenyl)-6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl- pyrido [2, 3-d] pyridazine-2,5-dione
[00488] To a solution of 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-8-(3- nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (100 mg, 156.64 pmol, 1 eq) in EtOH (1.5 mL), EhO (1.5 mL) and THF (1.5 mL) was added NH4CI (83.79 mg, 1.57 mmol, 10 eq) and Fe (43.74 mg, 783.19 pmol, 5 eq). The mixture was stirred at 90 °C for 3 h. The reaction mixture was filtered to remove the insoluble. The filter liquor was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Boston Prime Cl 8 150*30mm*5um; mobile phase: [water(NH3H20+NH4HC03)-ACN]; B%: 64%-94%,10min), followed by lyophilization to yield 8-(3-aminophenyl)-6-cyclopropyl-4-(2-fluoro-4-iodo- anilino)-l,3-dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (55.23 mg, 99.09 pmol, 63.3% yield, 100.0% purity) as a yellow solid. ¾NMR (400MHz, CD3OD) d ppm 7.55 (d, J= 1.8, 10.3 Hz, 1H), 7.45 (d, J= 8.5 Hz, 1H), 7.21 (t, J= 7.7 Hz, 1H), 6.82 (d, J= 1.5, 8.0 Hz, 1H), 6.79-6.76 (m, 1H), 6.71 (d, J= 7.7 Hz, 1H), 6.64 (t, J= 8.6 Hz, 1H), 4.04 (t, J= 3.9, 7.5 Hz, 1H), 3.13 (s, 3H), 1.76 (s, 3H), 1.17-1.11 (m, 2H), 1.07-0.99 (m, 2H); ES-LCMS m/z 558.0 [M+H]+.
Step 13: Methanesulfinyl chloride
[00489] To a solution of (methyldisulfanyl)methane (5.35 g, 56.79 mmol, 5.10 mL, 1 eq) in AcOH (6.82 g, 113.59 mmol, 6.50 mL, 2 eq) was added SO2CI2 (20.27 g, 170.38 mmol, 12.36 mL, 3 eq) at -20 °C under N2. The mixture was stirred at 20 °C for 12 h. The reaction mixture was concentrated to yield crude methanesulfmyl chloride (8.9 g, crude) as light yellow oil, which was used in the next step without further purification. 'H NMR (500 MHz, CDCh) S ppm 3.39 (s, 3H).
Step 14: A-[3-[6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-2,5-dioxo-pyrido[2,3- d]pyridazin-8-yl]phenyl]methanesulfinamide
[00490] To a solution of 8-(3-aminophenyl)-6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3- dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (500 mg, 897.09 pmol, 100%, 1 eq) in DCM (30 mL) was added DIEA (907.77 mg, 7.02 mmol, 1.22 mL, 7.83 eq) and methanesulfmyl chloride (176.82 mg, 1.79 mmol, 2 eq). The mixture was stirred at 20 °C for 1 h. TLC (PE/EtOAc = 1/1, Rf = 0.07) indicated the starting material was consumed completely and one new spot formed. The reaction mixture was concentrated to yield a residue which was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 0/1, TLC: PE/EtOAc = 1/1, Rf = 0.07) to yield Af-[3- [6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-2,5-dioxo-pyrido[2,3-d]pyridazin-8- yl]phenyl]methanesulfmamide (350 mg, 553.72 pmol, 61.7% yield, 98.0% purity) as a white solid. ¾ NMR (500 MHz, CDCh) S ppm 10.85 (br s, 1H), 7.48-7.33 (m, 3H), 7.23-7.02 (m, 3H), 6.54 (t, J = 7.8 Hz, 1H), 6.33 (br s, 1H), 4.05 (br s, lH), 3.11 (s, 3H), 2.87 (s, 3H), 1.82 (s, 3H), 1.25-1.05 (m, 4H); ES-LCMS m/z 620.2 [M+H]+.
Step 15: 6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-8-[3-[[methyl- (methylamino)-oxo-L6-sulfanylidene] amino] phenyl] pyrido [2, 3-d] pyridazine-2,5-dione
[00491] To a solution of N-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-2,5- dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]methanesulfmamide (150 mg, 237.31 pmol, 98%, 1 eq) and MeNEh (0.35 g, 3.72 mmol, 33%, 15.67 eq) in MeCN (45 mL) was added /-BuOK (1 M, 1.42 mL, 6 eq), followed by the addition of NCS (126.75 mg, 949.23 umol, 4 eq) at -20 °C under N2. The mixture was stirred at 20 °C for 3 h. TLC (PE/EtOAc = 0/1, Rf = 0.28) indicated the starting material was consumed completely and one new spot formed. The reaction mixture was quenched by addition of water (50 mL), extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (10 mL), dried over NaiSCL, filtered and concentrated under reduced pressure to yield a residue. The residue was purified by flash silica gel chromatography (from PE/EtOAc = 1/0 to 0/1, TLC: PE/EtOAc = 0/1, Rf = 0.28) to yield 6- cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l ,3 -dim ethyl -8-[3 -[[methyl -(methyl ami ho)-oco-l6- sulfanylidene]amino]phenyl]pyrido[2,3-d]pyridazine-2,5-dione (80 mg, 109.79 pmol, 46.2% yield, 89.0% purity) as a white solid. ES-LCMS m/z 649.2 [M+H]+.
Step 16: (A)-A'-(3-(6-Cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-l,3-dimethyl-2,5-dioxo- l,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N-methylmethanesulfonimidamide & (/?)-A'-(3-(6-Cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-l,3-dimethyl-2,5-dioxo- l,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N-methylmethanesulfonimidamide
[00492] 6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-8-[3-[[methyl- (methylamino)-oxo-k6-sulfanylidene]amino]phenyl]pyrido[2,3-d]pyridazine-2,5-dione (80 mg, 109.79 pmol, 89%, 1 eq) was separated by SFC (AD_IPA_DEA_5_40_4ML_4MIN_5CM). The Desired fraction was concentrated to yield a residue, and followed by lyophilization to yield Peak 1 : (,S)-/V-(3-(6-cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-l,3-dimethyl-2,5-dioxo- l,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N-methylmethanesulfonimidamide (20.27 mg, 30.91 pmol, 28.1% yield, 98.9% purity) (ee=100%) as a white solid. ¾ NMR (500 MHz, CD3OD) d ppm 7.58-7.52 (m, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.19 (d, J = 7.8 Hz, 1H), 7.15 (s, 1H), 7.07 (d, J = 7.5 Hz, 1H), 6.65 (t, J = 8.5 Hz, 1H), 4.05 (td, J = 3.6, 7.4 Hz, 1H), 3.12 (d, J = 7.0 Hz, 6H), 2.72 (s, 3H), 1.77 (s, 3H), 1.14 (d, J = 2.7 Hz, 2H), 1.03 (d, J = 5.2 Hz, 2H); ES-LCMS m/z 649.2 [M+H]+. Peak 2: (f?)-/V-(3-(6-cyclopropyl-4-((2- fluoro-4-iodophenyl)amino)-l,3-dimethyl-2,5-dioxo-l,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8- yl)phenyl)-/V-methylmethanesulfonimidamide (20.68 mg, 31.67 pmol, 28.8% yield, 99.3% purity) (ee=100%) as a white solid. ¾ NMR (500 MHz, CD3OD) d ppm 7.55 (dd, J = 1.8, 10.3 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 7.15 (s,
1H), 7.07 (d, J = 6.7 Hz, 1H), 6.65 (t, J= 8.6 Hz, 1H), 4.05 (tt, J = 3.9, 7.5 Hz, 1H), 3.18-3.06 (m, 6H), 2.72 (s, 3H), 1.77 (s, 3H), 1.20-1.09 (m, 2H), 1.07-0.98 (m, 2H); ES-LCMS m/z 649.2 [M+H]+.
Synthesis of l-[3-[6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-2,5-dioxo- pyrido[2,3-d]pyridazin-8-yl]phenyl]-3-methyl-guanidine (1-122)
Step 1: Eth 5-dioxo-
pyrido[2,3-d]pyridazin-8-yl]phenyl]carbamothioyl]carbamate [00493] A solution of 8-(
luoro-4-iodo-anilino)-1,3- dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (300 mg, 538.25 µmol, 100.0%, 1 eq) and ethyl N- (thioxomethylene)carbamate (155.31 mg, 1.18 mmol, 2.2 eq) in DCM (10 mL) was stirred at 15 °C for 12 h. The mixture was added PE, filtered and concentrated under reduced pressure to yield ethyl N-[[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-2,5-dioxo-pyrido[2,3- d]pyridazin-8-yl]phenyl]carbamothioyl]carbamate (330 mg, 460.12 µmol, 85.5% yield, 96.0% purity) as a yellow solid, which was used in the next step without further purification.1H NMR (400 MHz, CDCl3) δ ppm 11.58 (s, 1H), 10.83 (br s, 1H), 8.12 (s, 1H), 7.86 (s, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.45 (d, J = 9.9 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.30- 7.27 (m, 1H), 6.54 (t, J = 8.5 Hz, 1H), 4.32 (q, J = 7.0 Hz, 2H), 4.06 (tt, J = 3.9, 7.4 Hz, 1H),
3.17 (s, 3H), 1.82 (s, 3H), 1.38 (t, J= 7.0 Hz, 3H), 1.19-1.14 (m, 2H), 1.10-1.04 (m, 2H); ES- LCMS m/z 689.2 [M+H]+.
Step 2: Ethyl /V-[(Z)-/V-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-2,5- dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]-/V-methyl-carbamimidoyl]carbamate
[00494] To a solution of ethyl /V-[[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl- 2,5-dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]carbamothioyl]carbamate (270 mg, 376.47 pmol, 96.0% purity, 1 eq), DIEA (316.25 mg, 2.45 mmol, 426.22 pL, 6.5 eq) and methanamine;hydrochloride (101.67 mg, 1.51 mmol, 4 eq) in DCM (20 mL) was added EDCI (288.67 mg, 1.51 mmol, 4 eq) at 0 °C. The mixture was stirred at 15°C for 12 h. TLC (DCM/MeOH = 10/1, Rf = 0.50) indicated starting material was consumed completely. The mixture was diluted with water (30 mL) and extracted with DCM (20 mL x 3). The combined organic layers were dried over NaiSCE, filtered and concentrated under reduced pressure to yield a residue which was purified by flash silica gel chromatography (from DCM/MeOH = 100/1 to 50/1, TLC: DCM/MeOH = 10/1, Rf = 0.50) to yield ethyl /V-[(Z)-/V-[3-[6-cyclopropyl-4-(2- fluoro-4-iodo-anilino)-l,3-dimethyl-2,5-dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]-/V -methyl- carbamimidoyljcarbamate (260 mg, 371.71 pmol, 98.7% yield, 98.0% purity) as a yellow solid. 1HNMR (400 MHz, CDCh) S ppm 10.81 (s, 1H), 7.54-7.18 (m, 6H), 6.53 (t, J= 8.5 Hz, 1H), 4.19 (q, J= 7.2 Hz, 2H), 4.08-4.00 (m, 1H), 3.10 (s, 3H), 2.97 (d, J= 4.6 Hz, 3H), 1.81 (s, 3H), 1.37-1.29 (m, 3H), 1.18-1.11 (m, 2H), 1.11-1.04 (m, 2H); ES-LCMS m/z 686.1 [M+H]+.
Step 3: l-[3-[6-Cyclopropyl-4-(2-fluoro-4-iodo-anilino)-l,3-dimethyl-2,5-dioxo-pyrido[2,3- d]pyridazin-8-yl]phenyl]-3-methyl-guanidine
[00495] To a solution of ethyl N-[(Z)-N-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3- dimethyl-2,5-dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]-N'-methyl-carbamimidoyl]carbamate (100 mg, 142.96 µmol, 98.0% purity, 1 eq) in EtOH (4 mL) was added KOH (2 M, 1.14 mL, 16 eq). The mixture was stirred at 40 °C for 12 h. The mixture was concentrated under reduced pressure to yield a residue which was purified by preparative HPLC (column: Boston Green ODS 150*30mm*5um; mobile phase: [water (FA)-ACN]; B%: 26%-46%, 12 min), followed by lyophilization to yield 1-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-2,5-dioxo- pyrido[2,3-d]pyridazin-8-yl]phenyl]-3-methyl-guanidine (15.28 mg, 23.17 ^mol, 16.2% yield, 100.0% purity, FA) as a yellow solid.1H NMR (400 MHz, CDCl3) δ ppm 7.64-7.59 (m, 1H), 7.56 (d, J = 10.4 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.44-7.34 (m, 2H), 6.66 (t, J = 8.5 Hz, 1H), 4.13-4.01 (m, 1H), 3.10 (s, 3H), 2.94 (s, 3H), 1.77 (s, 3H), 1.16-1.09 (m, 2H), 1.08-1.02 (m, 2H); ES-LCMS m/z 614.1 [M+H]+. Synthesis of (S)-N'-(3-(6-Cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-1,3-dimethyl-2,5- dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N,N- dimethylmethanesulfonimidamide (I-123) ethyl-2,5-dioxo-pyrido[2,3-
d]pyridazin-8-yl]phenyl]methanesulfinamide
[00496] A mixture of 8-(3-am
2-fluoro-4-iodo-anilino)-1,3- dimethyl-pyrido[2,3-d]pyridazine-2,5-dione (100 mg, 179.42 µmol, 100.0%, 1 eq), methanesulfinyl chloride (26.52 mg, 269.13 µmol, N/A, 1.5 eq) and DIEA (69.57 mg, 538.25 µmol, 93.75 µL, 3 eq) in DCM (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 0 °C for 10 min under N2 atmosphere. The reaction mixture was washed with the saturated NaHCO3 (30 mL) solution, extracted with DCM (30 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield N-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-2,5-dioxo- pyrido[2,3-d]pyridazin-8-yl]phenyl]methanesulfinamide (110 mg, 163.37 µmol, 91.1% yield, 92.0% purity) as a yellow solid which was used directly in the next step without further purification. ES-LCMS m/z 620.0 [M+H]+. Step 2: (S)-N'-(3-(6-Cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-1,3-dimethyl-2,5-dioxo- 1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N,N- dimethylmethanesulfonimidamide
[00497] To a solution of N-[3-[6-cyclopropyl-4-(2-fluoro-4-iodo-anilino)-1,3-dimethyl-2,5- dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]methanesulfinamide (110 mg, 163.37 µmol, 92.0%, 1 eq) in MeCN (30 mL) was added N-methylmethanamine (2 M, 816.86 µL, 10 eq) and t-BuOK (1 M, 1.31 mL, 8 eq) followed by the addition of NCS (141.80 mg, 1.06 mmol, 6.5 eq). The mixture was stirred under N2 atmosphere at 40 °C for 12 h. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (TLC: PE/EtOAc = 2/3, Rf = 0.2). The desired fraction was concentrated under reduced pressure to yield a residue which was separated by chiral SFC (column: DAICEL CHIRALPAK AD(column: DAICEL CHIRALPAK AD(250mm*30mm,10um); mobile phase: [0.1%NH3H2O/ETOH]; B%: 40%-40%) to yield peak 1 and peak 2. Peak 1 was concentrated under reduced pressure to yield a residue which was dissolved in MeCN (20 mL) and water (20 mL) and lyophilized to yield (S)-N'-(3-(6-cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-1,3- dimethyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N,N- dimethylmethanesulfonimidamide (18.06 mg, 27.26 µmol, 16.7% yield, 100.0% purity, SFC: Rt = 5.737, ee = 100.0%) as a white solid.1H NMR (400 MHz, CDCl3) δ ppm 10.87 (s, 1H), 7.45 (dd, J = 1.8, 10.0 Hz, 1H), 7.35 (d, J = 9.7 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 8.9 Hz, 1H), 7.14-6.97 (m, 2H), 6.53 (t, J = 8.5 Hz, 1H), 4.05 (s, 1H), 3.12 (s, 3H), 2.99 (s, 3H), 2.91 (s, 6H), 1.81 (s, 3H), 1.19-1.13 (m, 2H), 1.09-1.01 (m, 2H); ES-LCMS m/z 663.1 [M+H]+. Synthesis of (R)-N'-(3-(6-Cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-1,3-dimethyl-2,5- dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N,N- dimethylmethanesulfonimidamide (I-124) I F I F I F yl-2,5-dioxo-
dimethylmethanesulfonimidamide
[00498] To a solution of N-[3
-iodo-anilino)-1,3-dimethyl-2,5- dioxo-pyrido[2,3-d]pyridazin-8-yl]phenyl]methanesulfinamide (110 mg, 163.37 µmol, 92.0%, 1 eq) in MeCN (30 mL) was added N-methylmethanamine (2 M, 816.86 µL, 10 eq) and t-BuOK (1 M, 1.31 mL, 8 eq) followed by the addition of NCS (141.80 mg, 1.06 mmol, 6.5 eq). The mixture was stirred under N2 atmosphere at 40 °C for 12 h. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL x 3). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield a residue which was purified by preparative TLC (TLC: PE/EtOAc = 2/3, Rf = 0.2). The desired fraction was concentrated under reduced pressure to yield a residue which was separated by chiral SFC (column: DAICEL CHIRALPAK AD(column: DAICEL CHIRALPAK AD(250mm*30mm,10um); mobile phase: [0.1%NH3H2O/ETOH]; B%: 40%-40%) to yield peak 1 and peak 2. Peak 2 was concentrated under reduced pressure to yield a residue which was dissolved in MeCN (20 mL) and water (20 mL) and lyophilized to yield (R)-N'-(3-(6-cyclopropyl-4-((2-fluoro-4-iodophenyl)amino)-1,3- dimethyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)-N,N- dimethylmethanesulfonimidamide (19.63 mg, 28.75 µmol, 17.6% yield, 97.0% purity, SFC: Rt = 6.270, ee = 97.7%) as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.87 (s, 1H), 7.45 (dd, J =1.8, 10.0 Hz, 1H), 7.35 (d, J = 9.7 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 7.14-6.98 (m, 2H), 6.53 (t, J = 8.5 Hz, 1H), 4.04 (d, J = 3.6 Hz, 1H), 3.12 (s, 3H), 2.99 (s, 3H), 2.91 (s, 6H), 1.81 (s, 3H), 1.18-1.13 (m, 2H), 1.08-1.02 (m, 2H); ES-LCMS m/z 663.1 [M+H]+. Synthesis of 6-cyclopropyl-4-[(2-fluoro-4-iodophenyl)amino]-3-methyl-8-{3- [(methylsulfamoyl)amino]phenyl}pyrano[2,3-d]pyridazine-2,5-dione (I-129)
Step 1
[00499] To a solution of DIPA (10.55 g, 104.26 mmol, 6.00 equiv) in THF (20.00 mL) was added n-BuLi (41.70 mL, 104.26 mmol, 6.00 equiv) dropwised at -78 ℃ under N2 atmosphere. The reaction mixture was stirred at -50 ℃ for 0.5 hr. A solution of tert-butyl propionate (6.79 g, 52.13 mmol, 3.00 equiv) in THF (20.00 mL) was added dropwise to previous reaction mixture at -78 ℃ and stirred for another 1 hr at -78 ℃. Then a solution of ethyl 2-cyclopropyl-5-hydroxy- 6-(3-nitrophenyl)-3-oxopyridazine-4-carboxylate (6.00 g, 17.38 mmol, 1.00 equiv) in THF (120.00 mL) was added dropwise at -78 ℃ and the mixture was stirred for another 2 hrs at -50 ℃. The reaction was quenched with sat. NH4Cl (500 mL), and then extracted with EtOAc (2 x 200 mL). The combined organic was washed with brine (400 mL), dried over anhydrous Na2SO4, and concentrated under vacuum to afford tert-butyl 3-[2-cyclopropyl-5-hydroxy-6-(3- nitrophenyl)-3-oxopyridazin-4-yl]-2-methyl-3-oxopropanoate (6.00 g, crude) as a yellow solid. Step 2 [00500]
n a -m roun ottom as , a so ut on o tert- uty -[ -cyc opropyl-5-hydroxy- 6-(3-nitrophenyl)-3-oxopyridazin-4-yl]-2-methyl-3-oxopropanoate (6.00 g, 13.97 mmol, 1.00 equiv) in TFA (50.00 mL) was stirred at 60 ℃ for 3 hrs. The reaction mixture was concentrated under vacuum to yield a crude product which was directly purified by flash chromatography (PE:EA=1:1) to afford 6-cyclopropyl-3-methyl-8-(3-nitrophenyl)-3H-pyrano[2,3-d]pyridazine- 2,4,5-trione (1.70 g, 34.27%) as a yellow solid. Step 3
[00501] To a
so ut on o -cyc opropy - - y roxy- -met y - -( -n trop enyl)pyrano[2,3- d]pyridazine-2,5-dione (1.70 g, 4.79 mmol, 1.00 equiv) and TEA (1.33 mL, 9.57 mmol, 2.00 equiv) in DCM (20.00 mL) was added a solution of TsCl (1.09 g, 5.72 mmol, 1.20 equiv) in DCM (20.00 mL) dropwised at 0 ℃. The mixture was stirred at 25 ℃ for 16 hrs. The reaction mixture was treated by the addition of 100.00 mL H2O and extracted with EA (3 x 100.00 mL). The combined organic layers were washed with brine (150.00 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give a crude product which was directly purified by flash chromatography ( PE:EA=3:1) to afford 6- cyclopropyl-3-methyl-8-(3-nitrophenyl)-2,5-dioxopyrano[2,3-d]pyridazin-4-yl 4- methylbenzenesulfonate (1.70 g, 51.55%) as a yellow solid. Step 4 [00502] To
a so ut on o - uoro- -o oan ne ( . g, . mmo , . equiv) in THF (30.00 mL) was added LiHMDS (10.01 mL, 10.01 mmol, 3.00 equiv) dropwise at -78 ℃ and stirred at -78 ℃ for 0.5 hrs. Then a solution of 6-cyclopropyl-3-methyl-8-(3-nitrophenyl)-2,5- dioxopyrano[2,3-d]pyridazin-4-yl 4-methylbenzenesulfonate (1.70 g, 3.34 mmol, 1.00 equiv) in THF (30.00 mL) was dropwise added to the reaction at -78 ℃ and stirred at -78
℃ for 0.5 hrs. The reaction mixture was treated by the addition of Sat.NH4Cl (150.00 mL ) and extracted with EA (3 x 100.00 mL). The combined organic layers were washed with brine (150.00 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give a crude product which was directly purified by flash chromatography ( PE:EA=5:1) to afford 6-cyclopropyl-4-[(2-fluoro-4-iodophenyl)amino]-3-methyl-8-(3- nitrophenyl)pyrano[2,3-d]pyridazine-2,5-dione (1.41 g, 73.58%) as a yellow solid. Step 5 [00503] To
a so ut on o -cyc opropy - -[( - uoro- -o op eny )am no]- -methyl-8-(3- nitrophenyl)pyrano[2,3-d]pyridazine-2,5-dione (1.06 g, 1.85 mmol, 1.00 equiv) in AcOH (20.00 mL) was added Fe (1.03 g, 18.5 mmol, 10.00 equiv) at 25 ℃ and stirred at 50 ℃ for 12 hrs. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in 50.00 mL Sat.NaHCO3 and extracted with EA (3 x 50.00 mL). The combined organic layers were washed with brine (50.00 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford 6-cyclopropyl-4-[(2-fluoro-4-iodophenyl)amino]- 3-methyl-8-(3-nitrophenyl)pyrano[2,3-d]pyridazine-2,5-dione (0.78 g, 73.58%) as a yellow solid, which was directly used in next step without further purification. Step 6
I F I F [0050 l)amino]- 3-me
thylpyrano[2,3-d]pyridazine-2,5-dione (0.24 g, 0.44 mmol, 1.00 equiv) and Pyridine (0.11 g, 1.32 mmol, 3.00 equiv) in DMF (1.50 mL) was dropwise added N-methylsulfamoyl chloride (0.09 g, 0.66 mmol, 1.50 equiv) in CH3CN (1.50 mL) at 0 ℃. The resulting mixture was stirred at 0 ℃ for 0.5 hrs. The reaction mixture was treated by the addition of 20.00 mL H2O and extracted with EA (3 x 30.00 mL). The combined organic layers were washed with brine (50.00 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give a crude product which was directly purified by Prep-HPLC (Column: Welch Xtimate C18 ExRS, 250 mm, 10μm; Mobile Phase A: Water (0.05%NH3.H2O), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient: 90% B to 90% B in 10 min, 90% B; Wave Length: 254 nm; RT1(min): 7; Number Of Runs: 5) to afford 6-cyclopropyl-4-[(2-fluoro-4- iodophenyl)amino]-3-methyl-8-{3-[(methylsulfamoyl)amino]phenyl}pyrano[2,3-d]pyridazine- 2,5-dione (62 mg, 33.09%) as a yellow solid. LCMS: (ES, m/z) [M+H]+: 638.1.1H NMR: (400 MHz, DMSO-d6): δ 7.72 - 7.71 (m, 1H), 7.63 - 7.60 (m, 1H), 7.57 - 7.50 (m, 2H), 7.46 - 7.42 (m, 1H), 7.35 - 7.32 (m, 1H), 6.92 (t, J=8.4 Hz, 1H), 4.20 - 4.16 (m, 1H), 2.62 (s, 3H), 1.65 (s, 3H), 1.25 - 1.23 (m, 2H), 1.11 - 1.06 (m, 2H). Synthesis of 6-cyclopropyl-3-fluoro-4-[(2-fluoro-4-iodophenyl)amino]-1-methyl-8-{3- [(methylsulfamoyl)amino]phenyl}pyrido[2,3-d]pyridazine-2,5-dione (I-128)
oxopyridazine -4-carboxylate (3.5 g, 1.45 mmol, 1.0 equiv) in DCM (30 mL) was added (COCl)2 (12.9 g, 14.48 mmol, 10 equiv) and DMF (0.7 mL, 1.30 mmol, 0.9 equiv) dropwise at room temperature. The resulting mixture was stirred for 1 h at 40°C. The solvent and excess oxalyl dichloride were removed under reduced pressure. The residue was layered with DCM (50 mL) and H2O (30mL), the water layer was extracted with DCM (2*30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford ethyl 5-chloro-2-cyclopropyl-6-(3- nitrophenyl)-3-oxopyridazine-4-carboxylate (5.3 g, crude) as a brown oil. ES-LCMS m/z 364.0 [M+H]+ Step 2
[00506] To a stirred solution of ethyl 5-chloro-2-cyclopropyl-6-(3-nitrophenyl)-3- oxopyridazine-4- carboxylate (4 g, 11.00 mmol, 1.0 equiv) in DCM (40 mL) was added CH3NH2/THF (45 mL, 90.00 mmol, 8.18 equiv) dropwise at 0 °C. The resulting mixture was stirred for additional 4 h at room temperature. The solvent was removed under reduced pressure. The residue was diluted in H2O (100 mL) and extracted with DCM (3 x lOOmL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure to afford ethyl 2-cyclopropyl-5- (methylamino)-6-(3-nitrophenyl)-3-oxopyridazine-4 -carboxylate (5.06 g, crude) as a brown yellow solid. ES-LCMS m/z 359.2 [M+H]+
Step 3
[00507] To a stirred solution of ethyl 2-cyclopropyl-5-(methylamino)-6-(3-nitrophenyl)-3- oxopyridazine-4-carboxylate (3.6 g, 10.05 mmol, 1.0 equiv) in ACN (36 mL) was added ethyl 3- chloro-3-oxopropanoate (3.6 mL) in portions at room temperature. The resulting mixture was stirred for additional 2 h at 80°C. The reaction mixture was cooled and quenched by pouring into water/ice (150 mL). The resulting mixture was extracted with EtOAc (3 x 150mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (5:1) to afford ethyl 2-cyclopropyl-5-(3- ethoxy-N-methyl-3-oxopropanamido)- 6-(3-nitrophenyl)-3-oxopyridazine-4-carboxylate (4.42 g, 93%) as a brown solid. ES-LCMS m/z 473.2 [M+H]+
Step 4
[00508] To a stirred solution of ethyl 2-cyclopropyl-5-(3-ethoxy-N-methyl-3- oxopropanamido) -6-(3-nitrophenyl)-3-oxopyridazine-4-carboxylate (4.4 g, 9.31 mmol, 1.0 equiv) in MeOH (45 mL) was added sodium methoxide (1.0 g, 18.63 mmol, 2.0 equiv) in portions at 0°C under air atmosphere. The resulting mixture was stirred for additional 1 h at 0°C. The resulting mixture was concentrated and acidified to pH 4 with IN HC1 (aq.), then extracted with EtOAc (3 x 50mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaiSCL. After filtration, the filtrate was concentrated under reduced pressure to afford ethyl 6-cyclopropyl-l-methyl-8-(3-nitrophenyl)-2,4,5-trioxo-3H-pyrido[2,3-d]pyridazine- 3-carboxylate (3.7 g, 92%) as a brown solid. ES-LCMS m/z 427.2 [M+H]+
Step 5
[00509] To a stirred solution of ethyl 6-cyclopropyl-l-methyl-8-(3-nitrophenyl)-2,4,5-trioxo - 3H-pyrido[2,3-d]pyridazine-3-carboxylate acetate (3.1 g, 6.16 mmol, 1.0 equiv) and sodium acetate (1.0 g, 12.31 mmol, 2.0 equiv) in ACN (35 mL) was added Selectfluor (3.3 g, 9.23 mmol, 1.5 equiv) in portions at 0°C under air atmosphere. The resulting mixture was stirred for additional 3 h at 0°C. The reaction was quenched by the addition of water/ice (5mL) at 0°C, then extracted with EtOAc (3 x lOmL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2S04. After filtration, the filtrate was concentrated under reduced pressure to afford ethyl 6-cyclopropyl-3-fluoro-l-methyl-8-(3-nitrophenyl)-2,4,5- trioxopyrido[2,3-d]pyridazine-3-carboxylate (2.4 g, 88%) as a yellow solid. ES-LCMS m/z 445.1 [M+H]+.
Step 6
[00510] To a stirred solution of ethy
-3-fluoro-1-methyl-8-(3-nitrophenyl)- 2,4,5- trioxopyrido[2,3-d] pyridazine-3-carboxylate (2.4 g, 5.45 mmol, 1.0 equiv) in THF (25 mL) was added H2SO4 (24 mL) dropwise at room temperature under air atmosphere. The resulting mixture was stirred for 3 h at 90°C. Then THF was removed, the residue was diluted with water (10 mL) and extracted with DCM (3 x 20mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (5:1) to afford 6-cyclopropyl-3-fluoro- 4-hydroxy-1- methyl-8-(3-nitrophenyl) pyrido[2,3-d] pyridazine-2,5-dione (1.1 g, 54%) as a yellow solid. ES- LCMS m/z 373.1 [M+H]+. [00511] 1H NMR (400 MHz, DMSO-d6) δ 13.12 (s, 1H), 8.44 - 8.41 (m, 1H), 8.40 - 8.34 (m, 1H), 8.04 - 7.98 (m, 1H), 7.87 - 7.79 (m, 1H), 3.78-3.70 (m, 1H), 2.93 (s, 3H), 1.10 - 1.07 (m, 2H), 1.07 - 1.04 (m, 2H). Step 7 [00512] To a stirred solution of 6-cy
oro-4-hydroxy-1-methyl-8-(3-nitrophenyl) pyrido[2,3-d] pyridazine-2,5-dione (1.1 g, 2.96 mmol, 1.0 equiv) and pyridine (0.7 g, 8.87 mmol, 3.0 equiv) in DCM (10 mL), Tf2O (1.7 g, 5.91 mmol, 2.0 equiv) in DCM (2 mL) was added dropwise at 0°C. The resulting mixture was stirred for 0.5 h at room temperature. The mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 20mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / THF (5:1) to afford 6-cyclopropyl-3-fluoro-1-methyl-8- (3-
nitrophenyl)-2,5-dioxopyrido[2,3-d] pyridazin-4-yl trifluoromethanesulfonate (460 mg, 30%) as a yellow solid. ES-LCMS m/z 505.1 [M+H]+. [00513] 1H NMR (400 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.39 - 8.32 (m, 1H), 8.10 - 8.03 (m, 1H), 7.88 - 7.79 (m, 1H), 4.10-4.0 (m, 1H), 2.97 (s, 3H), 1.49 - 1.22 (m, 2H), 0.94 - 0.76 (m, 2H). Step 8 I F NH O2 [00514] To a stirred solution of 2-f
e (648 mg, 2.74 mmol, 3.0 equiv) in THF (2 mL) were added LDA (2M in THF) (1.82ml, 3.65 mmol, 4.0 equiv) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 30 min at 0°C under nitrogen atmosphere. To the above mixture was added 6-cyclopropyl-3-fluoro- 1-methyl-8-(3- nitrophenyl)-2,5-dioxopyrido[2,3-d]pyridazin-4-yl trifluoromethanesulfonate (460 mg, 0.91 mmol, 1.0 equiv) in THF (3 mL) dropwise at 0°C. The resulting mixture was stirred for additional 30 min at room temperature. The reaction was monitored by LCMS. The reaction was quenched by the addition of water (20 mL) at 0°C, extracted with EtOAc (3 x 20mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA (2:1) to afford 6-cyclopropyl-3-fluoro-4-[(2- fluoro-4-iodophenyl)amino]- 1-methyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (210 mg, 39%) as a white solid. ES-LCMS m/z 592.0 [M+H]+. Step 9
[00515] To a stirred solution of 6-cyclopropyl-3-fluoro-4-[(2-fluoro-4- iodophenyl)amino]-1- methyl-8-(3-nitrophenyl)pyrido[2,3-d]pyridazine-2,5-dione (240 mg, 0.40 mmol, 1.0 equiv) in AcOH (5 mL) was added Fe (226 mg, 4.06 mmol, 10 equiv) in portions at rt.. The resulting mixture was stirred for 30 min at 60°C under nitrogen atmosphere. The reaction was monitored by LCMS. The resulting mixture was cooled to room temperature, diluted with water (20 mL), neutralized to pH 7 with saturated NaHCO3 (aq.), extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE/EA (1:1) to afford 8-(3-aminophenyl)-6- cyclopropyl-3-fluoro-4-[(2-fluoro-4-iodophenyl)amino]-1-methylpyrido[2,3-d]pyridazine-2,5- dione (150 mg, 66%) as a white solid. ES-LCMS m/z 562.0 [M+H]+. Step 10 [00516] To a stirred solution of 8
yclopropyl-3-fluoro -4-[(2-fluoro-4- iodophenyl)amino]-1-methylpyrido[2,3-d]pyridazine-2,5-dione (150 mg, 0.27 mmol, 1.0 equiv) and Et3N (81 mg, 0.80 mmol, 3.0 equiv) in DCM (1.5 mL) was added N-methylsulfamoyl chloride (69 mg, 0.53 mmol, 2.0 equiv) in DCM (0.5 mL) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 1 h at room temperature. The reaction was monitored by LCMS. The reaction was quenched by the addition of water (20 mL) at 0°C, extracted with EtOAc (3 x 20mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product (200 mg) was purified by Prep-HPLC with the following conditions (Complete Non-WJ SC Hardware 50 mm x 40 cm, 7 μm, 40 - 60 % 18 min, NH3 H2O+NH4HCO3/CAN, 80 mL/min flash) to afford 6-cyclopropyl-3-fluoro-4-[(2-fluoro-4- iodophenyl)amino]-1-methyl-8-{3-[(methylsulfamoyl)amino]phenyl}pyrido[2,3-d]pyridazine- 2,5-dione (68.4 mg, 39%) as a white solid. ES-LCMS m/z 655.0 [M+H]+.
[00517] 1H NMR(400 MHz, DMSO-d6) δ 10.92 (d, J = 2.6 Hz, 1H), 9.87 (s, 1H), 7.76 - 7.68 (m, 1H), 7.59 - 7.52 (m, 1H), 7.46 - 7.35 (m, 2H), 7.30 - 7.22 (m, 2H), 7.20 - 7.13 (m, 1H), 7.06 - 6.96 (m, 1H), 4.03 - 3.93 (m, 1H), 2.93 (s, 3H), 2.47 (d, J = 4.8 Hz, 3H), 1.06 - 0.99 (m, 4H). Synthesis of 6-cyclopropyl-4-[(2-fluoro-4-iodophenyl)amino]-8-{3- [(methylsulfamoyl)amino]phenyl}pyridazino[4,5-e][1,3]oxazine-2,5-dione (I-127) Step 1
[00518] A mixtur l)-3-oxopyridazine-4-
carboxylate (5 g, 15.093 mmol, 1 equiv) and NH3*H2O (10 mL, 256.805 mmol, 17.12 equiv) in 1,4-dioxane (40 mL) was stirred for 2 h at 80°C. The resulting mixture was concentrated under
reduced pressure and purified by trituration with ethyl ether (30 mL). This resulted in 2- cyclopropyl-5-hydroxy-6-(3-nitrophenyl)-3-oxopyridazine-4-carboxamide (4.6 g, 96.37%) as a light brown solid.
Step 2
[00519] A mixture of 2-cyclopropyl-5-hydroxy-6-(3-nitrophenyl)-3-oxopyridazine-4- carboxamide (4.6 g, 14.544 mmol, 1 equiv) and CDI (3.54 g, 21.816 mmol, 1.5 equiv) in DMF was stirred at room temperature overnight. The precipitated solids were collected by filtration and washed with MeOH (3x20 mL). This resulted in 6-cyclopropyl-4-hydroxy-8-(3- nitrophenyl)pyridazino[4,5-e][l,3]oxazine-2,5-dione (4.2 g, 84.37%) as a yellow solid.
Step 3
[00520] A mixture of 6-cyclopropyl-4-hydroxy-8-(3-nitrophenyl)pyridazino[4,5- e][l,3]oxazine-2,5-dione (4.2 g, 12.271 mmol, 1 equiv) and PCb (5.11 g, 24.542 mmol, 2 equiv) in DCE was stirred for 2 h at 80 °C under nitrogen atmosphere. The solvent was removed under reduced pressure to afford 4-chloro-6-cyclopropyl-8-(3-nitrophenyl)pyridazino[4,5- e][l,3]oxazine-2,5-dione (6 g, crude) as a yellow solid. The crude product was used in next step directly without further purification.
Step 4
[00521] A mixture of 2-fluoro-4-iodoaniline (5.91 g, 24.951 mmol, 1.5 equiv) and 4-chloro-6- cyclopropyl-8-(3-nitrophenyl)pyridazino[4,5-e][l,3]oxazine-2,5-dione (6 g, 16.634 mmol, 1 equiv) in acetonitrile was stirred for 2 h at room temperature under nitrogen atmosphere. The precipitated solids were collected by filtration and washed with ACN (3x10 mL). The collected solid was purified by trituration with MeOH (20 mL). This resulted in 6-cyclopropyl-4-[(2- fluoro-4-iodophenyl)amino]-8-(3-nitrophenyl)pyridazino[4,5-e][l,3]oxazine-2,5-dione (3.8 g, 55.15%) as a yellow solid.
Step 5
[00522] A mixture of 6-cyclopropyl-4-[(2-fluoro-4-iodophenyl)amino]-8-(3- nitrophenyl)pyridazino[4,5-e][l,3]oxazine-2,5-dione (250 mg, 0.445 mmol, 1 equiv) and SnCh (2.54 g, 13.230 mmol, 29.73 equiv) in DMF (10 mL) was stirred at room temperature overnight. The resulting solution was diluted with EtOAc (50 mL) and washed with 3x 20 mL of water. The organic layer was dried over anhydrous NaiSCL and concentrated under reduced pressure. This resulted in 8-(3-aminophenyl)-6-cyclopropyl-4-[(2-fluoro-4-iodophenyl)amino]pyridazino[4,5- e][l,3]oxazine-2,5-dione (280 mg, crude) as a yellow green solid.
Step 6
[00523] To a stirred solution of 8-(3-aminophenyl)-6-cyclopropyl-4-[(2-fluoro-4- iodophenyl)amino]pyridazino[4,5-e][l,3]oxazine-2,5-dione (280 mg, 0.527 mmol, 1 equiv) and pyridine (125.06 mg, 1.581 mmol, 3 equiv) in DMF(2.8 mL), N-methylsulfamoyl chloride (102.42 mg, 0.790 mmol, 1.5 equiv) in ACN (1 mL) was added dropwise at 0°C. The resulting mixture was stirred for 30 min at room temperature, then diluted with EtOAc (2*20 mL). The combined organic phase was washed with 3x20 mL of water and concentrated under vacuum. The residue was purified by Prep-HPLC (Column: Welch Ultimate XB-C18, 50*250 mm, 10pm; Mobile Phase A: Water (0.1% FA), Mobile Phase B: ACN; Flow rate: 90 mL/min; Gradient:
30% B to 65% B in 12 min, 65% B in 9 min; Wave Length: 254 nm.) to afford 6-cyclopropyl-4- [(2-fluoro-4-iodophenyl)amino]-8-{3-[(methylsulfamoyl)amino]phenyl}pyridazino[4,5- e][l,3]oxazine-2,5-dione (66.9 mg, 20.33%) as an off-white solid. LCMS: (ES, m/z) [M+H]+: 625.1. 1HNMR: (300 MHz, DMSO-^) S 12.02 (br, s, 1H), 9.93 (br, s, 1H), 8.29-8.18 (m, 1H), 7.92-7.82 (m, 1H), 7.76-7.67 (m, 1H), 7.58 (s, 1H), 7.50-7.42 (m, 2H), 7.41-7.28 (m, 2H), 4.24- 4.13 (m, 1H), 2.50 (s, 3H), 1.19-1.05 (m, 4H).
[00524] While a number of embodiments of this invention are described, it is apparent that the basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the application and appended claims rather than by the specific embodiments that have been represented by way of example.
Claims (26)
1. A compound of Formula G:
(I ) or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from:
each = independently represents a single bond or a double bond; each R1 is independently H, halogen, -CN, or optionally substituted Ci-6 aliphatic;
X is C, CH, orN;
Y is CR6, C(O), orN;
L’ is a covalent bond, -0-, -C(R9)2-, or -NR8-; each of R2, R5, and R8 is independently H or optionally substituted Ci-6 aliphatic; each of R3, R4, R6, and R9 is independently H, halogen, or optionally substituted Ci-6 aliphatic; Ring B is an optionally substituted ring selected from a 3-8 membered monocyclic carbocyclic ring, a 3-8 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a 5-11 membered bicyclic carbocyclic ring, a 5-11 membered
bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, O, or S, a phenyl ring, a 5-6 membered monocyclic heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S, a 8-11 membered bicyclic aromatic ring, and a 8-11 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S; L is a covalent bond or a C1-10 bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -S-, - N(R)-, -N+(R)2-, -CH(R)-, -CH(OR)-, -CH(SR)-, –CH(N(R)2)-, -C(=N-R)-, -C(=N-OR)-, - C(O)-, -S(O)2-, -(CH2-CH2-O)1-10-, -S(O)-, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-N(R)-, - S(O)2-N(R)-, -P(O)(OR)-, or -Cy-; each -Cy- is independently an optionally substituted ring selected from a 3-7 membered carbocyclic ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, O, or S, a phenyl ring, and a 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S; R7 is R, -CN, -S(O)2-N(R)2, -NR-S(O)2-R, -P(O)(OR)-N(R)2, -C(=N-R)-N(R)2, -C(=N-OR)- ; eac
phatic; and n is 0, 1,
2,
3, 4, or 5. 2. The compound of claim 1, wherein Rin .
3. The compound of claim 1, wherein Rin .
4. The compound of claim 1, wherein Ring
5. The compound of claim 1, wherein Ring
6. The compound of any one of claims 1-5, wherein each R1 is independently halogen.
7. The compound of any one of claims 1-6, wherein R2 is H.
8. The compound of any one of claims 1-7, wherein R3 is optionally substituted Ci-6 alkyl.
9. The compound of any one of claims 1-8, wherein R4 is optionally substituted Ci-6 alkyl.
10. The compound of any one of claims 1-9, wherein R5 is optionally substituted 3, 4, 5, or 6 membered saturated or unsaturated carbocyclyl.
11. The compound of any one of claims 1-10, wherein R is optionally substituted Ci-6 alkyl.
12. The compound of any one of claims 1-11, wherein Ring B is an optionally substituted phenyl ring.
13. The compound of any one of claims 1-11, wherein Ring B is an optionally substituted 5-6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, O, or S.
14. The compound of any one of claims 1-11, wherein Ring B is an optionally substituted 8- 10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from N, O, or S.
15. The compound of any one of claims 1-14, wherein L is a Ci-io bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -0-, -N(R)-, -CH(R)-, -C(=N-R)-, -C(=N-OR)-, -C(O)-, -S(0)2-, - P(0)(0R)-, or -Cy-.
16. The compound of any one of claims 1-15, wherein -Cy- is an optionally substituted 3, 4, 5, 6, or 7 membered heterocyclic ring having 1, 2, or 3 heteroatoms independently selected from N, O, or S.
17. The compound of any one of claims 1-16, wherein R7 is -CN, -S(0)2-N(R)2, -NR-S(0)2-
18. The compound of any one of claims 1-17, wherein n is 2.
19. The compound of any one of claims 1-18, wherein the compound is a compound of Formulae (II), (III), or (IV):
(II) (III) (IV) or a pharmaceutically acceptable salt thereof.
20. The compound of any one of claims 1-19, wherein the compound is a compound selected
or a pharmaceutically acceptable salt thereof.
21. The compound of any one of claims 1-20, wherein the compound is selected from the compounds in Table 1.
22. A pharmaceutical composition comprising the compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
23. A method of treating a disorder mediated by MEK, comprising administering a therapeutically effective amount of a compound of any one of claims 1-21, or a pharmaceutical composition of claim 22, to a subject in need thereof to treat the disorder.
24. The method of claim 23, wherein the disorder is cancer.
25. A method for treating a cancer in a patient, comprising administering the compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 22, to the patient.
26. A method of inhibiting MEK activity, comprising contacting MEK or a KSR-MEK complex or a RAF-MEK complex with an effective amount of a compound of any one of claims 1-21, or a pharmaceutical composition of claim 22, to inhibit MEK activity.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163175837P | 2021-04-16 | 2021-04-16 | |
US63/175,837 | 2021-04-16 | ||
US202163262093P | 2021-10-05 | 2021-10-05 | |
US63/262,093 | 2021-10-05 | ||
PCT/US2022/071732 WO2022221866A1 (en) | 2021-04-16 | 2022-04-15 | Mek inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2022258968A1 true AU2022258968A1 (en) | 2023-10-19 |
Family
ID=81579550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022258968A Pending AU2022258968A1 (en) | 2021-04-16 | 2022-04-15 | Mek inhibitors and uses thereof |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4323066A1 (en) |
JP (1) | JP2024514879A (en) |
KR (1) | KR20230172548A (en) |
AU (1) | AU2022258968A1 (en) |
CA (1) | CA3215081A1 (en) |
IL (1) | IL307673A (en) |
WO (1) | WO2022221866A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023230205A1 (en) * | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
PL218519B1 (en) | 1999-12-10 | 2014-12-31 | Pfizer Prod Inc | PYRROLO[2,3−d]PYRIMIDINE COMPOUNDS |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
ATE350376T1 (en) | 2001-04-27 | 2007-01-15 | Zenyaku Kogyo Kk | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS AN ACTIVE INGREDIENT |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2495072A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
JP2006523237A (en) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ, インコーポレイテッド | PI-3 kinase inhibitor prodrug |
EP1644363B1 (en) | 2003-05-30 | 2012-02-22 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer |
EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
SI3153514T1 (en) | 2004-05-13 | 2022-02-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
CN101912400B (en) * | 2004-06-11 | 2013-06-26 | 日本烟草产业株式会社 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
DK1856135T3 (en) | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
JP5238936B2 (en) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | GITR binding molecules and uses thereof |
WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN105330741B (en) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
EA019255B1 (en) | 2005-10-07 | 2014-02-28 | Экселиксис, Инк. | Phosphatidylinositol 3-kinase inhibitors and pharmaceutical compositions containing them |
PT1951684T (en) | 2005-11-01 | 2016-10-13 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
CN103214483B (en) | 2005-12-13 | 2014-12-17 | 因塞特公司 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
CA2650303C (en) | 2006-04-26 | 2015-03-24 | F. Hoffmann-La Roche Ag | Thienopyrimidine pharmaceutical compounds and their use |
PL2081435T3 (en) | 2006-09-22 | 2016-11-30 | Inhibitors of bruton's tyrosine kinase | |
RS54533B1 (en) | 2007-03-12 | 2016-06-30 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
JP5275371B2 (en) | 2008-03-11 | 2013-08-28 | インサイト・コーポレイション | Azetidine derivatives and cyclobutane derivatives as JAK inhibitors |
WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
EP3023438B1 (en) | 2009-09-03 | 2020-03-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
EP2510010B1 (en) | 2009-12-10 | 2015-11-25 | F.Hoffmann-La Roche Ag | Antibodies binding to human CSF1R extracellular domain 4 and their use |
JP5989547B2 (en) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Antibody to human CSF-1R and use thereof |
EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
NZ603193A (en) | 2010-05-04 | 2014-07-25 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
HUE041958T2 (en) | 2010-09-09 | 2019-06-28 | Pfizer | 4-1bb binding molecules |
EA027153B1 (en) | 2010-12-09 | 2017-06-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Use of chimeric antigen receptor-modified t cells to treat cancer |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
JP6072771B2 (en) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | Antibodies and other molecules that bind to B7-H1 and PD-1 |
EA036814B9 (en) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Anti-pd-l1 antibody (embodiments), composition comprising this antibody and use thereof |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
RU2014136332A (en) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | COMPOSITIONS AND METHODS OF APPLICATION OF CSF1R INHIBITORS |
AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
KR102241111B1 (en) * | 2012-03-14 | 2021-04-15 | 루핀 리미티드 | Heterocyclyl compounds as mek inhibitors |
RU2670743C9 (en) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
US20140079699A1 (en) | 2012-08-31 | 2014-03-20 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2014169843A1 (en) * | 2013-04-18 | 2014-10-23 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
WO2016009306A1 (en) * | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
JP6887996B2 (en) | 2015-09-23 | 2021-06-16 | ザ ジェネラル ホスピタル コーポレイション | TEAD transcription factor autopalmitoylation inhibitor |
CA3009159C (en) | 2015-12-24 | 2024-03-19 | Kyowa Hakko Kirin Co., Ltd. | .alpha.,.beta.-unsaturated amide compound |
EP3618818A4 (en) | 2017-05-03 | 2020-12-09 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
CN111201225B (en) * | 2017-06-23 | 2021-11-05 | 基石药业 | Coumarin-like ring compound as MEK inhibitor and application thereof |
JP7221202B2 (en) | 2017-06-23 | 2023-02-13 | 協和キリン株式会社 | α, β unsaturated amide compounds |
WO2019040380A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
US11247082B2 (en) | 2018-05-04 | 2022-02-15 | ArchAngel Fire Systems Holdings, LLC | System, method, and apparatus for the suppression of fire growth |
WO2019222431A1 (en) | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
EP3802543A1 (en) | 2018-05-31 | 2021-04-14 | F. Hoffmann-La Roche AG | Therapeutic compounds |
TW202024023A (en) | 2018-09-03 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | Therapeutic compounds and methods of use |
CA3113823A1 (en) | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
KR20210108367A (en) | 2018-11-09 | 2021-09-02 | 비바체 테라퓨틱스, 인크. | Bicyclic Compounds |
MX2021011209A (en) | 2019-03-15 | 2022-01-19 | Massachusetts Gen Hospital | Novel small molecule inhibitors of tead transcription factors. |
AU2020257207A1 (en) | 2019-04-16 | 2021-11-25 | Vivace Therapeutics, Inc. | Bicyclic compounds |
WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
AU2020282757A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
EP4087868A4 (en) | 2020-01-08 | 2024-03-20 | Icahn School of Medicine at Mount Sinai | Small molecule modulators ksr-bound mek |
WO2022051565A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
WO2022051567A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions |
WO2022051569A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
WO2022051568A1 (en) | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions |
-
2022
- 2022-04-15 KR KR1020237039396A patent/KR20230172548A/en unknown
- 2022-04-15 CA CA3215081A patent/CA3215081A1/en active Pending
- 2022-04-15 EP EP22720905.3A patent/EP4323066A1/en not_active Withdrawn
- 2022-04-15 WO PCT/US2022/071732 patent/WO2022221866A1/en active Application Filing
- 2022-04-15 AU AU2022258968A patent/AU2022258968A1/en active Pending
- 2022-04-15 IL IL307673A patent/IL307673A/en unknown
- 2022-04-15 JP JP2023562904A patent/JP2024514879A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4323066A1 (en) | 2024-02-21 |
IL307673A (en) | 2023-12-01 |
CA3215081A1 (en) | 2022-10-20 |
JP2024514879A (en) | 2024-04-03 |
WO2022221866A1 (en) | 2022-10-20 |
KR20230172548A (en) | 2023-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109562106B (en) | CXCR4 inhibitors and uses thereof | |
JP2022534426A (en) | TEAD inhibitors and uses thereof | |
JP2019518768A (en) | CXCR4 inhibitors and uses thereof | |
JP2019524665A (en) | CXCR4 inhibitors and uses thereof | |
AU2021392040A1 (en) | Tead inhibitors and uses thereof | |
WO2022120353A1 (en) | Tead inhibitors and uses thereof | |
EP3846793B1 (en) | Eif4e inhibitors and uses thereof | |
WO2022051565A1 (en) | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions | |
JP2023515888A (en) | eIF4E inhibitors and uses thereof | |
AU2022258968A1 (en) | Mek inhibitors and uses thereof | |
WO2022187518A1 (en) | Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions | |
US11878958B2 (en) | MEK inhibitors and uses thereof | |
CN117580835A (en) | MEK inhibitors and uses thereof | |
WO2023173057A1 (en) | Mek inhibitors and uses thereof | |
WO2023173053A1 (en) | Mek inhibitors and uses thereof | |
WO2024081311A1 (en) | Cbl-b modulators and uses thereof | |
WO2020264292A1 (en) | Cxcr4 inhibitors and uses thereof | |
WO2022187849A1 (en) | Salinomycin derivatives and uses thereof | |
WO2022187520A1 (en) | Substituted 3-piperidinyl-pyrazolo[3,4-b]pyridines and related compounds and their use in treating medical conditions |